Sythesis of retinoic acid analogues & investigations into their ability to induce stem cell differentation by Bridgens, Caroline Emma
Durham E-Theses
Sythesis of retinoic acid analogues & investigations
into their ability to induce stem cell differentation
Bridgens, Caroline Emma
How to cite:
Bridgens, Caroline Emma (2009) Sythesis of retinoic acid analogues & investigations into their ability to
induce stem cell differentation, Durham theses, Durham University. Available at Durham E-Theses Online:
http://etheses.dur.ac.uk/2068/
Use policy
The full-text may be used and/or reproduced, and given to third parties in any format or medium, without prior permission or
charge, for personal research or study, educational, or not-for-profit purposes provided that:
• a full bibliographic reference is made to the original source
• a link is made to the metadata record in Durham E-Theses
• the full-text is not changed in any way
The full-text must not be sold in any format or medium without the formal permission of the copyright holders.
Please consult the full Durham E-Theses policy for further details.
Academic Support Office, Durham University, University Office, Old Elvet, Durham DH1 3HP
e-mail: e-theses.admin@dur.ac.uk Tel: +44 0191 334 6107
http://etheses.dur.ac.uk
Synthesis of Retinoic Acid Analogues 
& 
Investigations into their Ability 
to Induce Stem Cell Differentiation 
Caroline Emma Bridgens 
A thesis submitted for the degree of 
Doctor of Philosophy 
The copyright of this thesis rests with the 
author or the university to which it was 
submitted. No quotation from it, or 
information derived from it may be 
published without the prior written 
consent of the author or university, and 
any information derived from it should be 
acknowledged. 
School of Biological and Biomedical Sciences 
& 
Department of Chemistry 
Durham 
University 
2 0 APi-
Abstract 
Human embryogenesis and ensuing adult homeostasis are directed by the complex interplay o f a wide 
range o f exquisitely controlled signalling molecules and pathways. All-Zroni-retinoic acid ( A T R A ) is 
one such important hormone-like compound that regulates a wide range o f processes. The endogenous 
effects o f A T R A have the potential to be translated into treatment for numerous clinical indications; 
however administration at efficacious concentrations is associated with severe side effects. 
Consequently, a large group o f synthetic molecules - known as retinoids - that are structurally and/or 
functionally analogous to A T R A have been prepared and tested in vitro in the search for a panacea and 
for use as pharmacological tools to elucidate the retinoid molecular pathway. 
A small library o f stable synthetic retinoids was prepared and their biological activity investigated 
using TERA2.cl.SP12 human embryonal carcinoma (EC) stem cells. Three compounds, CEB16, 
CEB17 and CEB18 were found to inhibit cellular proliferation and induce neural and non-neural 
differentiation. These effects were thoroughly characterised and quantified by monitoring phenotypic 
changes and the expression o f established antigenic markers. Compared to the ability o f A T R A and its 
geometric isomers 9-c/5-retinoic acid and 13-c/5-retinoic acid, the order o f efficacy o f induction o f 
neural differentiation was found to be: 
13-c/5-retinoic acid>9-C75-retinoic acid=ATRA>CEB 18>CEB 1 7 » C E B 16. 
The molecular mechanism o f natural and synthetic retinoid action during TERA2.cl.SP12 
differentiation was investigated by performing a detailed temporal analysis o f the gene expression o f 
eleven transcripts involved in retinoid transport, activation and metabolism. To date, limited data have 
been published on the effects o f synthetic retinoids on the retinoid pathway during differentiation o f 
human cells and no human studies have examined the activity o f synthetic retinoids on the HOX 
genes. A l l o f the retinoic acid inducible genes examined in this study were found to be modulated in 
TERA2.cl.SP12 cells in response to both A T R A and two isomeric synthetic retinoids, CEB16 and 
CEB17, albeit relatively slowly compared to other cell lines. These compounds are therefore believed 
to activate the same pathway as the natural metabolite in these cells and that this is responsible for at 
least some o f the observed effects. Genes were regulated in a concentration and retinoid dependent 
manner and this modulation was often multi-phasic demonstrating the complex behaviour o f the 
retinoid system. Interestingly, A T R A was not the most effective inductive agent in all gene analyses. 
For example 10 n M CEB17 induced up-regulation o f RAR-P more strongly than 10 n M A T R A and 
10 |aM CEB16 induced the greatest increase in RAR-y transcripts. 
Further experimentation is required to confirm an apparent relationship between the t iming o f addition 
o f inductive agent and the expression pattern of several genes. This behaviour highlights the 
importance o f retinoid degradation in culture, which is often overlooked. The three synthetic 
compounds described extensively herein should be more stable, and thus may be suitable and 
convenient alternatives for molecular biologists to use in place o f A T R A . 
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C H A P T E R 1: T H E RETINOIDS 
1.1 Introduction 
Vitamin A has long been established as an essential micronutrient for normal embryonic development 
and for a wide range o f physiological processes in the adult. The major active metabolite o f vitamin A 
is all-rram-retinoic acid ( A T R A , also known as tretinoin), a small, lipophilic, isoprenoid molecule 
consisting o f a trimethylcyclohexenyl group and an aW-lrans conjugated tetraene side chain terminated 
by a carboxylic acid group. 
The biological roles of A T R A make it an obvious drug candidate for many clinical indications, 
however the administration o f efficacious doses is associated with undesirable side effects. These 
observations have led to the design, synthesis, biological evaluation and - in some cases - clinical 
trials o f a large group o f molecules that are structurally and/or functionally analogous to A T R A . These 
synthetic compounds and their natural counterparts are known as "retinoids". More than 4000 
retinoids have been prepared by a large number of academic research groups and commercial 
organisations searching for safe, effective and stable alternatives to A T R A 
CO2H 
a\\-trans-veimo\c acid, 
(2£:,4£,6£:,8£r)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1 -enyl)nona-2,4,6,8-tetraen-1 -ol 
The structures of retinoids discussed in the text are presented in Appendix 1. 
1.2 Functions of endogenous retinoids 
The term "retinoid" was proposed by Sporn in 1976 to broaden the base of thinking about the vitamin 
A family o f molecules beyond nutrition and vision, and to emphasize the potential biological and 
mechanistic relationships between metabolites o f retinol and steroids.' This description evolved into a 
formal lUPAC structure-based definition, " A class o f compounds consisting o f four isoprenoid units 
joined in a head-to-tail manner."" Standard usage o f the term has subsequently been extended to 
describe a family o f compounds that includes natural dietary vitamin A (retinol), its metabolites and 
several thousand synthetic analogues that are structurally related to retinol and/or can elicit specific 
biological responses by binding to one or more o f the retinoid receptors.^ '' However, the lUPAC has 
advised that retinoic acid analogues which are unable to replace the fu l l range o f biological activities 
o f vitamin A should be distinguished as "retinoate analogues".' 
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Figure 1-1: Functions o f naturally occurring retinoids. From Napoli , 1996. 
Endogenous retinoids are distributed through many tissues in v/vo,' and regulate a wide range of 
essential processes during chordate embryogenesis and adult homeostasis including embryonic 
development,^ vision, ' reproduction,'" immune competence" and cellular differentiation, proliferation 
and apoptosis'^ (Figure 1-1). The role o f 1 l -c«-ret inal in the transduction o f light into a visual signal 
is well established,''' ''' but our understanding o f the other functions o f retinoids remains to be fu l ly 
elucidated and represents an area which continues to be actively investigated. 
During early embryogenesis, the antero-posterior (AP, head-tail) and dorso-ventral (DV, back-front) 
axes are established within the embryo. These axes specify what has been described as Cartesian co-
ordinates that predict the overall body plan o f the developing e m b r y o , t h r o u g h the position-specific 
expression o f developmental control genes.Studies in the chick limb bud and Xenopus and zebrafish 
embryos have established the requirement for a number o f synergistic morphogenic signals in 
determining positional identities along the AP axis o f the vertebrate nervous system." '^ ATRA, 
together with a number o f other molecules including Sonic hedgehog homologue (SHH), fibroblast 
growth factors (FGFs), transforming growth factor beta (TGF-P) ligands and W N T proteins become 
established in concentration gradients along the AP and DV axes in humans.""'"^ Different 
combinations o f morphogen concentrations and duration o f signalling cause the induction o f specific 
genes, which in turn specify the spatial organisation of cell types. 
The A T R A gradient is precisely controlled by synthesis, facilitated by retinal dehydrogenase 2 
(RalDH2) at the posterior end o f the embryo, and expression o f CYP26A1 and CYP26C1 metabolising 
enzymes at the anterior m e s o d e r m . T h e small magnitude of the concentration gradient (2.5-fold) 
suggests the existence o f amplification mechanisms, such as the activation o f retinoic acid receptors 
(RARs) which may also be present in a gradient along the axis.'" Cells in the embryo respond 
differently to A T R A depending on their exposure, thus influencing pattern formation, limb 
development^'-" and development o f the central nervous system. 
The ability o f A T R A to regionalise the entire posterior central nervous system (CNS) is mediated, at 
least in part, by its direct action on the spatial regulation o f the homeobox Hox family of genes. Hox 
genes are putative master regulators o f development, responsible for specifying the antero-posterior 
axis and controlling segmental patterning during e m b r y o g e n e s i s . A T R A is also required beyond 
the initial stages o f neural induction for the continued development o f the nervous system in the 
embryo and regeneration and maintenance o f the CNS in the adult.^^ ''^  
Defects in the normal functioning o f any part o f the retinoid pathway may result in defects o f varying 
severity. For example, aberrant expression or regulation o f the RARs,"*"^* //OA'genes'*'"^'' and cellular 
retinol-binding protein-I (CRBP-I)"'^^ are all associated with the development o f human cancers. 
Retinoid therapy offers the potential to ameliorate aberrations o f the retinoid pathway.'"^'" 
1.3 Discovery, deficiency and excess 
1.3.1 Discovery of "vitamine A" 
Long before the concept o f "vita-amines" was defined," the ancient Egyptians realised that night 
blindness could be cured by feeding the patient liver,^* a symptom that is now recognised as one of the 
earliest signs o f vitamin A deficiency. Throughout the early 1900s deprivation studies in laboratory 
animals were used to isolate and identify a number o f vitamins. Vitamin A was first identified in 1913 
as an essential fat-soluble nutrient present in butterfat and cod liver o i l . It was initially named "fat-
soluble A " but subsequently re-designated "vitamine A " . " 
The molecular structure o f vitamin A was determined using a combination o f observations and 
classical techniques: P-carotene was demonstrated to be converted into vitamin A in vivo; the products 
formed by oxidative degradation o f P-carotene and retinol were examined and then, by applying the 
isoprene ru le , ' " the correct formulae o f P-carotene (eight isoprene units) and retinol (four units) were 
established.^" 
Once the nutritional requirement for vitamin A became evident, retinol was initially distilled f rom fish 
liver o i l , whilst synthetic preparations were developed to provide vitamin A and P-carotene for use as 
food and feed supplements and as colourants in cosmetic and pharmaceutical preparations. The 
synthesis o f A T R A was first published in 1946,^' en route to the synthesis o f re t inol ." It was at this 
time that the biological properties o f A T R A and other retinoids were first recognised. 
1.3.2 Vitamin A deficiency & fiypervitaminosis A 
A T R A is an essential morphogen during embryogenesis and disruption o f the precisely controlled 
gradient o f A T R A along the antero-posterior axis o f the developing central nervous system therefore 
results in a range o f congenital deformations. '"" Vitamin A deficiency ( V A D ) during pregnancy 
results in a spectrum o f developmental malformations known as V A D syndrome;"'" whereas 
exposure to excess retinoid is teratogenic and may result in spontaneous miscarriage or a range o f 
malformations referred to as retinoid embryopathy.^^'^^ Therapeutic doses of retinoids are therefore 
contraindicated during p r e g n a n c y . F u r t h e r m o r e , the teratogenic effects of ethanol (foetal alcohol 
* Wallach's "isoprene rule" was based on extensive natural product research and suggested that isoprene units 
can be linked together "head to tail" to form linear chains or rings. Although since superseded, this rule was 
extremely useful in predicting the structures of unknown plant products. 
syndrome) and birth defects associated with smoking have been suggested to result from their ability 
to disturb vitamin A metabolism or its signalling pathways. 70-72 
Vitamin A deficiency is a problem largely in developing countries. It can lead to night blindness and 
xerophthalmia, growth retardation, keratinisation o f epithelia, impaired hearing, taste and smell, 
increased susceptibility to infection, increased child mortality and reduced male f e r t i l i t y . ^ ' " ' ' " 
Deficiency in the developed world is usually limited to those with absorption difficulties, increased 
susceptibility to opportunistic infections, chronic liver disease and alcoholics." Vitamin A deficiency 
or dysfunctional regulation o f the retinoid genetic pathway may be associated with the development o f 
neurological disorders, including late onset Alzheimer's disease and schizophrenia." The observed 
symptoms o f hypervitaminosis A include weight loss, irritation and desquamation o f skin, hair loss, 
bone fractures, osteoporosis and liver toxicity. 
1.4 Absorption, transportation and metabolism of retinol 
Higher eukaryotic organisms depend on the dietary supply o f vitamin A for a range o f essential 
biological processes (Figure 1-1). In the U K , the recommended daily dietary allowance for adults is 
600 mg for women and 700 mg for men." Humans are not capable o f de novo vitamin A production, 
so are obliged to derive it either in active form as retinol or retinyl esters from animal sources (for 
example, dairy products, oily fish and liver) or as carotenoid provitamins from fruit and vegetables 
containing yellow, orange and dark green pigments. The absorption, transport and metabolism o f 
retinol are summarised in Figure 1-2. 
After ingestion, carotenoids are absorbed through the enterocytes o f the small intestine and oxidised 
by enzymes including carotene-] 5,15'-mono-oxygenase and carotene-9'10'- mono-oxygenase to give 
retinaldehydes (known simply as retinal, except in ocular studies) and then reduced to retinol by as yet 
unidentified retinal reductases.'' Dietary retinyl esters are hydrolysed to retinol in the intestinal lumen 
prior to uptake in the enterocytes.'* Within the enterocytes, retinol is converted to retinyl esters (retinyl 
palmitate/oieate and retinyl stearate) by two enzymes: free retinol is esterified by acyl-CoA retinol 
acytransferase ( A R A T ) whereas lecithin-retinol acyltransferase ( L R A T ) utilises both free retinol and 
retinol bound to cellular retinol-binding protein I I (CRBP-II , also known as RBP2) ." CRBP-II is a 
specific retinol binding protein localised to the enterocytes.*'''" In common with other retinoid binding 
proteins, the function o f CRBP-II is to solubilise its lipophilic ligand, protect it f rom metabolism and 
regulate its transport, metabolism and action."•*^'*^ Retinol may also be converted to retinyl esters by 
lipoprotein lipase (LPL) , the physiological role o f this process may be to increase uptake o f retinoids 
by adipocytes, the second largest retinoid store in the body.*'' The majority o f retinyl esters are then 
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Figure 1-2: Schematic diagram of vitamin A absorption, transportation and storage, significantly 
adapted from Goodman, 2006.'"^ For extensive reviews see Blomhoff et ah, 1991 and 2006."'*^ 
Abbreviations: APOE = apolipoprotein E, ARAT = acyl-CoA retinol acyltransferase, LPL = 
lipoprotein lipase, LRAT = lecithin-retinol acyltransferase, REH = retinyl ester hydroxylase and TTR 
= transthyretin. 
incorporated into chylomicrons,*^ exocytosed into the intestinal lymph and then moved into the 
general circulation where they are formed into chylomicron remnants.*' The majority o f chylomicron 
remnants are delivered to the parenchymal cells (hepatocytes) o f the liver, though a significant 
proportion are taken up by extra-hepatic tissues. 
The liver plays a pivotal role in maintaining blood retinol levels within a narrow range, by storing 
retinoids when in dietary excess and releasing retinol when dietary intake decreases.**'*' Upon delivery 
to the liver, retinyl esters are hydrolysed to retinol by retinyl ester hydrolase'" and bind to a second 
cellular retinol-binding protein (CRBP-I, also known as R B P l ) , which is highly homologous to 
CRBP-Il yet expressed in multiple tissues." Retinol is then processed for either hepatic storage or 
secretion into blood plasma. The liver is the main store for dietary retinoids with approximately 50-
90% o f total mammalian body vitamin A stored in the hepatic stellate cells (Ito cells) as retinyl esters, 
predominantly retinyl palmitate/oleate and retinyl stearate, depending on vitamin A status.'"'^ Retinol 
associates with plasma retinol-binding protein (RBP4) in a 1:1 ratio and is thus secreted from the 
l iver. ' ' The levels o f CRBP-I and RBP4 vary as required in order to maintain retinoic acid homeostasis 
in the body.*"'*^ '^ RBP4 is able to carry retinol alone, but the major carrier o f retinol f rom the liver is 
as RBP4-transthyretin complex; the association o f this second protein prevents the glomerular 
filtration of RBP4.'^ At the target tissue, this complex breaks up and retinol is released from TTR and 
RBP4. ' ' However, the majority o f plasma retinol that leaves the general circulation is returned to it 
without undergoing irreversible metabolism, a process known as retinol recycling.*' RBP4 is also able 
to bind to A T R A , but this protein has no aff ini ty for 9-c/5-retinoic acid (9-C/5-RA, structure B in 
Appendix 1), 13-c/5-retinoic acid (IS-cw-RA, C) or synthetic retinoids, which are transported directly 
to target cells bound to serum albumin.'* 
Two mechanisms are proposed to transport retinol into cells: simple diffusion and/or through binding 
with a specific receptor on the target cell membrane. Retinol and other retinoids are hydrophobic and 
readily partition into the lipid phase o f the membrane, whereupon they may be transferred by diffusion 
to intracellular binding proteins."''"' A specific glycoprotein cell membrane receptor, STRA6, has 
been identified in target epithelium that binds plasma RBP4 at the extracellular surface and facilitates 
the transfer o f retinol to cytoplasmic cellular retinol-binding proteins (CRBPs). '°"" '° ' The importance 
o f this receptor in the delivery o f retinol to cells is shown by the observation that patients with STRA6 
mutations present malformations consistent with vitamin A deficiency.'"^ There is little information 
available in the literature regarding how synthetic retinoids enter cells/tissues from the circulation,'"' 
the most likely route is therefore via indiscriminate passive diffusion. 
Within the cell, all-/ra«5-retinol can be oxidised in a two step process to ATRA, the major active 
metabolite o f vitamin A (Figure 1-3). The spatiotemporal concentration o f ATRA is regulated, to 
prevent toxicity and maintain normal gene functions, by the concerted control o f synthesis and 
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degradation. This is co-ordinated by a number of specific binding proteins and enzymes, including 
CRBPs, cellular retinoic acid-binding proteins (CRABPs), retinol dehydrogenases (RolDHs), retinal 
dehydrogenases (RalDHs) and cytochrome P450 enzymes. Specific ocular binding proteins are also 
known, including cellular retinal-binding protein (CRALBP).^^ '"^ 
ATRA 
STRA6 
Polar ATRA ««abolSSr: CYP26 ^ metabolites 
9-cis-RA 
13-clS-RA 
Nucleus 
Cytoplasm 
Figure 1-3: Schematic representation of the extra-visual retinoid signal transduction pathway. 
Abbreviations: ROL = retinol, RAL = retinal, RBP4 = serum retinol-binding protein, RolDH = retinol 
dehydrogenase, RalDH = retinal dehydrogenase, CRBP-I = cellular retinol-binding protein I , CRABP-
I-H 11 = cellular retinoic acid-binding proteins I and I I , RE = DNA response element. Adapted from 
Klaassen and Braakhuis, 2002.'°^ 
Intracellularly, retinol is bound to cellular-retinol binding proteins of which four human CRBP 
proteins have currently been identified, CRBP-I, - I I , - I I I and _ i v . « ° ' ° 2 . ' 0 9 , n o addition to its 
homeostatic roles, CRBP facilitates the reversible oxidation of retinol to retinal by microsomal 
RolDHs'""'" and secondly the irreversible and rate-limiting oxidation of retinal to ATRA, its major 
active metabolite, by retinal dehydrogenases (RalDH). 36,114-116 The CRBPs possess both high 
specificity and binding affinity for retinol and retinal, but discriminate against ATRA and cis forms of 
r e t i n o l . A T R A binds strongly to the cellular refinoic acid-binding proteins (CRABP-I and - I I ) , 
which serve to transport, stabilise, and protect their ligand." Furthermore, the CRABPs regulate the 
level of intracellular ATRA available for binding to the nuclear receptors, acting by soaking up free 
ATRA and modulating metabolism, thus protecting the cell from ATRA-excess.*^ "*"^ CRABP-II is 
responsible for delivering A T R A to the retinoid receptors in the nucleus'"" '^" and CRABP-I is 
associated with regulating the metabolic fate o f A T R A , by delivering it to the CYP26 family o f 
enzymes. 
120,121,123-125 
A T R A is metabolised and subsequently deactivated by the specific and non-specific activity o f 
cytochrome P450 (CYP) enzymes.'^^ The major CYP enzymes involved in the degradation o f A T R A 
in vivo are the A T R A hydroxylases, CYP26 , ' " currently divided into three subfamilies in humans: 
CYP26A1, 128,129 C Y P 2 6 B 1 " " and CYP26C1 , ' " The CYP26 enzymes play essential roles in the 
regulation o f A T R A exposure during embryogenesis and in adult tissues.'^'"'" Metabolites o f 
129,138-140 CYP26A1 include 4-hydroxy-ATRA, 4-oxo-ATRA, 18-hydroxy-ATRA and 4-oxo-retinol.' 
These intermediates can be further hydrolysed before they are converted to glucuronides and 
eliminated.^'"" The majority o f retinoid metabolites are inactive in the retinoid pathway, however 
exceptions include 4-oxo-retinol, 142-144 4-hydroxy-ATRA, 18-hydroxy-ATRA and retinoyi p-
glucuronide 28,145,146 9- and 13-cw-RA are similarly metabolised to their respective 4-hydroxy- and 4-
oxo-metabolites (Figure 1-4). 
The retinoid-binding proteins and CYP26 enzymes are reviewed in detail in Section 4.2.3. 
OH 
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CYPs 
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Figure 1-4: Metabolism of A T R A , 9-cis-RA and 13-cw-RA. Figure adapted from Bruon and Njar, 
2007."* 
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1.5 Molecular mechanism of retinoid action 
The precise regulation o f retinoid biological activities and ability to induce pleiotropic effects in vivo 
would appear to be related to the complex molecular pathway o f combinatorially diverse elements that 
convey and modulate its effects.''''''^" 
The mechanism by which vitamin A functions in the visual cycle was the first o f its actions to be 
elucidated, by Wald in 1968.' In the retina o f the eye 1 l-c/^-retinal acts as the chromophore o f 
rhodopsin: one molecule o f 11-cw-retinal is isomerised by one photon o f light to aW-trans retinal, 
which initiates a nerve impulse that is perceived as light. In vertebrates, aW-trans retinal is then 
enzymatically re-isomerised to 11-cw-retinal to complete the cycle.''"^' 
Progress in extra-visual retinoid research, beyond the systematic medicinal chemistry approach o f 
designing, synthesising and testing libraries o f compounds in the search for enhanced therapeutic 
efficacy, was previously impeded by a lack o f knowledge o f the nature o f the receptors that mediate 
the biological activity o f the retinoids. Specifically, how is it possible for such structurally simple 
molecules to exert such pleiotropic effects? The first key member o f the retinoid signalling pathway, a 
"Retinoic Acid Receptor" (now known as R A R - a O was identified in 1987, and heralded a greater 
understanding o f retinoid activities in vivo. The retinoid receptors have subsequently been classified 
into two subfamilies, each composed o f at least three isotypes - the retinoic acid receptors RAR-
a , ' " ' " R A R - P ' ^ ' ' " and RAR-y,'^" ' " and the retinoid X (or rexinoid) receptors RXR-a, RXR-p and 
RXR-y.'^^"'^" This categorisation is based upon differences in amino acid structure and ability to 
modulate gene expression o f various target genes, and is exemplified by their responsiveness toward 
natural and synthetic ligands: A T R A binds and activates all three RAR isoforms, while 9 -c«-RA 
activates both the RARs and RXRs. '^ '" '" 
In the absence o f a ligand, RAR-RXR heterodimers bind to retinoic acid response elements (RARE) in 
the promoter regions o f target genes and bind with co-repressor proteins which prevent transcriptional 
activation. Though rarely considered, gene silencing is itself essential for some developmental 
processes.'^'' Upon binding o f agonists for both RAR and RXR, the receptors undergo conformational 
changes that cause the co-repressors to be displaced, facilitating the recruitment o f co-activators, 
which initiate transcription (Figure 1-5).'""'^" Agonists and competitive antagonists bind at the same 
site within the core o f the ligand binding domain (LBD) , however antagonists appear to either disrupt 
the receptor structure to prevent co-activator b ind ing ' " ''^ or alternatively stabilise co-repressor 
binding in order to silence gene transcription.'^^ ' " 
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Figure 1-5: Mechanisms of transcriptional repression and activation by RAR-RXR heterodimers. In 
the absence of agonists, co-repressor complexes bind to the RAR-RXR heterodimer. The co-
repressors (CoRs) NCoR or SMRT link the heterodimer to histone deacetylases (HDACs) through 
SIN3. HDACs remove acetyl groups from nucleosomal histones, resulting in chromatin condensation 
and gene silencing. Binding of an agonist to the ligand-binding pocket induces an allosteric 
conformational change in the ligand-binding domain, including altered position of helix H12. This 
structural transition destabilises the interface with the co-repressor and allows interaction with co-
activators (CoAs) of the pl60 family (SRCl, TIF2 and A I B l in humans). CoAs recruit (or pre-exist in 
a complex with) histone acetyltransferases (HATs), such as CBP (CREB-binding protein) or p300. 
HAT action results in acetylation of histone amino-terminal tails, thereby inducing nucleosomal 
repulsion and chromatin decondensation. A third multi-subunit complex, variously termed thyroid-
hormone-receptor-associated protein (TRAP), vitamin D receptor-interacting protein (DRIP) or Srb 
and mediator protein-containing complex (SMCC) appears to establish contact with the basal 
transcription machinery, leading to increased frequency of transcription initiation. However, the order 
of formation, receptor selectivities and requirement for (or involvement in) transactivation of these 
complexes remain elusive.''* Abbreviations: RAR, retinoic acid receptor; RARE, retinoic acid 
response element; RXR, retinoid X (rexinoid) receptor. Adapted from Altucci and Gronemeyer, 
2001.'*' 
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The retinoid receptors are members o f the super-family o f steroid hormone receptors that function as 
regulators o f gene transcription.'^^ In excess o f 500 genes have been identified that are direct or 
indirect regulatory targets o f ATRA.'^* Nuclear receptors are ligand-inducible transcription factors 
which share a common architecture constituted of a DNA-binding domain and a ligand-binding 
domain ( L B D ) united by a short flexible hinge region (Figure 1-6).'^' The amino acid sequences of the 
C and E regions are highly conserved within RAR or RXR isotypes, whereas those o f the A / B and D 
regions are less well conserved.'''' In vitro, RARs predominantly bind to specific cognate response 
elements as heterodimers with RXRs,'^° which optimises their binding. 
149,181.182 RAR/RXR 
183,184 
heterodimers have been established as the functional units that transduce retinoid signals in vivo.' 
The RXRs, which can also bind in vivo to certain D N A response elements as homodimers,'^^"^ are 
heterodimerisation partners for a number o f other nuclear receptors including the thyroid hormone 
receptors,"' '^^''^^ vitamin D receptor'^*" '^' and peroxisome proliferator-activated receptor y (PPAR-
^ y i 9 o . i 9 i ^ p ^ . R X R g not bound to ligand) has been observed to form high-affinity homo-tetramers 
in solution,"" which dissociate rapidly upon ligand binding.' '^ The biological significance o f this 
phenomenon is unclear, though it is proposed that the tetramers could represent a storage form o f RXR 
in the cell. 194 
AF-1 
DNA binding 
domain (DBD) 
ligand binding domain ( L B D ) 
dimerisation domain 
AF-2 
r s 
A / B D F - C 0 2 H 
Figure 1-6: A schematic representation o f the six generic regions (A-F) present in steroid receptors. 
The NH2 terminal region (A/B) harbours a ligand-independent transcriptional activation function (AF-
1). Region C is the core DNA-binding domain, containing two highly conserved zinc finger motifs 
that target the receptor to specific D N A sequences known as hormone response elements. The hinge 
region (D) permits protein flexibility to allow for simultaneous receptor dimerisation and D N A 
binding. The ligand binding domain (E) includes a ligand-dependent activation function (AF-2) and 
dimerisation interface, it is adjoined to the C O 2 H terminal region (F). Adapted f rom Chawla et ai. 
2001. 179 
RAR-null and RXR-null mutant mice exhibit body-wide abnormalities, demonstrating the necessity o f 
both types o f receptor during development."^ Although gene disruption studies have revealed some 
functional redundancy among the different RAR isotypes, each RAR isotype performs unique 
functions in development and differentiation which cannot be entirely replaced by the actions of the 
other isotypes 74,195-198 The phenotypes observed are similar to those observed in vitamin A-deficient 
animals confirming their role in this pathway. 35,74 
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In the absence o f an RAR agonist, RXR agonists are unable to induce transcription. A ligand-bound 
RXR (holo-RXR) is unable to dissociate the CoR from apo-RAR and in this way the transcriptional 
activity o f RXR is described as subordinate to that of its RAR partner.'"'^"^ This phenomenon plays a 
crucial role in vivo in allowing RXRs to act concomitantly, within the same cell, as heterodimerisation 
partners for repression and for activation events in which they are transcriptionally active.'"^ 
Furthermore, RXR ligands have the ability to synergistically increase the potency o f RAR 
, i g , „ d 3 .99,200,20.-206 
1.5.1 Retinoid receptor complexity 
The retinoic acid receptors (RARs) and retinoid X receptors (RXRs) are each divided into three 
isotypes (-a, -p and - y ) which are encoded by genes on separate chromosomes and are differentially 
expressed within tissues. RAR-a is ubiquitous, R A R -P is common in heart, lung and spleen tissue and 
RAR-y is confined to lung and sk in . ' "" '* ' " " " ' RAR-a , P and y are more homologous to each other 
than the three RXR isotypes,^"* and the interspecies conservation o f a given member of the RAR 
subfamily (either a, P or y ) is much higher than the conservation between the three receptors within a 
given species.''* These observations indicate that each o f the RAR isotypes may perform specific 
functions. Each isotype can be further divided into a number of different isoforms with distinct 
regulatory and functional properties by the differential use o f two promoters and alternative splicing. 
There are two major isoforms for RAR-a ( a i and 02) and for RAR -y ( y i and y2), and five major 
isoforms for RAR -P ( p i to P s ) . Similarly, at least two isoforms have been identified for RXR-a ( U i 
and ai), RXR -P ( p i and P2) and RXR -y ( y i and y , ) '''.'^'•209,2io pu^hermore, a group o f receptors which 
lack identified ligands, termed retinoic acid-related orphan receptors (RORs), are known.^" This 
receptor diversity, as part o f a complex retinoid pathway, may go someway towards explaining the 
pleiotropic effects o f retinoids.•^°' 
The endogenous ligands for these receptors are A T R A , its natural geometric isomers 9-c/5-RA and 13-
c / j -RA and a number o f its metabolites. A large number o f synthetic retinoids have been prepared and 
many o f these bind to one or more retinoid receptors, although some possess some functionality 
independent o f the retinoid pathway."'^ The RARs and RXRs show differing aff ini ty towards 
individual ligands, which may also be concentration dependent, providing further evidence that the 
receptors may possess individual physiological roles that are yet to be fu l ly understood."" 
Activation of the RARs appears to be involved in mediating the systemic toxicity and teratogenicity of 
A T R A , TTNPB (structure D, Appendix 1) and several other synthetic retinoids. RXR-exclusive 
agonists elicit a minimal or much weaker teratogenic response than RAR a g o n i s t s . R X R activation 
also confers alternative biological activity to that of RAR agonists, by virtue o f their ability to 
heterodimerise with other receptors. Rexinoids are able to inhibit cell proliferation and induce 
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differentiation but, unlike RAR agonists, are themselves poor inducers o f apoptosis."'^ These 
properties have led to the development o f synthetic agonists that selectively activate RXR without 
influencing the activity o f the RARs."'^"' ' Compounds such as Targretin® (bexarotene, LGD1069, 
Ligand Pharmaceuticals, E ) and LG100268 (Ligand Pharmaceuticals, F ) are being investigated as 
potential therapies for the treatment of cancer, diabetes and other metabolic disorders."'^ "'^ 
Numerous receptor-selective agonists and antagonists have been designed, synthesised and tested in an 
attempt to delineate the structural biology o f the RARs and RXRs and their physiological 
roles.'"'"'' " " " " ' It was hoped that targeting the activation o f individual receptors would separate the 
multiple biological effects o f the natural retinoids and thus increase therapeutic efficacy whilst 
minimising the adverse effects that result from non-specifically activating all receptors."" However, 
this approach has yet to yield clinical results: the complexity o f the retinoid molecular pathway is not 
so easily overcome. 
Early in vitro experiments identified 9-c/5-RA as a ligand for RXR and also found it in animal 
tissues.'*' '^" Although generally accepted as the endogenous ligand for RXR, subsequent studies 
performed at low levels o f detection and quantitation have failed to detect 9-m-RA,"^^ leading to 
uncertainty.'*•"'' " " Its initial discovery may be attributable to the extreme sensitivity o f A T R A towards 
spontaneous isomerisation."'' ""^  The heterodimeric partner for RAR is RXR, but it appears possible 
that a ligand other than 9-cis-RA may be responsible for RXR activation in vivo. Other low affinity 
endogenous ligands for RXR have been identified, including phytanic acid""^ and unsaturated fatty 
acids, particularly linoleic, linolenic and docosahexanenoic acids.""' ""* The isomerase involved in the 
visual pathway has been identified"^'"" and it has been inferred that this mechanism is also involved 
in controlling RAR/RXR transduction pathways. '" '" ' There is evidence that 9-cis-RA can be 
converted to A T R A in mammalian cells,"^ a thermodynamically favoured process,"'* but the reverse 
isomerisation was not observed."" CRBP-I and CRBP-II also recognise 9-CM-retinal, though not 13-
c/5-retinal,"" which may suggest that 9-c/j-RA could be derived from dietary 9-c;5-retinoids naturally 
present in human foodstuffs, since no evidence supporting an enzyme-catalysed isomerisation o f 
A T R A to 9-C/5-RA has been reported.""'"''•"' A specific cw-retinol dehydrogenase for the hepatic 
oxidation o f 9-c/5-retinol to 9-c/s-retinal has been identified and it has also been shown that 9-cis-
retinol can be esterified for storage and subsequently hydrolysed by retinyl ester hydrolase(s)."* 
Although these data are from in vitro models, the controversy surrounding the existence, mode o f 
synthesis and function o f 9-c/5-retinoic acid appears to be approaching a conclusion. 
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7.5.2 Retinoid receptor independent gene regulation and non-genomic effects 
In addition to modulating the retinoid receptor pathway, as described above, a number o f synthetic 
retinoids have also been found to activate additional pathways, which may enable wider therapeutic 
application."" For example, A G N 193109 (structure G ) a pan-RAR antagonist, and two very weak 
RAR-agonists, A G N 190730 (H) and CD437 (AGN 192837, A H P N , I ) induce the aryl hydrocarbon 
(AhR) signal transduction pathway at pharmacological concentrations."* The AhR pathway is 
involved in mediating response to xenobiotics, liver development and immune function."'"^"' 
A number o f compounds described as retinoid-related molecules (RRMs) or atypical retinoids possess 
some RAR-activating ability but also exert growth regulatory or apoptotic activity that is retinoid 
receptor independent.'^''" Fenretinide (4-hydroxy-phenylretinamide or 4-HPR, J ) , CD437 (I) and 
ST1926 ( K ) are three o f the most effective retinoids included in this classification.'^•"'•^''•''"'''' 
Fenretinide is a modest but highly selective agonist o f RAR-P"' '^ "''^ and RAR-y,^'" but also has some 
retinoid pathway independent functionality.^''*'"^'' It is an effective inducer o f apoptosis o f cancer 
cells,"^^ with good clinical results for a number of malignancies including neuroblastoma.^^^ "^ 
An important feature o f RXR specific agonists is their ability to heterodimerise with a number o f 
different nuclear receptors which permits them to affect multiple signal transduction pathways. For 
example, activation o f the PPAR-y or thyroid hormone receptor modulates energy metabolism."'* " * 
Targretin® (LGD1069, bexarotene, Ligand Pharmaceuticals, E ) and LG100268 (Ligand 
Pharmaceuticals, F ) modulate many regulatory networks to inhibit cell proliferation or to induce 
differentiation."' ' These properties help to explain the powerful chemotherapeutic activity that such 
compounds have demonstrated against a wide range o f cancers, including breast, prostate, non-small 
cell lung cancer and cutaneous T-cell lymphoma.""'^" Rexinoids are also able to synergistically 
enhance the activity o f RAR ligands."""'^"' " ' 
1.6 Therapeutic applications 
Due to their ability to modulate cellular proliferation and differentiation, and in some cases to exhibit 
anti-inflammatory effects, natural and synthetic retinoids have been used successfully in the treatment 
o f a variety o f skin disorders, including acne vulgaris and psoriasis, for many years.^^""^" Topical 
application o f tretinoin ( A T R A ) , isotretinoin (13-c/5-RA, Accutane®, Roche Laboratories and 
generics), adapalene (Differin®, Galderma Laboratories, CD271, L ) and tazarotene (Zorac®, Allergan 
Ltd. , M) are all currently licensed in the U K for one or both o f these conditions. The adamantane 
group o f adapalene confers a number o f beneficial properties for dermatological therapy. The 
compounds are found to have high melting points, resulting in low flux through the skin and hence 
low systemic toxicity, and low solubility which further sustains high levels of the drug in the skin.'*'' 
Treatment with oral retinoids, including acitretin (Neotigason®, Roche Products Ltd., N) , tretinoin and 
isotretinoin, may be more effective, but also results in more severe side-effects."" " " Topical treatment 
with 9-cis-RA (alitretinoin) is approved for AIDS-related Kaposi's sarcoma.'*' More recently, 
retinoids have also been used in 'cosmeceuticals', to induce non-genomic dermatological effects."** 
The only selective retinoid currently approved for therapy is Tamibarotene (Am80, P), an RAR-a/p 
agonist used to treat relapsed or refractory acute promyelocytic leukaemia (APL) in Japan."*' APL is 
associated with a chromosomal translocation of RAR-a, which typically fuses with a gene known as 
promyelocytic leukaemia (PML) silencing the activity o f the retinoic acid receptor.^** "*' Treatment 
with A T R A or Tamibarotene induces apoptosis o f APL cells and the breakdown of the PML-RAR-a 
chimeric gene, allowing normal differentiation and function to be r e g a i n e d . W h i l e the RAR-a 
selectivity and physical stability o f Tamibarotene may play a role in its efficacy, the most important 
features o f its clinical profile are that patients do not develop resistance,"" unlike ATRA-treatment 
which induces hyper-metabolism,""""* presumably via the CYP26 enzymes, and that it is less toxic 
than A T R A partially due to poor binding affinity for RAR-y.^*''"" 
The strong association between cancer development and vitamin A is well established and has led to 
extensive research into the potential o f retinoids to be used for chemotherapy and chemoprevention. 
Early studies established a link between the development o f some cancers and a low dietary intake o f 
retinoids' "* and aberrant expression o f the RARs and retinoid metabolism has been found in a number 
o f malignant tissues."*"* Retinoic acid can inhibit proliferation and induce differentiation in a variety 
o f human cell lines (Section 3.1). Promising pre-clincal data'*' led to a large number o f clinical trials 
to evaluate the preventative or therapeutic ability o f retinoids with mixed success."'* Despite all the 
hype, only a limited number o f indications have shown results that counter-balance the adverse 
effects."' 
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A T R A , 13-C/5-RA and fenretinide are three retinoids that have been used with some success as 
chemotherapeutic agents in the treatment o f neuroblastoma.^'*"^ However, the search continues to 
find a treatment with improved pharmacokinetic properties and improved clinical results. 9-cis-KA, 
13-C/5-RA and A T R A all readily isomerise in biological systems.^*" A T R A is the most 
thermodynamically stable isomer and is the major isomer at equilibrium.^"'' The activity of 13-c/'5-RA 
in neuroblastoma differentiation therapy and a number o f other fields is believed to be due to 
isomerism to ATRA."*''^*' 13-c;5-RA thus acts as a pro-drug for A T R A , enabling a controlled 
synthesis o f the active isomer and resulting in a reduction o f the toxic events induced by treatment 
with A T R A directly."'*"*' Furthermore, 13-c/s-RA is better absorbed f rom the intestine than either 9-
cis-RA or ATRA,^*" and is metabolised more slowly than 9-cw-RA, which results in greater exposure 
to the ATRA."*^ Despite promising in vitro results for 9-c/s-RA in neuroblastoma cells,^ *"*""** in vivo 
studies revealed elevated levels o f toxicity.^*''^** 
The atypical retinoid fenretinide induces apoptosis in a wide range o f cancer cell lines including 
neuroblastoma,'*^'"" myeloid leukaemia (HL60)" '" and breast cancer cell lines.^"^ Promising pre-
clinical data suggested an improved therapeutic index relative to standard retinoid therapy for a wide 
range o f tumours." While some cancers did not respond in clinical trials,^'^ a number of phase I I I 
trials for a number o f cancers including breast, prostate and bladder are ongoing."''' Fenretinide has 
also received orphan drug status^ for Ewings's sarcoma family o f tumours, primary malignant bone 
tumours and neuroblastoma."'' 
As previously discussed, pre-clinical results using rexinoids such as LG100268 and Targretin® show 
the potential to treat metabolic syndromes including diabetes and obesity.^'*'"* Targretin® has been 
approved for use in cutaneous T-cell lymphoma and has shown good results in clinical trials for non-
small cell lung cancer and breast cancer.'*''""'^'* 
Retinoids are also prime candidates for cancer chemoprevention since they regulate cell proliferation 
and differentiation, and cancer is associated with abnormal growth and with the loss of 
differentiation."' ' Cancer prevention by retinoids was first demonstrated in the 1970s,^'*'^" and is 
effective in suppressing the development of several types o f tumours in animal m o d e l s . H o w e v e r , 
clinical trials using natural and synthetic analogues have generally not been successful, for as yet 
unknown reasons.'"' Furthermore, where promising results have been obtained, the therapeutic index 
is so strongly balanced on the risk side, with the side-effects that accompany long-term treatment 
generally outweighing perceived benefit, that retinoids have failed to enter common use in this field.'"" 
^ Sponsors of orphan drugs are provided with financial Incentives to assist the development of treatments for rare 
diseases or conditions that would otherwise be prohibitively expensive and/or un-profitable to develop. 
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It is hoped that the new generation o f atypical retinoids may be more successful;""^ for example 
fenretinide has been shown to provide long-term prevention against secondary breast cancer.^"^ 
Retinoids can also augment the activity o f other biological and chemotherapeutic agents, offering 
potentially effective combination regimens.'' ' ' ' '•'°' Successful applications include overcoming 
tolerance to breast cancer treatments,^"^ enhancing the sensitivity o f tumours to cytotoxic agents and 
overcoming drug resis tance. '° ' '"'* These synergistic effects have provided the impetus for synthesis 
and evaluation o f mutual prodrugs, i.e. a hybrid drug linking two active compounds.^"' 
1.7 Limitations and adverse effects 
Pharmacological nuclear receptor ligands may serve as important therapeutic agents. However these 
exogenous ligands may alternatively or additionally transactivate other nuclear receptors and pathways 
with potentially deleterious effects.-"" Systemic retinoid therapy is limited by severe toxicity, 
teratogenicity and other side-effects which are collectively defined as retinoic acid syndrome (RAS). 
These adverse effects present with wide inter-patient variation and are potentially life-threatening.^" 
Whilst the etiology o f RAS is poorly understood, it is generally believed to stem from the pleiotropic 
nature o f A T R A , regulated by its pan-RAR activational properties. Indeed, rexinoid therapy is 
generally bener tolerated than treatment with RAR agonists.^'" Some selective retinoids are also better 
tolerated than A T R A , for example the administration o f RAR-a selective Am80 for A M L " " and acne 
treatment with adapalene, which is moderately selective for RAR-p/y.-"^'^'^ Patient-specific dosing, 
adjusted in response to clinical response, allows for differential pharmacokinetic responses and 
enables optimal plasma drug levels to be achieved whilst minimising the risk o f adverse events.^'" 
Furthermore, the most widely used and studied retinoid, oral 13-c/s-RA for acne treatment, is 
associated with human psychiatric disorders,^''"^" (confirmed by mice developing depression related 
behaviours,^'* although this has not been observed in rat studies^") causes varying degrees o f loss of 
night vision,^"" may increase risk factors o f atherosclerosis,^^' cause altered brain function and 
decreased brain metabolism,'"^ induce insulin resistance,'" and result in decreased neurogenesis and 
learning ability in exposed mice.'^'' 
The other major problem with retinoid therapy is the development o f resistance. Continuous A T R A -
treatment may induce the up-regulation of CYP26A1 resulting in hypercatabolism and lower drug 
plasma levels, leading to reduced drug sensitivity and resistance."'"'" '"* Employing a high-dose, 
intermittent regimen, rather than continuous low-dose treatment is one way to improve clinical 
outcomes.""'"' Resistance to ATRA-treatment in APL can be overcome by the administration of 
Am80, which is not metabolised by the CYP26 enzymes."""" Another approach is to administer 
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retinoic acid metabolism blocking agents ( R A M B A s ) which specifically block CYP26 act ivi ty." ' 
R A M B A s may permit an increase in endogenous retinoid levels for therapeutic benefit,"^ or 
alternatively act synergistically with A T R A or 13-c/5-RA to inhibit the development of A T R A -
resistance."" This approach may yield effective agents for the treatment and/or prevention of cancers 
and dermatological diseases and appears to circumvent the extreme toxicities and resistance to 
traditional retinoid therapy. 
The bioavailability o f orally administered retinoids is poor and erratic, which may l imit the usefulness 
and practicality o f this route."^" This is partly attributable to the poor aqueous solubility o f retinoids 
and a tendency to self-associate in aqueous environments."" A T R A may be stabilised by incorporation 
into lipid based carriers: this approach also improves aqueous solubility, maintains a more constant 
concentration o f A T R A in plasma and may permit targeted administration to reduce systemic toxicity. 
However, a clinical trail o f an ATRA-liposomal formulation to treat APL failed to show a significant 
improvement on traditional therapy."' "^ 
Improving drug formulations and administration protocols may increase the clinical benefit of existing 
and novel retinoids. Several patents have recently been issued for topical preparations including 
microemulsion and foam formulations and gelatine microsphere encapsulation. These preparations 
may increase the rate o f drug release and penetration, and microspheres are additionally able to protect 
A T R A f rom photo-degradation."^'"' 
1.8 Conclusions 
A large amount o f research been conducted to investigate the wide ranging and essential in vivo effects 
o f A T R A and attempt to harness the perceived potential therapeutic applications that retinoids offer. 
Members o f this family are used successfully in the treatment o f dermatological disorders, APL and 
neuroblastoma. However, even with the development o f selective synthetic retinoids, promising in 
vitro data and pre-clinical trials have generally not been translated into clinical treatments. O f 
particular note are the fields o f chemotherapy and chemoprevention, o f growing significance to 
modern medicine, where it would appear that alternative ( for example non-classical retinoid activity) 
or synergistic approaches may be required. Further work is clearly required to ful ly understand the 
molecular basis of retinoid activity and to expand the scope o f retinoid therapy. 
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CHAPTER 2: SYNTHESIS OF RETINOIC 
ACID ANALOGUES 
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2.1 Design and synthesis of retinoids 
2.1.1 Introduction 
The preparation o f synthetic analogues o f all-fram-retinoic acid ( A T R A ) was initiated in 1968 when 
Roche prepared a series o f compounds by modifying the structure o f retinol with the objective o f 
identifying compounds with a better therapeutic ratio than the parent compound.^"" Over the past forty 
years, more than 4000 retinoids have been prepared and tested in an attempt to realise the enormous 
clinical potential o f the retinoid pathway and to provide pharmacological tools to investigate the 
endogenous functions of A T R A and its receptors, the retinoic acid receptors (RARs). 
A T R A is characterised by its pleiotropic nature: its ability to induce multiple effects in the embryo and 
adult by modulating a large number o f genes.'"'"* Ligands that are able to strongly activate individual 
receptors may elicit more targeted activity in vivo, whilst minimising the adverse effects that may 
derive f rom the non-specific activation when A T R A is used therapeutically. A further aspect of 
retinoid design is to engineer a molecule with greater physical stability than A T R A , which is 
notoriously labile. 
2 . 1 2 Basic structural requirements for retinoid activity 
The relationship between structure and activity o f different retinoids was first recognised in the 
1970s.^"' It was quickly realised that each component o f the basic structure o f A T R A could be 
modified in order to achieve an improved biological response whilst also reducing adverse effects.^" 
Since then the iterative modification o f putative key portions o f the structure o f A T R A and concurrent 
biological evaluation o f the resulting retinoids, has gradually established the A T R A pharmacophore 
and acceptable bioisosteric replacements. (See reviews by Altucci et o/.,"' Kagechika et o/."''^"^ and 
Dawson.^'^) 
The crystal structures o f many o f the RAR and retinoid X receptor (RXR) ligand-binding domains, 
both unbound (apo) and bound (holo) to ligands have also been determined. (See Greschik and Moras, 
2003^"'' for review.) This information reveals the interactions between ligand and receptor, identifying 
the important structural features o f effective ligands, which has permitted molecular models to be 
developed for in silico modelling and analysis o f quantitative structure-activity relationships.^"""'"' 
Such methods are ideal for the rational design o f agonists and antagonists,^"* and are particularly 
useful for screening large numbers o f potential ligands.^"^ 
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linker region 
C O 2 H 
acidic function 
hydrophobic 
region 
Figure 2-1: A molecule o f A T R A annotated to show the three general regions that define the 
pharmacophoric groups necessary to confer binding o f retinoids to RAR and/or RXR. 
The pharmacophore o f a molecule is defined as the essential features o f a ligand that are required for 
biological activity and includes electronegativity, steric size and lipophilicity. Three key structural 
components are required for RAR and/or RXR binding aff ini ty , as depicted in Figure 2-1: 
1 A relatively planar lipophilic cyclohexene, annular or polycyclic group with alkyl substituents. 
This bulky group is relatively hydrophobic and forms many van der Waals interactions with 
the surrounding amino acid residues. 
2 Conjugated polyene or conformationally restricted electron-rich "linker" unit. When 
heteroatoms are incorporated into this region they may confer isotype specificity. This unit 
must also provide the correct spacing and orientation between the two other regions to enable 
the molecule to fit the ligand binding domain ( L B D ) . ' ' " 
3 A carboxylic acidic functional group or appropriate bioisostere. This moiety is involved in a 
hydrophobic network including salt bridges and hydrogen bonds."" Where a phenyl ring is 
present, optimal activation is achieved with groups which are para with respect to the rest o f 
the molecule, '" whereas ortho substitution results in a complete loss of activity, as the 
resulting compounds are unable to bind in any o f the RAR or RXR binding pockets.''" Meta 
isomers may have relatively reduced retinoidal activity or even induce a different pattern o f 
d i f ferent ion . ' " 
Rational modification o f this general moti f can be achieved by replacing single atoms or groups with 
bioisosteres that elicit similar biological activity due to common physicochemical properties.'" The 
building blocks that have been successfully utilised to generate RAR and RXR ligands are 
summarised by Altucci et a/,'" Lipinski's Rule o f Five, a model used to predict the absorption or 
permeation o f a compound, and hence its likely bioavailability, cannot be applied to the retinoids. 
According to this model, both A T R A and its geometric isomer 9-c/5-retinoic acid (9-c/5-RA, structure 
B in Appendix 1) are predicted to be poorly absorbed."'' 
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A T R A binds to all three RAR isotypes (RAR-a, RAR-P and RAR-y), whereas 9-cis-RA is a pan-RAR 
and pan-RXR agonist.'^'"'"'"^'^^^ Analysis o f /20/0-receptor crystal structures has revealed the 
complexity o f interactions that retinoid ligands make with their L B D , as exemplified by Figure 2-2. 
The LBDs o f apo-RAR and apo-RXR are globally similar, although they share only 27% sequence 
h o m o l o g y . A s might be predicted from comparison o f the molecular structures o f A T R A and 9-cis-
RA, the binding pocket of the RXRs is L-shaped whereas the RAR L B D is more elongated and 
linear.""' ''"'^^* Therefore only flexible ligands, such as 9-c/5-RA, possess pan-agonist properties."' 
H 7 ^ ^ ^ _ ^ HIO 
^ . U 5 ''''''' "-^-^^ r. 
V0I342 s 
Phe439 
=- • Cv.v432 
Trp-^ 05 
Ma27l^.. Asn306 
= Lcu30 
A.la272 
lTe3IO 
( n275 
Vrg3l6 \la.327 
Lcu326 
Figure 2-2: Depiction o f the interactions between the amino acids o f the human RXR-a ligand-
binding domain and 9-c/5-RA. Figure f rom Love et al., 2002,^°' using co-ordinates f rom entry 
IFBY.pdb^" in the RCSB Protein Data Bank.^*° 
There are only three variable amino acid residues in the iigand-binding pockets o f RAR-a , P and y; 
these residues and the interactions they form with isotype specific retinoids have been reviewed by 
Zusi et al."° and de Lera et a/." '^ This divergence explains the differences in the binding affinities of 
each RAR isotype for a ligand and is useful for the design o f receptor-specific retinoids. Accordingly, 
a number o f receptor subtype retinoids have been prepared for all three RAR isotypes and a number of 
different isoforms, although RXR subtype specificity is more elusive due to the highly conserved 
nature o f the RXR L B D s . " ' Specific retinoid and rexinoid antagonists have also been designed, 
prepared and tested.""''^"' One approach to the design o f antagonists is based upon inhibiting the 
folding o f helix 12 ( H I 2 ) , which normally seals the ligand cavity and permits recruitment of co-
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activators to permit transcription (refer to Section 1.5 for further d e t a i l ) . T h e s e compounds are 
useful for inhibiting the activity o f individual receptors in order to investigate their biological role and 
that o f any co-administered retinoids.^'^ 
2.13 Evolution of retinoid structure 
Retinoid development can be organised into a series of generations, charting the structural divergence 
f rom A T R A to compounds which superficially bear little resemblance to the parent compound. The 
structures presented in Appendix 1 illustrate the structural diversity o f this family. 
The first generation o f synthetic derivatives were based very closely on A T R A and include 13-c/5-
retinoic acid (13-C/5-RA, structure C in Appendix 1) and fenretinide (4-hydroxy-phenylretinamide or 
4-HPR, J ) . Substituting the A T R A 2,6,6'-trimethylcyclohex-l-enyl group for the aromatic 4-methoxy-
2,3,6-trimethyiphenyl group generated acitretin (N), the pharmacologically active metabolite o f 
etretinate. The third generation consists o f polyaromatic compounds, in which part or all o f the labile 
polyene chain is incorporated into one or more aromatic rings. Included in this group are arotinoids 
(for example TTNPB, D and Targretin®, E)^*^ and heteroarotinoids (for example Tazarotene®, M and 
Tamibarotene, o).""'^"*^'^^^ These retinoids have greater physical stability and the restrained 
conformations engender receptor selectivity. A fourth generation o f compounds could be said to be 
comprised o f retinoid related molecules, which are also known as atypical retinoids, including CD437 
(I) , ST 1926 ( K ) and Adapalene (CD271, L ) . These compounds posses retinoid receptor dependent and 
independent functionality and show great chemotherapeutic potential.^*'' 
2.1.4 Synthetic approaclies to ttie preparation of retinoids 
The first synthesis o f A T R A was reported in 1946.*' Since then, the arsenal o f reagents and reaction 
procedures available to the synthetic chemist has evolved substantially and more rigorous separation 
and characterisation techniques have been developed.'*' In addition to the continued preparation of 
novel retinoids, improved syntheses o f A T R A and clinically or commercially interesting compounds 
continue to exploit these new t e c h n o l o g i e s . T h e synthetic methodologies employed to prepare 
retinoids have been thoroughly reviewed over the years,*"''**""' and most recently and extensively by 
Dominguez et a/.'*' 
Further developments in understanding both the biological mechanism o f action of A T R A and 
synthetic retinoids and the therapeutic requirements for efficacious retinoids, coupled with superior 
modelling and novel synthetic methodologies, provide continued opportunity for the design and 
synthesis o f novel retinoids. 
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2.2 Experimental overview 
A number o f synthetic retinoid analogues were identified as targets to establish the retinoid research 
theme and demonstrate proof of concept: that retinoids can be successfully synthesised and used to 
induce differentiation in the human TERA2.cl.SP12 embryonal carcinoma (EC) cell line. For this 
reason, the molecules chosen closely resemble known ligands o f the retinoic acid receptors (RAR) 
and/or retinoid X receptors (RXR); the targets are shown in Figure 2-3. Compounds with a para 
carboxylic acid group are structurally similar to all-/ram-retinoic acid ( A T R A ) , while meta-COjW 
isomers more closely resemble the structure o f 13-c/5-retinoic acid (13-cw-RA). Similar receptor 
binding properties and biological activities to the natural retinoids are therefore expected, namely 
A T R A binds and strongly activates all RAR receptors, whilst 13-c/5-RA is a strong pan-RAR and pan-
RXR agonist. These structures are also ideal targets to apply new synthetic methodology developed in 
the Marder and Whit ing research groups. 
CO2H 
1ap = TTNPB 
1b m-isomer 
1c o-isomer 
CO2H 
2a p = 3Me-TTNPB 
2b m-isomer 
2c o-isomer 
COjH 
3:CEB16 
CO2H 
4: CEB17 
CO2H 
5: CEB18, TTNN 
Figure 2-3: Target molecules: l a , lb and Ic: (E)-4, 3 and 2-[2-(5,5',8,8'-tetramethyl-5,6,7,8-
tetrahydro-2-naphthalenyl)-l-propenyl] benzoic acids. 2a, 2b and 2c: (E)- 4, 3 and 2-[2-(3,5,5',8,8'-
pentamethyl-5,6,7,8-tetrahydro-2-naphthalenyl)-l-propenyl] benzoic acids. 3-4: 3-[3 and 4-(5,5',8,8'-
tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl) phenyl]-acrylic acid respectively. 5: 6-(5,5',8,8'-
tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)naphthalene-2-carboxylic acid. 
26 
Compounds 3, 4 and 5 were prepared and carefully purified by the author. The preparation o f 
molecules la-c and 2a-c built upon previous work within Professor Marder's research group. Due to 
problematic synthesis, and a change in project direction, only partial synthesis o f these compounds is 
presented. 
The compounds are based on a l,r,4,4'-tetramethyl-l,2,3,4-tetrahydronaphthalene or 1,2,3,4-
tetrahydro-l,r,4,4',6-pentamethylnaphthalene lipophilic core. These cyclic moieties have been used 
extensively in the preparation o f synthetic retinoids, detailed in a recent extensive review by 
Dawson,"'^ as a bioisostere for the trimethylcyclohexyl group o f A T R A . Extensive structure activity 
relationship studies have shown that minor modifications and substitutions to this structure are 
tolerated without loss o f biological activity; the two geminal dimethyl groups at positions 1 and 4 
confer optimal activation and activity.^" The dimethyl groups in the 4-position block catabolism by 
hydroxylation by the major CYP enzymes involved in the degradation of A T R A . ' ^ ' The labile polyene 
chain o f A T R A is replaced by cyclic bioisosteres constraining the structure and conferring optimal 
activation, selectivity and stability on the synthetic retinoids. 
2.3 Preparation of TTNPB and its isomers 
Commencing with the commercially available l,r,4,4'-tetramethyl-l,2,3,4-tetrahydronaphthalene 6, a 
four-step reaction sequence o f alternating C-H activation and Suzuki-Miyaura coupling reactions was 
one step away f rom yielding TTNPB and its ortho- and /77e;a-isomers ( l a , lb and Ic) . Each step 
required optimisation, yields were often low and all reactions problematic to purify. 
2.3.1 C-H activation using iridium (l)/dtbpy 
5 mol% lrCI(C0E)2/ 
py, hexane, 80 
2 days, 60% 
dtb °C 
+ leq . B2Pin2 ^ 
Equation 2-1: lridium(l)/dtbpy catalysed borylation of 6. 
The first reaction in this sequence utilises the C-H activation methodology developed within the 
Marder group""""'' and an iridium (I) catalyst system devised by Ishiyama et with the di-
boron reagent bis(pinacolato)diboron (B2pin2). Di-boron reagents including B2pin2, 
bis(catechol)diboron (B2cat2) and bis(neopentylglycolato)diboron (B2neop2) can be used to 
functionalise a range o f organic s u b s t r a t e s . S i g n i f i c a n t features o f these reaction conditions 
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include: the use o f a non-polar solvent to facilitate faster reaction rates than more coordinating 
solvents such as D M E and D M F " ' and a strongly electron donating ligand, 4,4'-di-fe/-r-butyl-2,2'-
bipyridine (dtbpy), which is significantly more efficient than alkylphosphine ligands in Ir-catalysed 
aromatic C-H borylation. dtbpy enerates a relatively soluble iridium complex and, in combination with 
lr(CI)(C0E)2 as a catalyst precursor, enables high-yielding and efficient room-temperature 
reac t ions . " ' " ' "* 
This reaction was performed using a high catalyst loading (20 mol%) to ensure that the reaction would 
achieve complete consumption o f the starting material. This was achieved within 24 hours, and after 
work-up and purification the isolated yield was 90%. The reaction was subsequently repeated using a 
standard catalyst loading o f 5 mol%: under these conditions, only 55% conversion o f starting material 
was achieved. 
Small-scale test reactions using two different solvents (THF and cyclohexane) gave satisfactory 
consumption o f starting material and apparently clean product, as determined by GC-MS analysis of 
the reaction mixtures. However, when the reaction was performed on a larger scale (3 g) a by-product 
was observed (approximately 10% o f the final product, as estimated by GC-MS and " B N M R ) . From 
the mass ion o f 238 m/z and fragmentation pattern, the identity o f this product was determined to be 
COE-Bpin, from reaction o f B2pin2 with excess catalyst. Silica gel chromatography (1:1 
hexanes:DCM) failed to remove this impurity. The first preparation o f 7 was, therefore, used without 
further purification. Small-scale re-crystallisation from hot hexane subsequently yielded pure white 
crystalline material for characterisation. 
2.3.2 Optimising the Suzul<i-Miyaura coupling reaction between alkylboronate 7 and 
2-bromopropene 
1.1 cq. 
Pd catalyst, base 
or microwave 
Equation 2-2: Overview of Suzuki-Miyaura coupling o f 7 with 2-bromopropene. 
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Suitably functionalised, the next step was to couple 7 wi th 2-bromopropene to create the linker region 
o f the arotinoid. C-C bonds can be formed using a wide range o f different catalysts and reaction 
conditions,'*' however, the palladium-catalysed Suzuki-Miyaura cross-coupling reaction'*'*''*' is 
particularly well suited to the synthesis o f thermally unstable retinoids due to the mild reaction 
conditions.'** In total, six different experimental conditions were attempted to try to minimise 
formation o f 9, an oxidatively coupled homodimer. Catalyst, base, solvent and energy source were all 
varied in the five conditions described in Table 2-1. 
Table 2-1: Reaction variables for Suzuki-Miyaura coupling o f 7 and 2-bromopropene. 
R
ea
ct
io
n 
Catalyst 
system 
Base Solvent(s) 
Reaction 
Conditions 
Inert 
atmosphere 
& degassed 
solvents? 
no 
Approx. % of 
products * 
T M = 4 0 
HC = 25 
0 = 35 
R
ea
ct
io
n 
5 m o l % 
Pd(PPh3)2Cl2 
3 equiv. 
K3PO4 
1:6 
H20:dioxane 
microwave: 
150 °C, 300 W, 
60 min 
ii 
5 m o l % 
Pd(PPh3)2Cl2 
3 equiv. 
K2CO3 
1:6 
H20:dioxane 
microwave: 
100 °C, 300 W, 30 min 
then: 
150 °C, 300 W, 60 min 
no 
S!yi = 65, T M = 10 
HC = 25 
S M = 2 0 , T1V1= 15 
HC = 50, 0 = 15 
iii 
1 0 m o l % 
Pd(0Ac)2/ 
PPh3 
2.5 equiv. 
K3PO4 
1:5 
H20:dioxane 
thermal: 
80 °C, 19 h 
yes 
T M =25 
HC = 50 
0 = 25 
iv 5 m o l % 
Pd(dppf)Cl2 
1.5 equiv. 
K3PO4 
1:5 
H20 :DMF 
thermal: 
80 °C, 19 h yes 
S M = 5 ,TM = 55 
H C = 15 , 0 = 25 t 
V 
5 m o l % 
Pd(dppOCl2 
2.5 equiv. 
K3PO4.2H2O 
D M F 
thermal: 
80 °C, 19 h 
yes 
T M = 80 
HC = 5 
0 = 15 
* % o f each component in reaction mixture estimated by GC-MS: 
SM = starting material (7) 
T M = target molecule (8) 
HC = homo-coupled product (9) 
O = other un-determined by-product(s) 
t % of each component in crude product estimated by GC-MS 
Microwave irradiation has been favourably reviewed as a convenient, rate-enhancing method o f 
conducting a variety o f reactions, especially palladium catalysed coup l ings . ' * ' " ° Using conditions ( i ) 
and ( i i ) , notably without excluding oxygen, significant amounts o f a by-product were produced, which 
was identified as the homo-coupled product 9 by MS, without isolation. GC-MS analysis o f the 
reaction mixtures was used to determine the product composition o f the test reactions to compare the 
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different conditions. It should be noted that these GC-MS yields have not been standardised, so should 
only be viewed as an approximation. GC peak area is a function o f the total ions detected by the MS, 
which is dependent upon the relative ionisation abilities o f the different components of a sample. 
Using an inert atmosphere and thermal heating in ( i i i ) produced less homo-coupling. Changing the 
catalyst and solvent, and reducing the quantity of base ( iv) did reduce the quantity of 9 generated, but 
also appeared to increase the formation o f other by-products. It was therefore decided to try an 
alternative approach and replace the water added to the organic solvent with a hydrated base, to 
provide the trace amount o f water required for the reaction. The results obtained in (v) were a 
significant improvement, so were used on a one gram scale reaction. However, work-up and 
purification were problematic, such that the isolated yield was only 45%. 
Next, the microwave and thermal reaction conditions were compared directly using the best 
catalyst/base/solvent system (v). Both reactions were prepared in the glove box using the same starting 
materials, yet it can be seen from Table 2-2 that the two different conditions gave distinctly different 
product mixtures. 
Table 2-2: Direct comparison o f microwave and thermal Suzuki-Miyaura reactions 
Energy Source Microwave Thermal 
Reaction conditions 
60 min 
150 °C, 150 W 
4 hours 
80 °C 
23 hours 
80 °C 
Approx. % of 
products 
S M 0 20 10 
T M 30 50 50 
H C 10 15 25 
O 60 15 15 
In the microwave experiment all starting material was consumed within 60 minutes and the quantity o f 
homo-coupled product generated was low, but the yield o f desired product was poor. Thermal reaction 
conditions produced more homo-coupling than previously observed and product yield was also 
unsatisfactory. 
Finally, reaction conditions published for the coupling o f 5,6-dibromoacenaphthene with 4-methoxy 
phenyl boronic acid were attempted. These were much more successful with only 2% o f 9 detected in 
the reaction mixture. Using 3-4 mo l% Pd(PPh3)4 as catalyst and 2.5 equivalents o f Ba(OH)2.8H20 in a 
mixture o f 7y,A^-dimethylacetamide / HjO (5:1)^" improved the quaternerisation o f the boron atom, 
favouring formation o f 8 (isolated yield 95%, purity >95%). 
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2.3.3 Vinyl C-H activation using rtiodium Vasl<a's catalyst 
+ l . l e q . D2pin2 
3 mol% lffa/7s-RhCI(CO)(PPh3)2] 
toluene / acetonitrile (3:1) 
80°C, 20 hours, 18% 
Equation 2-3: C - H activation o f 8 to give vinylboronate 10. 
Preparation o f the second pinacolboron, 10, was achieved via another transition metal catalysed 
borylation to activate the propene for further reaction. 3 mol % o f rhodium Vaska's catalyst [trans-
Rh(CI)(CO)(PPh3)2],^'^ was used and the reaction was complete in under 43 hours. Attempted 
purification by silica gel chromatography yielded an impure yellow o i l , containing residual B2pin2. 
Washing with methanol solidified the product, and recrystallisation f rom hot hexane gave an impure 
off-white solid. Only one alkenic proton was observed by ' H N M R , indicating that only one isomer o f 
10 was formed. Due to the steric bulk o f the pinacol group this was expected to be the E isomer, 
which was confirmed by X-ray crystallography.'" 
2.3.4 Proposed final step - preparation of retinoids 
Insufficient alkeneboronate (10) was available to attempt the final coupling steps: three Suzuki-
Miyaura couplings with o-, m- and p- iodobenzoic acids to give (£)-2, 3 and ¥-[2-(5,5,8,8-tetramethyl-
5,6,7,8-tetrahydro-2-naphthalenyl)-l-propenyl] benzoic acids, I c , l b and l a , respectively (Equation 
2-4). 
Suzuki-Miyaura coupling 
0. m. p-iodo-benzoic acids 
CO2H 
1ap = TTNPB 
1b m-isomer 
1c o-isomer 
Equation 2-4: Proposed synthesis o f la , lb and Ic . 
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2.4 Preparation of 3-IVIe TTNPB series of compounds 
The initial steps used to prepare 3-Me TTNPB and its ortho- and we/a-isomers (2a, 2c and 2b 
respectively) are well established and use classical reactions (Scheme 2-1).""'^'^ The Ir(I)/dtbpy 
borylation used to prepare 7 cannot be used with 13 as the substrate because the reaction is sterically 
disfavoured. 
c, HCl 
RT, 2 hours 
» 
59% 
2 eq. toluene 
2.3eq. AICI3 
DCM, RT/reflux 
1 hour, 84% 
2.7 eq. C H 3 C O C I 
2.6 eq. AlCI, 
DCM, reflux 
30 mins 
83% 
Scheme 2-1: Initial reactions towards the preparation o f 2a, 2b and 2c. 
The commercially available diol starting material 11 was cleanly and easily converted to the di-chloro 
alkane 12. Friedel-Crafts alkylation o f 12 to give 13 was followed by Friedel-Crafts acylation with 
acetyl chloride to give a good yield o f ketone 14. The alkylation reaction produced a by-product, 
identified as 1,2,3,4-tetrahydro-l ,r,4,4',6,7-hexamethylnaphthalene by GC-MS, formed by the 
reaction o f 12 with trace amounts o f xylene that were present in the toluene. Xylene is more reactive 
than toluene in this reaction and therefore magnified a trace impurity to a notable by-product. 
1.6 eq. CHjPPhjl 
2.0 eq. r-BuGH 
THF, RT 
24h 
16 t 
Suzuki-Miyaura coupling 
0, m, p-iodo-benzoic acids 
[frans-RhCI(CO)(PPh3)2l 
I > 
CO2H 
2a p = 3Me-TTNPB 
2b m-isomer 
2c o-isomer 
Scheme 2-2: Proposed synthetic route to complete the preparation o f 3Me-TTNPB and its isomers. 
The final proposed reaction steps to complete the synthesis o f 2a, 2b and 2c are detailed in Scheme 
2-2. Subjecting 14 to a Wit t ig reaction produced olefin 15, though these reaction conditions produced 
large quantities o f PPhsO which were di f f icul t to remove from the product.^'* (Product 15 was worked 
up by Dr. Ibraheem Mkhalid.) The final proposed reactions are a rhodium catalysed dehydrogenative 
borylation to produce the vinylboronate ester 16 and finally Suzuki-Miyaura coupling o f iodo- or 
bromo-benzoic acids to give 2a, 2b and 2c. 
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2.5 Synthesis of a naphthoic acid and two acrylic acid retinoids 
Three retinoid analogues, known as CEB16, CEB17 and CEB18 (3, 4 and 5 respectively) were 
prepared in one step from alkylboronate (7). The Suzuki-Miyaura coupling reaction was used to react 
7 with 3- and 4-bromocinnamic acids and 6-bromo-2-naphthoic acid to produce retinoids 3, 4 and 5 
respectively (Scheme 2-3). 
1.1 eq. 
Br 
7 + l . leq. 
Br 
CO2H 
CO2H 
CO2H 
3 mol% Pd(PPh3)4 
2.5 eq. Ba(OH)2.2H20 
N,N-DMA/H20(5:1) 
80 °C, 3 d 
3 = CEB16 
37°/! 
4 = CEB17 
66°/, 
5 = CEB18 
41% 
CO2H 
CO2H 
CO2H 
Scheme 2-3: Preparation o f CEB16 (3), CEB17 (4) and CEBI8 (5). 
Analysis o f the reaction mixtures by GC-MS showed complete consumption o f 7, but little or no 
product was detected. ' H N M R analysis confirmed that the major products were the target molecules. 
The crude products o f 4 and 5 were contaminated with approximately 25 and 10 mol% respectively o f 
their respective bromide starting materials. The trans-geometry o f the double bonds o f 3 and 4 was 
established by ' H N M R ; the spectra o f both products displayed two doublets with coupling constants 
o f -16 Hz for the vinylic protons whereas the Z-isomers would be expected to have smaller coupling 
constants o f - 1 2 . 5 Hz. 
A major problem with the handling and purification o f these products was their low solubility, which 
resulted in low yields. During work-up, excess EtOAc was used to dissolve and extract all the 
products. During subsequent purification, EtOAc was used to dissolve 3, toluene to dissolve 4, and 
acetone to dissolve 5. The use o f such solvents is not ideal, as they tend to dissolve anything else they 
come into contact with, and purification on the basis o f differences in solubility is poor. 
A l l three products were purified by passing through a silica pad (deactivating the silica by washing 
with dilute acid may have helped to prevent the compounds sticking) to remove the catalyst from the 
crude product. Column chromatography failed to remove residual starting material f rom 4 and 5. Final 
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purification was achieved by multiple re-crystallisations from EtOAc (3), toluene (4), or acetone (5), 
to yield white crystalline products. Crystals suitable for diffraction were grown during re-
crystallisation o f 4 and 5. Final yields (o f completely pure material suitable for biological testing) 
were 37% (CEB16, 3), 66% (CEBI7 , 4) and 4 1 % (CEB18, 5). 
2.6 Crystal structures 
A number o f both the intermediate compounds and target retinoids synthesised thus far have been 
found to be crystalline. Single crystals suitable for X-ray diffraction have been grown for four of the 
compounds described (4, 5, 20 and 26). The crystal structures o f compounds 11, 15, 18 and 21 had 
been solved previously."^ The results o f the crystallographic refinements are summarised in Appendix 
2. 
Crystal structures o f the retinoids provide valuable data about the orientation o f the molecule in the 
solid state and, in combination with the structures o f RAR and R X R nuclear receptor ligand-binding 
pockets, may enable a greater understanding o f the molecular interactions involved in successful 
binding. The crystal structures o f many o f the RAR and R X R ligand-binding domains bound to 
agonists and antagonists have been determined."'^"'' This information w i l l guide the rational design o f 
ligands,'"^ and permit in silico modelling o f receptor-ligand complexes - a particularly useful 
technique for screening large numbers o f potential ligands.^'*^ 
C(20) 
Figure 2-4: Single molecule of 4-[4-(5,6,7,8-tetrahydro-5,5',8,8'-tetramethyl-2-napthalenyl)phenyl] 
acrylic acid (CEB17, 4). Triclinic crystals (space group P-1) were grown f rom a concentrated solution 
o f CEB17 in toluene at low temperature. The dihedral angle between the l,r,4,4'-tetramethyI-1,2,3,4-
tetrahydronaphthalene and cinnamic acid groups is 39.5°. The crystals show disorder over two 
crystallographically independent positions with occupancy of 37% and 63%. 
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Figure 2-5: Six molecules o f CEB17 (4). The packing mot i f consists o f parallel stacks o f dimers, 
which are formed through intermolecular 0 -H. . .H hydrogen bonds. 
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Figure 2-6: 6-(l,]',4,4 '-tetramethyl-l,2,3,4-tetrahydro-6-naphthyl)-2-napthalene carboxylic acid 
(CEB18, 5) also crystallises with two crystallographically disordered independent positions. Triclinic 
crystals (space group P-1) were grown f rom a concentrated solution of 5 in acetone at low 
temperature. The two disordered molecules are almost co-planar (2.4°), the dihedral angle between the 
l,r,4,4 '-tetramethyl-l,2,3,4-tetrahydronaphthalene group and the naphthoic acid groups is 31.1° for 
the major molecule and 28.8° for the minor, which have occupancies o f 63% and 37% respectively. 
This compound also dimerises through intermolecular hydrogen bonding. 
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Figure 2-7: Single molecule o f (5,6,7,8-tetrahydro-3,5,5',8,8'-pentamethyl-2-naphthyl)ethan-l-one 
(14). Orthorhombic crystals (space group P2i2 |2i) were grown by slow evaporation o f solvent from a 
concentrated solution o f 14 in ethyl acetate. 
Figure 2-8: Single molecule o f 6-bromo-l,r,4,4'-tetramethyl-l,2,3,4-tetrahydronaphthalene (17). 
Monoclinic crystals (space group P2(l)/c) were grown from a concentrated methanolic solution o f 17 
at low temperature. 
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2.7 Conclusions 
These experiments illustrate the successful application o f emerging C-H activation methodologies to 
the preparation o f biologically active retinoids. Three compounds (3, 4 and 5) were prepared, 
rigorously purified and have been screened for biological activity (Chapter 3). Significant progress 
was also made towards the synthesis o f two groups o f styrene arotinoids (1 and 2), investigating and 
optimising the reactions. However, due to low yields after rigorous purification o f the intermediates, 
insufficient material was available to complete the synthesis. The meta and para isomers o f the methyl 
esters of both TTNPB and 3-Me TTNPB series have subsequently been prepared by other 
researchers.^'^ TTNPB is a strong pan-RAR agonist and the archetypal arotinoid which served as a 
lead for a large number o f analogues.^"'• '"• ' ' '• ' '*^™ Introducing the sterically demanding methyl group 
at the 3 position produces eclipsed torsional interactions that force TTNPB from its near co-planar 
conformation such that the benzoic acid and pentamethyltetrahydronaphthalene groups lie orthogonal 
to each other. In this conformation, 3-Me TTNPB has a 50-fold selectivity for RXR over RAR.^' ' 
Crude purification o f intermediates should be performed throughout the synthesis, but ultimately the 
final product must be completely pure to be useful for biological testing. Any impurities may 
themselves effect cell differentiation, disrupt the normal behaviour o f the cells or interact with the 
retinoid. I f the identity o f impurities is known they can be tested alongside the target molecules with 
the aim o f subtracting any observed effect. The only incidental advantage to this would be the 
preliminary assessment of cytotoxicity of impurities, which may help to assess the tolerance o f 
impurities. Fortunately less than 10 mg o f material is sufficient to perform initial biological screening. 
The retinoids CEB16 (3), CEB17 (4) and CEB18 (5) were problematic to purify. It should be possible 
to improve the yield and simplify the purification o f these compounds by reducing the proportion of 
bromo carboxylic acid starting materials. It would also be advantageous to the synthesis o f retinoids to 
develop HPLC methods to analyse and purify the products. Such methods could also be used to 
determine the stability o f synthetic compounds and perform simple metabolic studies in vitro. 
All-/A-<3«5-retinoic acid ( A T R A ) is notoriously unstable and is readily isomerised when exposed to light 
and heat.'"" Over the past thirty years thousands o f synthetic retinoids have been designed by 
modifying the structure o f the natural retinoids with numerous permutations of hydrophobic rings, 
linker groups and bioisosteres for carboxylic acid.'" Some of the resuhing compounds have been 
found to be agonists or antagonists o f individual or multiple isoforms o f the RAR and RXR receptors. 
Replacing the labile polyene chain of A T R A and modifying other elements o f its structure is likely to 
increase the stability o f the compound and improve selectivity for one or more o f the receptor binding 
domains. Compounds CEB16 (3), CEB17 (4) and CEB18 (5) proved to be stable during synthesis and 
lengthy purification and a preliminary stability study confirmed that these compounds were more 
stable than the natural retinoids under daylight and after heating although CEB16 (3) and CEB17 (4) 
decomposed slightly on exposure to U V light.""' 
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CHAPTER 3: BIOLOGICAL SCREENING 
AND CHARACTERISATION OF NATURAL 
& SYNTHETIC RETINOIDS IN HUMAN 
E C STEM C E L L S 
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3.1 In vitro retinoid screening 
3.1.1 Introduction 
All-frara-retinoic acid ( A T R A ) , the parent compound o f a large family o f natural and synthetic 
retinoids, possesses a wide range o f fundamental endogenous activities that are believed to present 
considerable opportunity for clinical therapy (see Section 1.6). In order to study the biological effects 
o f retinoids, and thus explore their therapeutic potential, a suitable model system o f an appropriate 
endogenous effect must be identified. Classical retinoids bind and activate one or more o f the retinoic 
acid receptors (RARs) or retinoid X receptors (RXRs) to control the expression o f their target genes 
and realise their biological effects.^"''^^ Many researchers have therefore used retinoid receptor 
binding and transactivation assays to compare the effects o f novel retinoids using various cell types, as 
appropriate to the investigators' area o f interest."*"^ Although well suited to high-throughput 
screening,"" not only does binding aff ini ty not correlate directly with ability to activate receptors, but 
the data f rom different assays may give inconsistent r e s u l t s . F o r example, the synthetic retinoid 
Am580 (Table 3-1) is described as an RAR-a selective agonist in its binding aff ini ty, but actually 
transactivates all three RAR isotypes.^^'"'"'"'"'^ 
It is therefore preferable to use functional assays to investigate characteristic gene expression. Early 
structure-activity relationship (SAR) studies utilised the standard hamster tracheal organ culture 
(TOC) assay, which measures the ability o f biologically active retinoids to reverse keratinisation.^'" '"'' 
More recently, stem cells have been used extensively to investigate the ability o f retinoids to control 
cellular differentiation in an in vitro model system that closely resembles in vivo development.'"'*''"" 
The characteristic ability o f classical retinoids to induce differentiation is o f particular interest as 
retinoids have great potential to act as chemo-preventative and chemo-therapeutic agents. 12,301 
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3.1.2 Stem cells 
Stem cells are characterised by two fundamental properties: their capacity to self-renew by generating 
identical progeny and the ability to differentiate into multiple yet distinct specialised cell types. A t 
each cell division the alternative outcomes o f self-renewal and differentiation are decided by the 
interplay between intrinsic factors and extrinsic instructive or selective signals."'""'"^ During the course 
o f development, totipotent stem cells o f the zygote that have the potential to form all types o f cells in 
the foetus or adult are succeeded by those wi th a more restricted potential. These multipotent stem 
cells differentiate into a smaller range of cell types as exemplified by embryonic neural stem cells that 
differentiate into neurons, astrocytes, and oligodendrocytes.'"'* '*'^  A l l tissues o f the embryo are derived 
f rom the three germ layers o f the inner cell mass (Figure 3-1). Stem cells that are able to differentiate 
into cell types o f the mesodenn, ectoderm and endoderm, either in response to exogenous stimuli or 
when xenographed, are described as pluripotent and offer the most representative model o f embryonic 
development. 
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Figure 3-1: Human development begins when a sperm fertilises an egg and creates a single cell that 
has the potential to form an entire organism, called the zygote. In the first hours after fertilisation, this 
cell divides into identical cells. These cells then begin to specialise, forming a hollow sphere of cells, 
called a blastocyst. The blastocyst has an outer layer o f cells (yellow), and inside this hollow sphere, 
there is a cluster o f cells called the inner cell mass (light blue). The inner cell mass can give rise to 
germ cells, as wel l as cells derived f rom all three germ layers (ectoderm, light blue; mesoderm, light 
green; and endoderm, light yellow), including nerve cells, muscle cells, skin cells, blood cells, bone 
cells, and cartilage. Figure f rom National Institutes o f Health website.'"^ 
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Embryonal carcinoma (EC) cells are the stem cells o f teratocarcinomas, i.e. germ cell tumours, which 
contain an array o f haphazardly arranged differentiated cell types and are thought to reflect the process 
o f embryonic development/'^""" In vitro cultures o f EC cells were initially obtained from murine 
xenografts and subsequently isolated directly from tumours."'' "•^ Although early teratocarcinoma lines 
showed little capacity for differentiation, EC lines were eventually obtained that were pluripotent and 
able to differentiate.''"' F9 and PI9 are two well characterised murine EC cell lines that have been used 
extensively as models o f early embryonal differentiation.''^"'''"'' Several human EC lineages have also 
been developed including TERA2.cl.SP12, which was clonally derived from TERA2 huEC cells.''"' 
TERA2.cl.SP12 cells were isolated from the more heterogeneous parent line to provide an EC model 
o f human embryonic development that is highly homogeneous and capable o f differentiating into both 
neurons and glia.'*"'"^* Although EC cells cannot yield any kind o f therapy directly due to their 
cancerous nature, such clones are useful models and aid the understanding of molecular mechanisms 
that control cell differentiation.''^^'''"* 
Embryonic stem (ES) cells are derived from the inner cell mass o f mammalian blastocysts. ES cells 
proliferate rapidly and infinitely while maintaining pluripotency and offer a greater differentiation 
potential than EC cells.""' Murine ES (muES) cells were first described in 1981,"^°" ' and have been 
used extensively in vitro to study the molecular control o f lineage commitment and differentiation. 
Human ES (huES) cells were finally isolated in 1998"" and are believed to hold great potential in the 
fields o f cell therapy, tissue engineering, drug discovery, in vitro toxicology and the chemical testing 
required under REACH.* 40^''"-435 ^ ^ i ^ ^ i^^p^j ^^^^ ^^^^5 ^.^H^ ^ ^ ^ i ^ j ^^^^^ ^^^^^ ^ ^^^^ 
degenerative diseases such as Alzheimer's, Parkinson's disease and diabetes."^^'"'* Unfortunately, the 
majority o f existing human ES cell lineages have been found to be contaminated with animal antigens, 
as they were established and maintained on animal-derived feeder layers and in media supplemented 
with foetal calf serum."" Though it is proposed that this xeno-antigen contamination is largely 
reversible,""" all stem cell lines derived using animal components are now considered unsuitable for 
human transplants. Human ES cells have subsequently been successfully derived under defined, 
animal-free conditions.""' """ 
Contentious ethical and supply issues have resulted in legislation governing the use of human embryos 
to produce ES cells."" ""^  Although there are many similar characteristics between mouse and human 
ES cells, there are clear differences between the gene expression profiles, growth requirements, 
expression o f surface markers, and response to various developmental signals."""""' It is therefore 
preferable to use human stem cells as an in vitro system in which to study embryonic development, 
since species differences may exist, making huEC cells a less controversial alternative for initial 
* Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) is an EU regulation that came 
into force in June 2007 to control the production and use of chemical substances. Chemicals must be tested to 
establish the effects on human health and the environment. 
studies. Furthermore, EC lines have several advantages as standards for comparison between 
laboratories: they grow without feeder cells, are relatively simple to passage, resist spontaneous 
differentiation, and are a rich source o f the proteins and mRNAs used to characterize huES cells."''^ It 
is therefore convenient for the researcher to use a more robust model, such as EC cells, that replicates 
the behaviour o f ES cel ls . ' -* ' ' " ' ' ' 
Stem cell pluripotency is maintained by the precise control o f a complex transcriptional regulatory 
ne twork ."*" ' The forced expression o f four o f these master regulators, Oct4, Sox2, K l f 4 , and c-Myc 
has recently enabled the reprogramming of somatic cells into induced pluripotent stem cells (iPS).'^°" 
'^^ This exciting discovery circumnavigates the ethical issues which hamper the derivation o f ES cells 
and could enable patient specific stem cells to be generated for stem cell therapy.' ' ' 
ES and EC cells can be propagated indefinitely in an undifferentiated state by maintaining them under 
optimal cuhure conditions. However, they also undergo differentiation to more specialised cell types 
spontaneously in response to exogenous stimuli and under sub-optimal culture conditions. '" A key 
step in controlling differentiation is defining the pathways that function in undifferentiated cells and 
the ways in which culture conditions and extrinsic factors can activate or repress them.' '" A wide 
range o f chemicals have been shown to potentiate the differentiation o f stem cells into numerous 
different cell types. Given its role as a putative morphogen, A T R A has been used extensively to 
induce the differentiation o f EC cells and ES cells in an attempt to delineate its in vivo roles.'"*'^' ' " 
Other agents including H M B A (hexamethylene bisacetamide)'"""*'" and DMSO (dimethyl 
sulfoxide)'"" '" ' also induce differentiation in EC cells, but result in distinctly different terminal cell 
types. A major barrier to the use o f ES cell-derived tissues for treating human disease is the inability to 
control, with high efficiency, the differentiation o f ES cells into transplantable precursors o f a specific 
lineage. Researchers therefore aim to develop a greater understanding o f the molecular mechanisms 
underlying pluripotency and differentiation to harness the potential o f ES cells. 
Despite the convenient nature o f cell culture, it is an inherently artificial environment for cell growth. 
Although efforts have been made to mimic the complexity and natural stimuli found in l iving tissue, 
for example through co-culture, three-dimensional scaffolds and surface functionalisation,'"""'"' the 
behaviour o f cells in vitro cannot be taken as ful ly representative o f developmental processes in 
animal or clinical studies. 
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3.13 Retinoid induced cell differentiation 
ATRA-induced differentiation o f stem cells has been widely reported and extensively 
characterised.'"'*'''"''"'^ Retinoid treatment typically induces a heterogeneous range o f cell types and its 
effects vary depending on the concentration and cell line, making it d i f f icul t to compare data.^'^ In PI9 
muEC cells A T R A induces endodermal and neural differentiation,''*''''^* whilst F9 muEC cells can be 
induced to differentiate into cells o f the endodermal lineage."" "*' The huEC cell line NTERA2/D1 
cells yield a variety o f cell types including functional, post-mitotic neurons,""'"™""'^ and similarly 
treating adherent monolayers o f TERA2.cl.SP12 cells with A T R A induces the formation o f 
approximately 10-15% o f terminally differentiated neurons, whilst the remainder o f the culture 
differentiates into non-neural cell types."" Electrophysiological experiments have determined that 
electrical impulses are communicated between perikarya, just like their in vivo counterparts."'" 
It is believed that this heterogeneous behaviour is due to the activation o f multiple receptors and 
genes, mirroring the in vivo pleiotropic abilities of endogenous A T R A . ' " ' The inability to generate 
specific cell types "on demand" currently precludes the potential to use such derivatives for cell 
replacement. A range o f culture strategies have consequently been developed to expedite and increase 
the neuronal differentiation efficiency."'*'"^^'"'' Terminally differentiated functional neurons, for 
example, are a valuable resource for screening drugs, testing the toxicity o f new compounds, and as a 
potential source o f transplantable material to correct neurological deficits."^* "'* 
Differentiation is characterised by marked changes in gene expression that can be monitored to 
investigate the nature and maturity o f resulting cell types. In excess o f 500 genes have been identified 
as targets o f A T R A ; " * these genes or their protein products can also be used to characterise and 
quantify differentiation products. For example, a number o f cell surface antigens have been used 
extensively to investigate ATRA-induced differentiation o f EC and ES cells.""' " " ' " " EC stem cell 
markers including SSEA-3, SSEA-4, TRA-1-60, TRA-1-81 , TRA-2-49 and TRA-2-54 are suppressed 
after cells commit to differentiate."'*^*' In a reciprocal fashion, markers of differentiated cells that 
were absent in the stem cell population are up-regulated, for example VrN-IS-53, VIN-IS-56, VrN-2B-
22, A2B5 and ME311."' ' '"*-
A wide range o f other retinoids have also been tested in similar systems, initially comparing to them to 
the activity o f natural retinoids,"** and subsequently screening the biological effects of a large number 
o f novel synthetic retinoids that have been prepared in the search for therapeutic entities that are safer 
and more efficacious than ATRA.^'^ 
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3.1.4 Retinoid (in)stability 
It is well known that A T R A and its geometric isomers 9-c/i-retinoic acid (9-C /5-RA) and 13-C/5-
retinoic acid (13-cis-RA), by virtue of their common labile polyene chain, are highly unstable in the 
presence o f oxidants, heat and light, which cause oxidative degradation or isomerisation.-^° '°^ '^^' '^' It 
is therefore routine laboratory practice to handle these retinoids in subdued light and to store them at 
low temperature, ideally in an inert atmosphere.^^' ' '° ' The degradation o f retinoids during culture w i l l 
reduce cellular exposure and may lead to concentration dependent effects. The isomers, metabolites 
and other degradants produced may also affect cell development, leading to a heterogeneous and 
poorly reproducible response. 
However, relatively little research has been published into the nature and magnitude of retinoid 
degradation and its effects on in vitro experiments. This is particularly surprising given the large 
number o f papers published in this f ield that apparently ignore the consequences o f retinoid 
degradation on their data. Under standard cell culture conditions several factors w i l l contribute to the 
degradation o f A T R A including: incubation at 37 °C, exposure to oxygen, dissolution in aqueous 
media and interaction with media supplements, in addition to absorption and metabolism by cells. 
A limited number o f studies have analysed the degradation o f retinoids in culture. The initial 
concentration o f applied retinoid is observed to decline rapidly, in some instances to less than 5% o f 
the original concentration within 24 hours,^*° though the rate o f degradation is significantly affected by 
the cultured cell type and cell density,'*" '* ' media and presence o f supplements such as serum 488.489 
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Figure 3-2: Decline o f retinoid levels in medium o f cultured LA-N-5 cells. Cells were treated with 
1 ^ M o f either A T R A ( O ) or 9-c/5-RA ( • ) under similar conditions. From Han et ai, 1995.^*' 
Two independent groups have presented kinetics o f ATRA-degradation that are in very good 
agreement. After 24 hours 75% of the original concentration o f A T R A remains, declining to 40-50% 
after 48 hours and 35-40% after 72 hours (Figure 3.2).^"'''^^ It is unclear whether this significant 
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decrease in retinoid concentration w i l l affect cell behaviour under normal culture conditions. Although 
a number o f synthetic retinoids are more stable than A T R A outside o f the cell culture 
environment,""'""^ their stability in vitro has yet to be tested. 
3.15 Chapter aims 
TERA2.cl .SPl2 human embryonal carcinoma stem cells wi l l be used to investigate the biological 
activity o f the stable retinoic acid analogues prepared in Chapter 2. All- / ra«5-ret inoic acid has 
previously been demonstrated to induce differentiation of this cell line, although it has not been 
established i f this activation is achieved via the classical retinoid molecular pathway (Section 1.5). The 
activity o f the synthetic retinoids w i l l be thoroughly characterised and compared to the differentiation 
induced by A T R A and its geometric isomers. 
45 
3.2 Methodology and compounds investigated 
The retinoids listed in Table 3-1 were screened for the ability to induce differentiation in the 
TERA2.cl.SP12 human embryonal carcinoma cell line. The compounds were dissolved in solvent and 
diluted in culture media to a final concentration o f 10 | i M and applied to the cells for up to 28 days. 
During this time, morphological changes were observed and f l ow cytometry was used to analyse the 
expression o f antigens specific to pluripotent stem cells and their differentiated derivatives. A number 
o f other compounds were also screened at 10 | i M for 14 days using the above methods but were not 
comprehensively investigated by the author (Table 3-2). The compounds presented in Table 3-2 were 
tested because their structures bear a superficial similarity to known retinoids. 
Table 3-1; Retinoid compounds. 
Compound Synonym(s) Comment 
retinoic acid LiL 
ATRA 
tretinoin 
Natural metabolite. Strong pan-RAR agonist. 
Extensively studied in vivo and in v///-o.'" 
9-cis- CX^*^^ 
retinoic acid 
C O j H 
9-c/^-RA 
alitretinoin 
Putative endogenous ATRA isomer. 
Pan-RAR & RXR agonist.'*'''" 
retinoic acid k , ^ - ^ 
13-C/5-RA 
isotretinoin 
Putative endogenous ATRA isomer. 
Pan-RAR & RXR agonist.'*'"'"'"" 
CEB16 >OOCX^ 
3 
CD2908 
Synthesis and dermal applications patented. No 
biological data published."'""'^ 
— 
Examined in QSAR study. RAR-p & RAR-y 
• c • ^ 494 495 
specific agonist. 
TTNN 
AGN 191650 
SR3957 
RAR-(3 & RAR-Y specific agonist."'* " " 
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Compound Synonym(s) Comment 
TTNPB C X ^ ) " ' ^ 
TTNPB 
Ro 13-7410 
Purchased from Sigma. 
Highly teratogenic. Pan-RAR agonist, no RXR 
activity. Strong inducer of apoptosis. >500-fold 
greater potency than ATRA.^'^' '"- ' '* ' ' ' ' -^ ' ' '^"' 
AmSSO (^^Or^""^ CD366 
Purchased from Sigma. 
Binds selectively to RAR-a, but actually 
transact!vates all three RAR subtypes and with 
greater potency at R A R - a . No RXR activity. 
This specificity causes lower topical toxicity, but 
has higher teratogenic potency than RAR-P & 
RAR-y specificity. Improved therapeutic effects 
compared to ATRA.^"'"""'^"*''"^ 
LG100268 r j P T i r ~ ^ — RXR-P specific agonist.""' "'^ 
Table 3-2: Other compounds screened for differentiation activity 
Compound 
NMej tolan Q = 
Synonym(s) Comment 
Prepared by Dr. Tolu Fasina. Donor-acceptor 
tolan (diphenylacetylene). 
OMe tolan •-O—0-" Prepared by Dr. Tolu Fasina. Donor-acceptor tolan (diphenylacetylene). 
BPEB 
Prepared by Dr. Tolu Fasina. Donor-acceptor 
BPEB (l,4-bis(phenylethynyl) benzene). 
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The BPEB compound was dissolved in D M F and all other compounds were dissolved in DMSO 
before dilution in culture media to a final concentration o f 10 [iM. These vehicles were also tested in 
the same manner to confirm that the solvents had no effect on the cells. Ethanol (an alternative 
vehicle) and an acetone solution equivalent to 5 mol% contamination, a potential synthetic impurity, 
were also tested. 
Compounds found to be o f interest in the initial screen were investigated further to confirm these data 
and rigorously characterise the observed differentiation. Analyses included: repeat f l ow cytometric 
analysis to confirm the reproducibility o f differentiation, immunocytochemical localisation and 
western blot analysis o f antigens associated with neural and non-neural differentiation and, in some 
cases, proliferation studies. 
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3.3 Observations of changes to cell phenotype 
Proliferative TERA2.cl .SPi2 EC stem cells are morphologically homogeneous, consisting o f rounded 
cells with a high nuclear to cytosol ratio. Below approximately 30 passages, cell growth can be 
maintained in a reproducible and robust manner with a doubling time o f approximately one day. 
Under certain conditions, for example the addition o f an exogenous compound such as aW-trans-
retinoic acid ( A T R A ) , reduced serum content o f media or other non-ideal growth conditions, and 
sometimes spontaneously, these self-renewing stem cells may be induced to differentiate. Initially 
committed progenitor cells are produced, which may continue to proliferate. I f the culture conditions 
are appropriate, this progenitor may develop into one o f a restricted number o f terminally 
differentiated cell types. The simplest method o f monitoring the effects o f test compounds is to 
regularly observe the morphology o f the culture by phase microscopy, in comparison to a negative 
control (cells in normal proliferative media) and a positive control (cells grown in media 
supplemented with A T R A ) . Identification o f cell types by morphology alone is unreliable; 
assumptions should be confirmed using immunocytochemical localisation (ICC) o f phenotypic 
antibodies. Further images are presented in Section 3.6. 
3.3.7 Results 
Control cultures, LG100268, tolans and BPEB do not induce differentiation of EC cells 
The control cultures, LG 100268 culture and all cultures grown with the tolans and BPEB shown in 
Figure 3-3 failed to differentiate; representative phase images are shown in Figure 3-3. No discernable 
differentiation or other morphological changes were observed during typical culture periods. Elevated 
levels o f cell debris were observed in cultures grown with LGl00268 (but not control cultures), 
possibly due to apoptosis. 
On one occasion, cells f rom a 28 day old DMSO culture were re-plated after harvesting for flow 
cytometric analysis and maintained for a further four weeks. After this time, a number o f neuron-like 
cell types were observed (Figure 3-4). These conditions are sub-optimal for EC cell growth, but 
representative o f the results that might be expected in an experiment with a compound that fails to 
induce differentiation. 
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Figure 3-3: Control cultures: all of the control cultures failed to differentiate, no discemable morphological 
changes were observed during typical culture periods. Al l scale bars represent 50 |am. 
A: TERA2.cl.SP 12 control on day 1. Freshly plated ceils divide rapidly and extend cytoplasmic extensions (C) 
towards adjacent cells. 
B: TERA2.cl.SP12 control on day 5. Culture is confluent, cells exhibit typical high nuclear to cytosol ratio. 
C: DMSO culture after 9 days. Cells are tightly packed, at this density cells are stressed and become sub-optimal 
- they may undergo spontaneous differentiation. 
D: DMSO culture after 28 days. Dense culture, with some heterogeneity of cell types and lots of overgrowing 
cells (O). The top cell layers are lost into the media. 
Figure 3-4: DMSO culture after 57 days showing putative neuronal colony (N). Culture was harvested for flow 
cytometric analysis at 28 days, and then replated and maintained for ftirther 29 days. Scale bar = 50 [xm. 
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ATRA, 9-cis-retinoic acid and 13-cis-retinoic acid cultures 
Cultures grown in the presence of 10 ) iM A T R A , 9-c/5-RA or H-cw-RA, the three natural retinoids, 
were highly comparable (Figure 3-5). As previously observed in TERA2.cl.SP12 cells induced to 
differentiate with A T R A , heterogeneous cultures develop, rosette-like aggregations o f cells are visible 
(Figure 3-5A), and at about 2 weeks' maturity young neurons can be identified by their dense rounded 
cell bodies and extending processes (Figure 3-5B)."^* These neurons migrate and aggregate to form 
perikarya connected by extensive neurites that coalesce to form nerve bundles, reaching a maximal 
length o f 150 p.m in length after 28 days. These neuronal cells grow over a background o f non-neural 
cell morphologies and some epithelial colonies are also observed. Cultures were less confluent and 
significantly more mature than those observed in response to CEB compounds (Figure 3-6). 
CEB16, CEB17 and CEB18 cultures 
The cultures grown with l O f i M CEB16, CEB17 and CEB18 initially developed similarly to each 
other, becoming heterogeneous within a few days (Figure 3-6). The cultures reached confluency in 
about 6 days, were reproducibly composed o f multiple cell layers, and had high media demands 
relative to A T R A and its isomers. The cultures matured differentially, with CEB 18 effecting the 
development of highly neural cultures, whilst CEB 17 and CEB 16 in particular, possessed less 
morphologically identifiable neural cell types. A l l these synthetic retinoids, but especially CEB 16, 
caused the TERA2.cl.SP12 cells to develop into significant numbers o f large flat epithelial colonies 
(Figure 3-6B). Undifferentiated EC cell colonies were also observed in CEB 16, which appear to be 
resistant to the retinoid (Figure 3-6B). 
Am580 and TTNPB 
These two commercially available synthetic retinoids are also highly effective at inducing phenotypic 
neural differentiation at the screening concentration o f l O f i M . The rate o f apparent neurogenesis 
appears comparable to that o f A T R A and its isomers, but both synthetic retinoids seem to enable a 
slightly greater level o f maturity in the neural networks observed after 28 days' culture. (Figure 3-7) 
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Figure 3-5: TERA2.cl.SP12 cells differentiated with 10 nM ATRA, 9-m-RA or 13-c«-RA for 28 days. Scale 
bars represent 50 ^m. 
A: 9-cis-RA RA culture after 13 days. Large numbers of rosettes (R) are present. These features are rich in 
nestin (see immunocytochemical studies), a marker of neural progenitors. 
B: 20 day-old 13-cw-RA culture. Significant numbers of neurons present (N), which are starting to migrate 
together. Overgrowing area of apparently un-response cells (O) also visible. 
C: 13-C/5-RA culture after 28 days' culture showing large numbers of interconnecting cells with neuronal 
phenotype. 
D: The morphology of the ATRA-treated cells after 28 days is highly neural and mature. 
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Figure 3-6: TERA2.cl.SP12 cells differentiated with 10 nM CEBI6, CEB17 or CEB18 for 28 days. Scale bars 
represent 50 fim. 
A: CEB17 after 9 days' culture. Heterogenous, multi-layered culture. Majority of cells retain EC morphology 
(EC), a small epithelial colony is also visible (EP). 
B: CEB16 after 28 days' culture. A large epithelial colony (EP) composed of a single layer of large flat cells 
surrounded by areas of overgrowing cells. 
C: CEB16 on day 28. Neural rosettes (R), a few individual neurons (N) and an epithelial colony (EP, out of 
focus due to different focal depth) are visible: culture appears to be at an earlier stage of neurogenesis than 
observed with other retinoids at this time point. 
D: CEB18 after 28 days (fixed with MAA for ICC and stained with TUJ-1, a neuron-specific antibody, see 
Section 3.6). TUJ-1 staining emphasised a large neuronal aggregate (A) amongst numerous individual neurons. 
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Figure 3-7: TERA2.cl.SP12 cells treated with 10 Am580 and TTNPB for 28 days. Scale bars represent 
50 urn. 
A : TTNPB culture after 28 days. Apparent large neuronal aggregate ( A ) with extensive neurites and large 
numbers of individual neuron-like cells ( N ) are visible. 
B: Am580 after 28 days' culture. This culture had been stained with TUJ-1, highlighting two large neuronal 
aggregates ( A ) connected to an extensive network of nerve bundles (Section 3.6). Neuronal soma are tight, and 
extensions are normally bipolar indicating well formed neurons. 
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3.4 Flow cytometry: quantitative determination of cell fate 
Flow cytometry was chosen as the technique to confirm morphological observations that showed 
TERA2.cl .SPl2 cells either undergoing differentiation or not responding to test compounds. This 
method also provided the first characterisation o f differentiation by using phenotype specific 
antibodies to provide a quantitative comparison of the effects induced by the different treatments. 
Primary monoclonal antibodies specific to the antigens associated with globoseries glycolipids and 
glycoproteins o f pluripotent stem cells (SSEA-3 and TRA-l-60)"* ' '*° and neural cell types (VIN-IS-53 
and A 2 B 5 ) ' " ' ' * ' were used in indirect fluorescence. TERA2.cl.SP12 cells were analysed before 
treatment and after 7, 14 and 28 days' treatment with 10 |xM retinoids. 
Cells were incubated with one of the primary antibodies and then with a fluorophore-conjugated 
secondary antibody. The percentage o f single, live and fluorescent cells was measured by f low 
cytometry. A minimum o f three independent batches o f TERA2.cl.SP12 cells were treated with 10 
CEB16, CEB17, CEB18, A T R A , 9-cis-RA, \3-cis-KA and LG100268 for up to 28 days. DMSO 
( 0 . 1 % 7v, vehicle), 5mol% acetone (a potential synthetic impurity) and normal media were also used 
to maintain cells for this period. Fresh retinoids were added at every media change, which was 
performed initially after three/four days and then every one/two days as required. The percentages o f 
live cells positive for each antigen were averaged and standard deviations calculated. Statistical 
analysis was performed on arcsin transformed data. Analysis o f variance ( A N O V A ) was used to 
compare the effects o f the different retinoid treatments on antigen expression, with Bonferroni 
correction post-hoc analysis. Significance levels were set at: * P-value < 0.05, ** /"-value < 0.01 and 
***P-value< 0.001. 
One batch of cells was tested with 10 ^M Am580 or TTNPB and tested after 7 and 14 days' culture, to 
confirm morphological observations. A further batch o f cells was tested with the BPEB, two tolans, 
D M F and ethanol after 7 and 14 days' growth. The two tolan compounds were soluble in DMSO and 
were applied to the cells at a final concentration o f 10 nM. The BPEB compound was poorly soluble 
in both DMSO and D M F , and insoluble in a number o f other common vehicles (ethanol, glycerol, PBS 
+ 0 .1% BSA and 4 m M HCI + 0 .1% BSA). D M F and DMSO solutions o f BPEB were tested, at~3 i^M 
and ~5 | i M , respectively. 
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3.4.1 Results 
Retinoid compounds from Table 3-1 
Seven day f l ow cytometric data o f cultures grown wi th retinoids confirm the initiation o f 
differentiation (Figure 3-8 and Figure 3-9). The piuripotency markers SSEA-3 and TRA-1-60 are 
down-regulated relative to undifferentiated EC cells (day 0), whilst markers o f neural phenotypes are 
concomitantly up-regulated (VIN-IS-53 and A2B5) . The control cultures and LG100268 culture show 
no significant differences in any o f the antigens f rom the seven day control culture (2"^ * group of bars, 
TERA2.cl.SF12 cells grown in normal media). These cells have grown beyond confluency, resulting 
in sub-optimal culture conditions as revealed in the down-regulation o f SSEA-3 {P < 0.001 for all 
7 day cultures), the most sensitive stem cell marker tested. This may be due to spontaneous 
differentiation. 
The different efficacies o f the retinoid treatments are highlighted by comparing the results for TRA-1 -
60 (Figure 3-9, B and D ) . Significant down-regulation is observed in all retinoid conditions compared 
to the DMSO control. A T R A , 9-cis-RA, 13-cw-RA and CEB18 show the greatest down-regulation (P 
< 0.001), and CEB16 and CEB17 show a significant, but smaller difference (P < 0.05). The TRA-1-60 
results for CEB16 and CEB17 are also significantly different to the expression of TRA-1-60 in the 
A T R A culture (P < 0.01), confirming the slower rate o f differentiation observed morphologically. A 
significant difference between A T R A and CEB16 is also observed in the A2B5 results (P < 0.01, 
Figure 3-9 C ) consistent wi th a slower exit o f the cell cycle."'^'' No statistically significant differences 
in the expression o f VIN-IS-53 were found between any o f the 7 day old cultures. 
• SSEA-3 
• TRA-1-60 
• VIN-IS-53 
• A2B5 
dO control DMSO acetone LG 100268 ATRA 9-cis-RA 13-cis-RA CEB16 CEB17 CEB18 
growth condition 
Figure 3-8: Expression o f cell surface antigens in TERA2.cl.SP12 huEC cells after treatment wi th 
10 p M retinoid or control conditions for 7 days (mean percent positive cells o f >3 batches +1SD). 
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Figure 3-9: Mean percent positive cell expression o f SSEA-3 (A), TRA-1-60 ( B and D ) and A2B5 ( C ) in TERA2.cl.SP12 iiuEC cells after treatment 
wi th 10 |nM retinoid or control conditions for 7 days (n>3). Significant differences f rom dO (A, SSEA-3), DMSO ( B , TRA-1-60) and A T R A ( C , 
A2B5 and D , T R A - i - 6 0 ) are presented. Statistical significance between the growth conditions is denoted by * (P-value < 0.05), ** (P-value < 0.01) 
and ***(P-value< 0.001). 
14 day data show the continued commitment towards neural cell types (Figure 3-10). A l l retinoid 
cultures (excluding LG100268) have suppressed both stem cell markers completely, and strongly 
express VrN-lS-53 and A2B5. The distinction between differentiating cultures and non-differentiating 
cultures is very clear. There are no significant differences in antigen expression between the 
differentiating cultures. There are significant differences between the control/LG 100268 cultures and 
the other retinoid cultures in the expression o f TRA-1-60 (P < 0.001), VIN-IS-53 (P < 0.05) and A2B5 
{P < 0.05). 
After 28 days' culture, the antigen expression pattern has changed again (Figure 3-11). The control, 
DMSO, acetone and LG 100268 data show some evidence o f differentiation. In differentiated cultures, 
the levels of VI'N-IS-53 are maintained, but A2B5 is starting to be down-regulated. A2B5 is 
characteristic o f neural progenitor cells and is not acquired permanently.^"' 
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Figure 3-10: Expression o f cell surface antigens in TERA2.cl.SP12 huEC cells after treatment wi th 
10 |uM retinoid or control conditions for 14 days (mean percent positive cells o f >3 batches ±1SD) . 
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growth condition 
Figure 3-11: Expression o f cell surface antigens in TERA2.cl.SP12 huEC cells after treatment with 
10 pM retinoid or control conditions for 28 days (mean percent positive cells o f 3 batches (2 for 
"control")+1SD). 
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Compounds from Table 3-2 
Flow cytometric analysis clearly confirms that the BPEB and tolans do not induce differentiation and 
that D M F and ethanol induce only the same phenotypic changes seen in similarly maintained control 
cultures. By contrast, l O ^ M Am580 and TTNPB appear to be as effective as A T R A at inducing 
neural differentiation (Figure 3-12 and Figure 3-13). 
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Figure 3-12: Expression o f cell surface antigens in TERA2.cl.SP12 huEC cells after treatment wi th 
10 j i M test compound or control conditions for 7 days ( n = l , except where error bars are shown when 
n = 3 , ± l S D ) . 
SSE / S r 3 
TRA-1-60 
• VINIS-53 
A2B5 
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Figure 3-13: Expression o f cell surface antigens in TERA2.cl.SP12 huEC cells after treatment with 
10 |a.M test compound or control conditions for 14 days ( n = l , except where error bars are shown when 
n = 3 , ± l S D ) . 
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3.5 Proliferation 
Flow cytometric analysis and morphological observations o f the differentiating cultures show that the 
different retinoids initiate differentiation at varying rates. A T R A and its isomers induce a faster 
response than CEB 18, and CEB16/CEB17 were the least efficacious. The initial response o f 
TERA2.cl.SP12 ceils (first seven days) to retinoid exposure is observed as a reduction in cell 
proliferation and the appearance of non-EC cell morphologies in characteristically heterogeneous 
cultures. This apparent delayed exit o f the cell cycle results in significantly more confluent cultures 
and higher media demands for the CEB compounds. 
In order to quantify this observation, a tetrazolium-based proliferation assay was use to measure the 
number o f viable cells in cultures exposed to 10 | i M o f each retinoid over 14 days. Metabolism in 
proliferating cells produces reducing equivalents such as N A D H or N A D P H that reduce MTS reagent 
(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner 
salt) f rom a yellow salt to a blue formazan product. The amount o f formazan produced during 4 hours' 
incubation with cultures was measured by reading the U V absorbance of the solution at 490 nm, and is 
proportional to the number o f viable cells in the culture. 
3.5.1 Results 
A total o f four independent batches o f cells were analysed independently after 0, 3, 7, 10 and 14 days' 
culture. The U V absorbencies o f each growth condition were averaged and used to generate growth 
curves (Figure 3-14). The number o f viable ceils present in the control (normal media) and DMSO 
(vehicle) cultures were similar and at time points after three days were substantially greater than any 
o f the cultures treated with retinoid. The retinoid cultures can be clearly divided into two different 
groups with appreciably different numbers o f cells: the natural retinoid cultures were less proliferative 
than those grown with synthetic retinoids. There were an average o f 18%, 60% and 39% more cells in 
the synthetic cultures, compared to those treated with natural retinoids, after 3, 7 and 10 days' culture 
respectively. A l l batches showed the same trend in results, but differences in proliferation between 
batches (biological variation) reduced the average magnitude o f difference between compounds and 
produced large standard deviations (Figure 3-15). Consequently, no statistically significant differences 
were observed between the retinoid compounds at any time point. 
Comparing the relative number o f cells in the retinoid cultures to the control cultures further 
highlighted differences between the two groups o f compounds (Figure 3-15). After three days, 
CEB 16, CEB 17 and CEB 18 cultures all contained more cells than the controls, while 9-cis-RA, 13-
C/5-RA and A T R A cultures had slightly suppressed proliferative capacity. Later time points 
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demonstrate a large reduction in cell number o f all retinoid cultures. The 7 and 10 day data provide the 
best comparison between retinoid groups. 
A t the 10 and 14 day time points, large number o f overgrowing cells were present in the cultures that 
were easily dislodged during media changes and in the PBS wash prior to addition o f MTS reagent. 
The data for these time points consequently show greater variation, and are more d i f f i cuh to compare. 
However, the growth curves o f all cultures appear to be in a stationary phase o f cell growth by the end 
o f the experiment (Figure 3-14). 
-•— control 
- • - D M S O 
CEB16 
X CEB17 
CEB18 
- • - A T R A 
•« 9cis-RA 
- * - 1 3 c i s - R A 
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age of culture (days) 
10 12 
Figure 3-14: TERA2.cl.SP12 huEC growth curves, derived f rom MTS viability assay data, after 
continuous treatment with 10 |a,M retinoid or control conditions (n>3). Error bars have been omitted 
f rom this figure for clarity; the magniture o f the standard deviations can be observed in Figure 3-15. 
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Figure 3-15: Relative number o f viable TERA2.cl.SP12 huEC cells produced after treatment with 
10 |u.M retinoid for 3, 7 and 10 days. Data are presented as ± percent difference o f the retinoid culture 
f r o m DMSO control (3 and 7 days) or control culture (10 day data), using the mean absorbance values 
for >3 batches o f independent cells, ±1SD. Statistical significance between the relevant control and the 
growth conditions indicated is denoted by * (/"-value < 0.05), ** (P-value < 0.01) and *** (P-value 
< 0.001). 
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3.6 Immunocytochemical (ICC) localisation of antibodies 
TERA2.cl .SPl2 cells were differentiated on cover-slips using the retinoids listed in Table 3-1. After 
14 and 28 days, the resulting cultures were fixed and a range o f phenotypically defined antibodies was 
used to localise cellular protein markers (Table 3-3). Phase images were compared with the 
fluorescent image(s) in same field o f view; stained features were visualised through an appropriately 
coloured filter on a fluorescence microscope. Co-staining with different antibodies raised in different 
species permitted the use o f species-specific secondary antibodies conjugated to different 
fluorophores. Fluorescent images from co-stained cultures were overlaid where appropriate to examine 
for interactions between different cell types. A l l cover-slips were mounted in a medium containing 
Hoechst to indiscriminately counterstain all nuclei blue. 
The presence and patterns o f expression o f each antibody were examined in each retinoid culture, and 
compared to the other conditions. 
Table 3-3: Primary antibodies used in ICC staining 
Antibody: 
anti-
Information 
nestin Visualises putative neural stem/progenitor cells. 
P-III-tubulin (clone TUJ-1) 
Neuron-specific tubulin, stains the nuclei and neurites of 
developing neurons. 
cytokeratin 8 (C8) Marker of epithelial cytoplasma. 
fibronectin 
This antibody recognises an extracellular matrix protein associated 
with epidermal layer development. 
neurofilament-68 (NF68) A low MW intermediate filament expressed in young neurons. 
neurofiiament-200 CNF200) A high MW intermediate filament expressed in mature neurons. 
neuron specific enolase (NSE) Detected only in mature neurons. 
microtubule associated protein-2 (MAP-2) Reacts with MAP-2a, MAP-2b and MAP-2c. Present in mature 
neuronal cytoskeleton. 
glial fibrillary associated protein (GFAP) An intermediate filament uniquely expressed in astrocytes. 
64 
3.6.1 Results 
A total o f nine antibodies for a range o f neural and non-neural cell types were used on cultures grown 
with eight different retinoids. Representative fluorescent and corresponding phase micrographs were 
recorded; a selection o f images is presented in Figures 3-16 to 3-30, and notable features are described 
in the figure legends. TERA2.cl.SPI2 cells were also grown in normal media to confiuency and 
stained to provide basal expression information (Figure 3-17). Antibody controls were also prepared 
alongside ordinary staining to confirm the absence o f non-specific binding (Figure 3-17). 
Four antibodies were used to stain all retinoid cultures: p-III-tubulin (clone TUJ-1), nestin, C8 and 
NSE, and six o f the 14 days old retinoid cultures were stained with fibronectin. The cover-slips were 
examined carefully and a qualitative assessment o f the relative intensity and degree o f phenotype 
maturity was made, these data are summarised in Table 3-4. 
Nestin expression was present in all cultures at all time points, although at varying levels. The most 
intense expression was seen on the 14 day cover-slips, distributed throughout the cultures, but 
especially radiating out f rom rosettes (for example Figure 3-18, 9-cis-RA and Figure 3-19, CEB18). 
By 28 days, the amount and intensity o f nestin staining was significantly decreased and it was 
typically isolated to proliferative centres (for example 13-C/5-RA in Figure 3-24 and TTNPB in Figure 
3-26). The exception to this observation was the CEB 16 cover-slip: nestin expression was still intense, 
and distributed throughout the culture indicating an earlier stage o f neurogenesis (Figure 3-25). Nestin 
has also been identified in a range o f non-neural cells and has more recently been proposed as a 
common marker o f multi-lineage progenitor cells capable o f forming derivatives of all three germ 
l a y e r s . W h e r e nestin expression is co-localised with distinctive features such as rosettes, which have 
previously been demonstrated to develop into neural tubes,'''^ these cells can be confidently described 
as neural progenitors. 
After fourteen days, the TUJ-1 antibody stained the cell bodies o f young neurons and the short 
processes extending towards other neurons; TUJ-1 positive cells were often found in islands, but were 
also present throughout the culture. Less TUJ-1 staining was present in CEB 16 and CEB 17 compared 
to the other retinoid-treated cultures, consistent with the less mature morphology observed. At the 28 
day time-point all cultures were highly stained with TUJ-1. The neurons had migrated and formed 
numerous aggregates in the upper layers o f the culture over a background o f non-neural cells (for 
example, Figure 3-25 CEB 17). Long neurites form networks o f connections between aggregates, 
coalescing into nerve bundles o f up to 160 |im in length ( A T R A in Figure 3-24 and Am580 image in 
Figure 3-26). Again, ICC staining reveals the CEB 16 culture to be significantly less mature: less 
neurons were present, which were distributed throughout the culture with little organisation and their 
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neurites are shorter and often not bi-polar (Figure 3-25). The TTNPB and Am580 cultures show some 
of the most advanced neuronal networks (Figure 3-26). 
Table 3-4: Qua itative analysis o TCC staining. 
Time-point Retinoid 
Antibody 
nestin TUJ-1 C8 fibronectin NSE 
14 days ATRA +++ ++ ++ ++ + 
9-cis-RA ++ + + + 
\3-cis-KA +++ ++ -n- ++ + 
CEB 16 ++ + +++ N -
CEB 17 ++ + ++ N -
CEB 18 ++ -H-l- ++ ++ + 
Am580 +++ ++ -i-i- + 
TTNPB +++ ++ + + -H-t- + 
28 days ATRA + + + ++ N +++ 
9-c/j-RA + +++ ++ N +•*•+ 
13-C75-RA + +++ ++ N +++ 
CEB 16 ++ ++ ++ + N ++ 
CEB 17 + ++ ++ + N +++ 
CEB 18 + ++ + ++ N ++•¥ 
Am580 + +++ ++ N ++ + 
TTNPB + +++ ++ N ++ + 
KEY: + positive - small amount present 
++ significant amounts of staining 
+++ antigen expression is extensive and well-developed 
absent 
N antibody not used 
TUJ-1 cell body staining and nestin staining were absent in the colonies of flat grey cells that were 
highly stained with cytokeratin 8 (C8) (Figure 3-18, 9-C/5-RA and Figure 3-25, CEB 17). As cultures 
matured, processes extended between these epithelial cells into the colony, as seen in the A T R A 
culture in Figure 3-24. C8 staining was observed in all cultures at all time-points. This cytoplasmic 
epithelial marker was localised in several different patterns distinguishing between different cell types 
(illustrated in Figure 3-16, (C) and (D) , and observed in Figure 3-22, CEB17). The largest epithelial 
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colonies were observed in cultures grown with 10 f i M CEB16 and CEB17, as previously noted (Figure 
3-22 CEB16, CEB17 and CEB18 in Figure 3-28). 
Fibronectin was present at a low level in all the cultures to which the antibody applied. This extra-
cellular protein marker showed little apparent correlation to features observed by phase contrast 
microscopy. Low levels were also observed in undifferentiated TERA2.cl.SP12 cells (Figure 3-17). 
Undifferentiated cells also showed low levels o f TUJ-1, cytokeratin 8 and nestin expression. The TUJ-
1 staining was cytoplasmic and diffuse, unlike neuronal staining observed in the retinoid cultures 
where it is intensely expressed in only the neuronal cell body and processes. Staining was not 
observed in the secondary control. Low levels o f nestin and C8 are present uniformly throughout the 
undifferentiated cultures. 
An antibody against neuron specific enolase (NSE) was used to stain all cover-slips. CEB16 and 
CEB17 treated cells did not express this protein after 14 days' culture, but low levels o f staining were 
observed in all other cultures at this time point (Figure 3-21, Figure 3-22 and Figure 3-23, data for 
CEB16 and CEB17 cultures is not shown). NSE is a marker o f mature neurons, so it is to be expected 
that it w i l l be expressed at a later stage in neurogenesis than TUJ-1. After 28 days' culture, NSE levels 
are highly up-regulated, demarcating mature perikarya and neurons (compare the staining o f the 
natural retinoid cultures. Figure 3-24, with CEB16 in Figure 3-25). The low molecular weight 
neurofilament NF68 is normally expressed in young neurons, as demonstrated by its expression in 
CEB16 and C E B l 7 cultures after 14 days (Figure 3-22). 
Three further antibodies were also used to stain the 28 day old cultures grown with ATRA and 
C E B l 8 . The results o f this staining are summarised in Table 3-5, Expression o f GFAP was not 
detected in either o f the mature cultures, consistent with previous analysis o f TERA2.cl.SP12 cells 
grown in monolayer.""* NF200 and MAP2 were expressed in both cultures (Figure 3-30) further 
demonstrating the level o f neuronal development and maturity induced by both synthetic and natural 
retinoids. 
Table 3-5: Qualitative assessment o f the results of staining A T R A and C E B l 8 28 day cultures with 
Time point Retinoid 
Antibody 
GFAP NF200 IVlAP-2 
28 days ATRA - +++ ++ 
CEBl 8 - ++ + 
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Figure 3-17: Antibody control images (top row) and undifferentiated TERA2.cl.SP12 huEC phase and ICC staining. Corresponding Hoechst images are shown 
inset. Scale bars represent 50 |j,m. 
ATRA 
rUJ-1 & I loechsl icslin t t I locehsl icslin ( C . ) & TU.I-1 (R 
9-cw-RA 
13-cw-RA 
ncslin (Ci). 
-TUJ-1 ( R ) & Hoechst 
T U J - I * # 
^ 4 
ncsliii ( (1 K'C 
TlJJ-1 (R) 
nc-^  in ncslin ( ( i ^ & 
1 r.i-i (R) 
'•CP 
. • • *. ^ 
o 
Figure 3-18: Phase and corresponding ICC images of TUJ-1 (stained red, R) and nestin (stained green, G) staining of cultures grown with 10 |uM ATRA, 9-m-
RA or 13-cK-RA for 14 days. In the ATRA images, nestin and TUJ-1 co-localise in a hyper-proliferative area, where rosettes are starting to form. An epithelial 
colony in 9-c/s--RA images expresses neither TUJ-1 nor nestin. Scale bars represent 50 |am. 
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Figure 3-19: Phase and corresponding ICC images of TUJ-1 (red, R) and nestin (green, G) staining of cultures grown with 10 CEB16, CEB17 or CEB18 for 
14 days. Note the small number of individual, immature neurons in the CEBl6 culture. A hyper-proliferative neuronal colony is shown in the second pair of 
CEB17 images. A neural rosette is clearly visible in the CEB18 images. Scale bars represent 50 nm. 
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Figure 3-20: Phase and corresponding I C C images of T U J - I (red, R) and nestin (green G ) staining of cultures grown with 10 [iM AmSSO or T T N P B for 14 days. 
Large numbers of neurons are observed in both cultures, some neurons are extending long neurites. Scale bars represent 50 fim. 
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Figure 3-21: Phase and corresponding I C C images of cultures co-stained with cytokeratin 8 (C8, green G)) and fibronectin (red, R ) , or N S E after 14 days' 
exposure to 10 ^iM A T R A , 9 - cw-RA or 1 3 - C M - R A . Scale bars represent 50 jim. 
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Figure 3-22: Phase and corresponding I C C images of cultures co-stained with cytokeratin 8 (C8, green G ) , fibronectin (red R) , N S E and NF68 after 14 days' 
exposure to 10 | i M C E B 1 6 , C E B 1 7 or C E B 1 8 . No N S E staining was observed in the C E B 1 6 and C E B 1 7 cultures (data not shown) and only a few neurons 
expressed N S E in the C E B 1 8 culture. C E B 1 6 and C E B 1 7 cultures were not stained with fibronectin, but were positive for NF68. A large C8 +ve epithelial colony 
is shown in the C E B 1 6 images; the C E B I T C8 images show different patterns of C8 staining in different phenotypes. Scale bars represent 50 |Lim. 
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Figure 3-23: Phase and corresponding I C C images of cultures co-stained with cytokeratin 8 (C8, green G ) and fibronectin (red R) , or N S E after 14 days' exposure 
to 10 nM Am580 or T T N P B . A dense colony of non-neuronal cells is highlighted by C8 in the Am580 culture. Scale bars represent 50 [im. 
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Figure 3-24: Phase and corresponding I C C images of T U J - 1 (red R ) and nestin (green G ) staining of cultures grown with 10 \iM A T R A , 9 - c w - R A or 1 3 - C M - R A 
for 28 days. Large numbers of T U J - 1 stained neurons are present. Some neurons have aggregated with long nerve fibres formed from coalesced neurites ( A T R A , 
nerve fibre - 1 6 0 |a,m long). Neurites extend into epithelial colonies ( A T R A ) . Nestin expression is restricted to weak staining in proliferative areas. Scale bars 
represent 5 0 ^ m. 
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Figure 3-25: Phase and corresponding I C C images of TUJ-1 (red R ) and nestin (green G) staining of cultures grown with 10 j^M C E B 1 6 , C E B I T or C E B 1 8 for 
28 days. Neurons appear immature in some areas of C E B 1 6 culmres, whereas neuronal aggregates and other mature features are common in C E B I T and C E B 1 8 
cultures. Nestin expression remains high in C E B 1 6 , but is barely visible in C E B I T and C E B l 8 cultures. Scale bars represent 50 ^m. 
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Figure 3-26: Phase and corresponding ICC images of TUJ-1 (red R) and nestin (green G) staining of cultures grown with 10 nM Am580 or T T N P B for 28 days. 
These are mature neuronal cultures. Nerve bundle in first Am580 view is -150 (im long. Scale bars represent 50 jam. 
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Figure 3-27: Phase and corresponding I C C images of cultures stained with cytokeratin 8 (C8) or N S E after 28 days' exposure to 10 j iM A T R A , 9 - c « - R A or 13-
c/ i -RA. The heterogeneous nature of these differentiated cultures is highlighted by the different patterns of C8 staining seen in these cultures. Large numbers of 
mamre neurons are visualised by N S E . Scale bars represent 50 \x.m. 
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Figure 3-28: Phase and corresponding I C C images of cultures stained with cytokeratin 8 (C8) or N S E after 28 days' exposure to 10 i^M C E B 1 6 , C E B 1 7 or 
C E B 1 8 . Numerous large epithelial colonies are present, especially in the C E B 1 6 culmre, which are highlighted by C8 staining (see also Figure 3-16). A 
proliferative colony, possibly resistant to retinoid, is depicted in the C E B 1 6 C8 images in this figure. Significant levels of N S E staining are observed. Scale bars 
represent 50 (xm. 
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Figure 3-29: Phase and corresponding I C C images of cultures stained with cytokeratin 8 (C8) or N S E after 28 days' exposure to 10 nM Am580 or T T N P B . Small 
numbers of C8-positive epithelial colonies are present and there is strong N S E expression. Scale bars represent 50 ^m. 
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Figure 3-30: Phase and corresponding I C C images of cultures stained with NF200 (green G) and T U J - I (red R ) or MAP2 after 28 days' exposure to 10 nM 
A T R A or C E B l 8. NF200 and MAP2 are markers of mature neuronal phenotypes. These staining results confirm that the A T R A cultures are more developed than 
those differentiated with C E B l 8. Both cultures express high levels of the high molecular weight neurofilament emphasising the maturity of the cultures and long 
neurites. Scale bars represent 50 \im. 
3.7 Protein expression profiling by western blot 
The retinoid-differentiated derivatives o f TERA2.cl.SP12 huEC cells were also analysed by western 
blot. Protein samples were collected from cells grown with 10 | i M o f the retinoids in Table 3-1 or 
maintained under control conditions (DMSO, acetone and normal media) after 7, 14 and 28 days' 
culture. Thirty three samples were analysed for the expression o f thirteen antigens associated with 
neural and non-neural differentiation and the three retinoic acid receptors (Table 3-6). 12 |j.g of each 
protein sample was loaded onto the gels and p-actin expression was used to confirm equal loading. 
Table 3-6: Antibodies used in western blot analysis 
Antibody 
anti-
Predicted 
M W 
(kDa) 
Information 
P-actin 42 Ubiquitous in TERA2.cl.SP12 cells. Used as loading control. 
OCT 4 43 A transcription factor expressed by undifferentiated EC, ES and embryonic germ cells. "Gatekeeper of piuripotency." 
NSE 45 Detected only in mature neurons. 
P-lIl-tubulin (clone TUJ-1) 50 Detects neuronal microtubulin. 
cytokeratin 8 (C8) 52.5 Marker of simple and complex epithelia. 
RAR-a 50/55 Retinoic acid receptor, subtypes and a .^ 
RAR-P 51 Retinoic acid receptor, subtypes Pi and P2. 
RAR-7 60 Refinoic acid receptor, subtype Y | . 
NF68 68 A low molecular weight (MW) intermediate filament expressed in young and mature neurons. 
NF160 160 Medium MW intermediate filament expressed in maturing neurons. 
NF200 200 High MW intermediate filament expressed in mature neurons. 
fibronectin 220-240 An extracellular matrix protein associated with epidermal layer development. 
nestin 220-240 Marker of putative neural stem/progenitor cells. 
Microtubule associated 
protein-2 (MAP-2) 2 X 280 & 70 
Antibody detects MAP-2a, MAP-2b and MAP-2c. Present in 
mature neuronal cytoskeieton. 
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3.7.1 Results 
Images o f the western blot data are presented in Figure 3-31. The pluripotency marker 0 C T 4 is 
expressed at high levels in the day 0 sample (dO, undifferentiated TERA2.cl.SP12 cells) and remains 
highly expressed in all control cultures up to 14 days. These cells continued to proliferate beyond 
confluency, and were maintained in sub-optimal conditions for EC cells, yet retained expression of 
OCT4. The 7 day sample from the LG100268 culture also expressed high levels o f OCT4. Although 
no expression was seen after 14 days' culture, the first time point confirms that this rexinoid is not 
inducing differentiation. 0 C T 4 was not detected in any o f the cultures grown with A T R A , 9-c«-RA, 
13-C/5-RA, Am580 or TTNPB demonstrating that these cultures had undergone differentiation. By 
comparison, OCT4 was observed in some o f the CEB retinoid cultures establishing that these 
compounds are less efficient than the natural retinoids at inducing differentiation. The low level of 
0 C T 4 present in CEB 17 and CEB 18 7 day cultures demonstrates that these cultures had begun to 
differentiate, but complete loss o f pluripotency was only observed after 14 days' culture. Expression 
o f this marker is maintained at a low level at all time points in the CEB 16 cultures highlighting its low 
efficacy. 
Expression o f the two neuronal markers TUJ-l and NSE was up-regulated in the retinoid treated 
cultures. TUJ-I was detected in all undifferentiated cultures but expression increased significantly 
during differentiation, which is seen most clearly in the CEB compounds, Am580 and TTNPB blots. 
Low levels o f NSE were also present in the EC sample and its expression increased slightly in the 
control cultures. The retinoid-treated cultures all show temporal increases in NSE expression, beyond 
that observed in the control cultures. Levels o f expression are consistent with the previously observed 
order o f efficacy. 
Expression o f the three retinoic acid receptors, RAR-a, R A R - P and RAR-y was also investigated. 
R A R - P was not detected in any o f the samples (data not shown), although a positive control was not 
analysed so this cannot be interpreted as absence o f expression in TERA2.cl.SP12 cells and their 
retinoid-differentiated derivatives. RAR-a expression was observed at very low levels in 
undifferentiated TERA2.cl.SP12 cells and cells maintained under control conditions. Moderately 
elevated levels o f RAR-a protein were detected in all retinoid cultures and also the day 7 LG100268 
culture. RAR-y is also expressed in TERA2.cl.SP12 cells. The control cultures contain the most 
protein although the day 0 result appears anomalous and further samples should be analysed to 
confirm the large difference. Expression o f RAR-y is decreased in the retinoid differentiated cultures. 
The levels o f both RAR-a and RAR-y appear to fluctuate between time points, which may suggest 
multi-phasic expression o f the receptors during differentiation, or be indicative o f high levels of 
biological variation. 
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Cytokeratin 8 (C8) and fibronectin protein expression were analysed as indicators o f non neural 
differentiation. The delicate C8 protein underwent significant fragmentation prior to analysis which 
resulted in the visualisation o f multiple bands of decreasing molecular weight. C8 expression at day 0 
is very low; it appears to increase slightly in the control cultures and more significantly in the retinoid 
cultures during the course o f the experiment. The highest levels o f C8 appear to be present in some o f 
the CEB cultures but fragmentation makes a thorough analysis o f expression impossible with these 
data. A trace amount o f fibronectin protein was observed in the undifferentiated sample, which 
increases in all other cultures in a time-dependent manner. The highest expression o f this protein was 
detected in cultures grown with the natural retinoids and CEB 16. 
NF68, NF160, NF200, RAR -P , nestin and MAP-2 were not detected by this procedure; however, 
positive controls were not attempted. 
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Figure 3-31: Western blot analysis of selected neural and non-neural antigens during retinoid-induced differentiation of TERA2.cl .SP12 huEC cells. Cells were continuously treated 
with 10 | iM of the specified retinoid or maintained under control conditions for 7, 14 or 28 days. Expression of p-actin was used as a loading control. 
Notes: * protein sample was unusually viscous and difficult to pipette accurately. Some of the resulting protein bands are broader or ran faster than expected ( 0 C T 4 , C8, P-actin). 
t Protein has degraded to varying degrees during storage/processing. J Protein samples were separated on a 5% polyacrylamide-SDS gel to enable detection of large (220-240 kDa) 
protein. Resulting elution was slower than a 10% gel and lead to large variations in elution rates between lanes. § Transfer from gel to membrane failed for these three samples. 
3.8 Synergism with a retinoid X selective agonist 
Retinoid X agonists (rexinoids) are unable to induce differentiation by themselves, as demonstrated by 
morphological and f low cytometric analysis o f the activity o f LG100268 on TERA2.cl.SP12 huEC 
cells. However, rexinoid agonists are able to synergistically increase the differentiation potential o f 
RAR agonists,""' as has previously been demonstrated in EC cel ls ." ' The synergistic potential of 
LG100268 was therefore investigated in combination with five o f the other retinoids in Table 3-1, 
applying a combination o f 5 | i M LG100268 and 5 |a.M o f RAR agonist simultaneously for a 
continuous period of 14 days. TERA2.cl.SP12 cells were grown in either a vehicle control ( 0 . 1 % 
DMSO), or culture media supplemented with 5 LG 100268, A T R A , 9-cis-RA, C E B l 6 , CEBIT or 
CEB18, or a combination o f 5 |aM LG 100268 and 5 A T R A , 9-C/5-RA, CEB16, CEB1T or CEB18. 
Phenotypic observations were made as the cultures matured, and f low cytometric analysis o f the stem 
cell marker TRA-1-60 and two markers o f neural phenotypes, VIN-IS-53 and A2B5, was performed 
after T and 14 days' culture. 
3.8.1 Results 
Phenotypic observations 
Representative phase micrographs o f the developing cultures were recorded after T and 14 days' 
culture (Figure 3-32-Figure 3-35). As observed previously, treatment with LG 100268 (LG268) alone 
did not induce morphological differentiation: the cultures developed identically to the DMSO control 
cultures (Figure 3-32 and Figure 3-34). Cultures treated with 5 | i M A T R A , 9-c/5-RA, CEB 16, CEBIT 
or CEB 18 all underwent phenotypic changes consistent with differentiation into neural and non-neural 
cell types, with the same order o f efficacy observed earlier, but to a lesser degree than the 
corresponding l O ^ M cultures. Addition o f 5 i^M LG 100268 to the retinoid cultures induced small 
changes in some o f the cultures consistent with enhanced differentiation, when compared to the 
corresponding 5 ) iM culture without LG 100268. At the T day time point, this was only noted in the 
CEB 18 + LG 100268 culture (Figure 3-33), but by 14 days' growth small differences were observed in 
the 9-cis-KA + LG 100268 culture (Figure 3-34) and significantly greater neural development was 
present in the CEB 16+, CEB1T+ and CEB 18+ LG 100268 cultures (Figure 3-35). 
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Figure 3-32: Phase images of 7 day old TERA2.cl.SP12 huEC cultures in LG100268 synergism study. Cultures grown with DMSO only and only 5 \iM 
LG268 possess only EC cell morphologies (EC), cells are tightly packed and starting to overgrow (O). The ATRA-only culture is low density and slightly 
heterogeneous, a few putative neuronal cell bodies are visible (arrow). The 5 |aM ATRA + 5 | i M LG268 culture has a slightly higher cell density than the 
culture treated with only 5 \iM ATRA, and has a similar number of individual neuron-like cells. Both 5 | i M 9-c«-RA cultures appear to be at a similar stage of 
differentiation as the ATRA-only culture, though the 9-c«-RA-only culture has a slightly higher cell density. Scale bars represent 50 |im. 
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Figure 3-33: Phase images of 7 day old TEElA2.cl.SP12 huEC cultures in LGI00268 synergism study. Both 5 CEB16 and 5 |.iM CEB16 + 5 nM LG268 
cultures appear to be at a very early stage of differentiation. Cell densities are lower than control cultures, but only a few areas show heterogeneity - the 
majority of cells present a typical EC morphology. Addition of 5 | i M LG268 to 5 j i M CEB17 and 5 nM CEB18 has enhanced phenotypic changes 
characteristic of differentiating cultures. Without LG268, the cultures are mostly EC like (CEB18 culture is slightly more mature). More putative neuronal cell 
bodies develop upon addition of the rexinoid, and cell densities are lower. Scale bars represent 50 (xm. 
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Figure 3-34: Phase images of 14 day old TERA2.cl.SP12 huEC cultures in LG100268 synergism study. The DMSO and 5 j iM LG268 cultures remain 
undifferentiated; EC-like cells are visible amongst dense and overgrowing (O) culmres. Both ATRA cultures are low density and composed of a range of cell 
phenotypes. Cultures are predominantly non neural, with a few small colonies of putative neurons and a few rosettes. The 5 \iM ATRA + 5 nM LG268 image 
shows a putative group of immature neurons, amongst large numbers of non neural (NN) phenotypes. The 9-c/5-RA cultures are more heterogeneous than the 
ATRA culmres, containing large areas of non neural cells and lots of apparent neurons. The 5 \iM 9-cis-RA + 5 |uM LG268 culture contained more neuron-like 
cells. Scale bars represent 50 jim. 
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Figure 3-35- Phase images of 14 day old TERA2.cl.SP12 huEC cultures in LG100268 synergism study. Addition of 5 LG268 to 5 nM CEB16, CEB17 and 
CEB18 cultures appears to potentiate enhanced neuronal differentiation. Al l + LG268 cultures are lower density, with larger numbers of putafve neurons and 
rosettes (R) than the corresponding 5 retinoid alone cultures. As seen previously (section 3.3), at this concentration CEB18 is the most efficacious mducer 
of neural differentiation and CEB16 the least. Scale bars represent 50 |im. 
Flow cytometric analysis 
The expression o f three cell surface antigens in the cultures we measured by indirect f low cytometry 
after 7 and 14 days' continuous exposure to retinoids. The geometric mean fluorescence intensity 
( M F l ) o f stem cell marker TRA-1-60 and neural markers VIN-IS-53 and A2B5 is presented in Figure 
3-36 and Figure 3-37. On both graphs the M F l o f one antigen is shown on a secondary axis for clarity. 
A t both time points, the results o f the 5 ]iM LG100268 culture are highly comparable to the DMSO 
control. As before (Section 3.4), LG 100268 did not up-regulate the neural antigens and expression o f 
the stem cell marker VrN-lS-53 remained high, confirming the morphological observation that no 
differentiation had occurred. A l l 5 | i M retinoid and 5 |a.M retinoid + 5 ^tM LG 100268 cultures 
underwent antigen changes consistent with the induction o f neural differentiation. In all conditions, 
TRA-1-60 was down regulated after 7 days' culture, with varying efficiency, and was further 
suppressed by 14 days. The levels of VrN-IS-53 and A2B5 were both up-regulated relative to the 
control cultures in all conditions. 
Data for the 5 | i M retinoids highlight large differences in differentiation-inducing efficiency. Cells 
from the A T R A and 9-c/5-RA cultures had similar MFIs for all antigens at both time points. A l l three 
synthetic retinoids induced a lower level of expression of neural antigens, and reduced suppression o f 
TRA-1-60 compared to either o f the natural retinoids. In particular, the CEB16 culture contained high 
levels o f TRA-1-60 after 7 days' culture (Figure 3-36). The results for 5 [xM CEB17 and 5 ^ M CEB18 
are similar at 7 days, but CEB17 appeared to induce neural differentiation more efficiently at the 14 
day time point. However, as the data are only drawn from one batch, this may be insignificant. 
Combining 5 LG 100268 with 5 \iM retinoid appears to potentiate differentiation in all of the 
cultures after 14 days. After seven days, the M F l o f both neural antigens was markedly higher in the 
CEB17 + LG100268 and CEB18 + LG100268 cultures than in cultures grown in the presence of only 
CEB17 or C E B I 8 respectively. No differences were observed in any o f the other cultures at this time 
point. After 14 days' culture, small differences are observed upon addition o f LG 100268 to both 
A T R A and 9-C/5-RA, although repeat analyses o f further batches would be required to confirm the 
trend. A large difference was observed when CEB18 was supplemented with LG 100268, continuing 
the trend observed after 7 days. Small differences in M F l were also visible in the CEB16 and CEBl 7 
+ LG 100268 combinations. 
The synergistic improvement o f differentiation upon addition o f the rexinoid LG 100268 is identical 
for all retinoids tested in this experiment, even 9-c/^-RA which has both RXR and RAR binding 
aff ini ty. It therefore seems likely that repeat analyses would confirm this relationship. 
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Figure 3-36: Flow cytometric analysis o f the ability o f rexinoid LGl00268 to synergistically 
potentiate retinoid-induced differentiation in TERA2.cl.SP12 huEC cells. A combination o f 5 |j.M 
LGl00268 and 5 retinoid were applied continuously. Data presented are the geometric mean 
fluorescent intensity o f three antigens after 7 days' culture. ( n = l ) 
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Figure 3-37: Flow cytometric analysis o f the ability o f rexinoid LGl00268 to synergistically 
potentiate retinoid-induced differentiation in TERA2.cl.SP12 huEC cells. A combination o f 5 \xM 
LGl00268 and 5 [iM retinoid were applied continuously. Data presented are the geometric mean 
fluorescent intensity o f three antigens after 14 days' culture. ( n = l ) 
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3.9 Retinoid effects on SIH-SYSY neuroblastoma cells 
Neuroblastoma is the most common extracranial solid tumour o f childhood and is responsible for 
approximately 15% o f all childhood cancer deaths.^"* It is an embryonal cancer o f the sympathetic 
nervous system, and presents both a heterogeneous malignancy and prognosis."' A T R A , 13-C/5-RA 
and fenretinide are three retinoids that have been used with some success as chemotherapeutic agents 
in the treatment o f neuroblastoma."^ However, the search continues to find a treatment with improved 
pharmacokinetic properties and improved clinical results. 
The third generation human neuroblastoma cell line SH-SY5Y shows morphological and biochemical 
properties o f cells similar to those derived from sympathetic neurons o f the embryonic neural crest. 
These cells can be used to further investigate the ability o f synthetic retinoids to induce differentiation 
in a clinically relevant model. Working in collaboration with Dr. Chris Redfem's research group at the 
Northern Institute for Cancer Research, Newcastle University, the effects o f CEB16, CEB17 and 
CEB18 compounds on SH-SY5Y cells were investigated. Data pertaining to the morphological 
changes induced in response to the compounds, and the ability o f these compounds to protect the cells 
against fenretinide-induced cell death are presented. 
3.9.1 Neurite outgrowth 
When cultured in the presence o f A T R A and a number o f other retinoids, SH-SY5Y cells 
morphologically differentiate towards mature ganglion-like c e l l s . C h a n g e s are observed within a 
few days such that the ability o f compounds to induce neuronal differentiation can be assessed quickly 
by comparing neurite outgrowth. This observation provides a simple and fast method o f screening the 
efficacy o f retinoids in the SH-SY5Y neuroblastoma cell line. 
Control cells treated with only the vehicle (ethanol, 0 . 1 % 7 .^) exhibited the same morphological 
appearance as before treatment. Cell bodies were rounded or slightly elongated, wi th short, stunted 
processes emanating f rom the cell body. After treatment, cells typically appear more neuronal with 
more rounded cell bodies and long thin processes, or neurites.^"* In this experiment the differentiating 
cell bodies have yet to adopt the dense, rounded morphology, but there are clear differences between 
the different treatments in neurite outgrowth. A T R A was the most effective, then CEB16, CEB17 and 
finally CEB18 (Figure 3-38). 
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Figure 3-38: SH-SY5Y morphological observations. 
A; Control (0.1% 7v ethanol): cell bodies are generally rounded, with short processes (arrows). 
B: Positive control (10 i^M ATRA + ethanol: cell bodies have become elongated, extending long neurites. 
C: 10 (iM CEB16 + ethanol: more processes are visible than in the control, but less than observed in response to 
ATRA. The most effective of the three synthetic retinoids tested. 
D: 10 \xM CEB17 + ethanol: some neurite extension visible. 
E: 10 i^M CEB18 + ethanol: least evidence of neuronal differentiation. 
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3.9.2 Fenretinide induced apoptosis 
Fenretinide (aII-/ram'-A'-(4-hydroxyphenyl)-retinamide, 4-HPR, structure J in Appendix 1) is an 
extremely active synthetic retinoid that inhibits proliferation in cancer cells and induces apoptosis in 
certain cancer cells. It also shows minimal toxicity during long-term administration to patients in 
clinical trials. These features have lead to large scale clinical trials in a range o f cancer studies."' It is 
a highly selective activator o f RAR-y,^'" which may explain its favourable pharmacological properties. 
but also exerts activity via non-retinoid pathways. 237,253 
As a second experiment to measure the activity o f the synthetic retinoids on SH-SY5Y neuroblastoma 
cells compared to A T R A , the ability of the retinoids to inhibit fenretinide-induced apoptosis was 
investigated. Cultures were treated with 10 [iM o f A T R A or test retinoid for 24 hours, then with 5 |j,M 
fenretinide for a further 24 hours to induce apoptosis. Apoptosis was quantified using f low cytometry 
to measure the percentage o f propidium iodide-stained cells. The activity o f CEB16, CEB17 and 
C E B l 8 was then expressed as a percentage o f the observed A T R A inhibition o f fenretinide-induced 
apoptosis (relative to non-retinoid-treated cells). As shown in Figure 3-39, all the synthetic retinoids 
were less effective at preventing apoptosis than A T R A at this concentration. C E B l 6 had the strongest 
effect, then C E B l 7 (with a large standard error o f mean (SEM)), and finally C E B l 8. 
ATRA CEB16 CEB17 CEB1£ 
Retinoid (10 nM) 
Figure 3-39: Apoptosis-inhibitory activity of three synthetic retinoids relative to 10 | i M A T R A (n=3, 
error bars +1 SEM). 
96 
3.10 Discussion 
All-/ra/75-retinoic acid has been used to modulate embryonal carcinoma (EC) stem cell fate for over 
thirty years and induces a range o f well defined morphological and immunological changes.''" The 
differentiation propensity of different EC lines varies, for example F9 murine (mu) EC cells 
differentiate into endodermal cell types,''^^ the PI9 muEC cell line undergoes neuro-ectodermal 
differentiation,''*" whereas NTERA-2 human EC (huEC) cells and their derivatives predominately 
differentiate in an ectodermal direction.''^' However, A T R A alone is not sufficient to recapitulate the 
neural specification observed in v/vo.' '" ' " ' Embryonic stem (ES) cell culture requires the addition o f 
further trophic factors, including sonic hedgehog, to induce development and specification beyond 
caudally fated neuroepithelial cells.' '" Furthermore, it has been suggested that neuro-epithelial 
differentiation may be the default differentiation pathway o f ES cells in v / / ro ' " and that induction o f 
this phenotype may not require addition o f exogenous A T R A . ' ' ' 
In common with many human EC cell lines, TERA2.cl.SP12 retains the capacity o f its germ cell 
origins to differentiate in v/Vro."'' "^ Spontaneous differentiation occurs in sub-optimal culture 
conditions, which can be limited by consistent handling. Treatment with compounds such as A T R A 
and hexamethylene bisacetamide ( H M B A ) also induces differentiation, enabling the convenient use o f 
huEC cells as a model o f embryonic development.'*^* In response to exogenous A T R A TERA2.cl.SP12 
cells differentiate into heterogeneous cultures; approximately 10-15% o f cells commit toward 
becoming mature neurons, the remainder o f cells produce non-neuronal cell types including epithelial 
colonies.''^*'''^* This pattern o f differentiation was observed in this work in response to natural"'' and 
synthetic retinoids, although the proportions o f cell types observed and the speed of exit f rom the cell 
cycle varied significantly between compounds. 
In the screening and characterisation experiments presented in this chapter, except for the rexinoid 
synergism study, the retinoids were all applied at a final concentration of 10 | i M . ATRA has 
previously been used to successfully differentiate TERA2.cl.SP12 huEC cells at this concentration.''"* 
10 ^ M A T R A is at the upper end o f the range o f retinoid concentrations that have been described in 
many published in vitro experiments,'" which may be partly explained by the reduced sensitivity o f 
EC cells and the ratio o f cell number to number of moles of retinoid in culture medium.''** Significant 
differences in uptake o f retinoids has previously been noted between different cell lines.''*' I f the cells 
were to metabolise the retinoid only slowly, then the exposure o f each cell to the retinoids would be 
constant throughout the experiment. However, it is known that A T R A is rapidly metabolised by cells 
and it is also degraded by the culture environment.'*' ''**'''** Furthermore, cell culture density increases 
rapidly during the experiment, as the cells continue to proliferate, such that the concentration o f 
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retinoid that the cells experience w i l l decrease significantly during the course o f the experiment. 
Anecdotal observations, based upon a unique experiment, indicate that the frequency o f media change 
appears to be a significant variable in differentiation studies (data not shown). When retinoid-
supplemented culture media was replaced daily, differentiation was induced more quickly compared to 
the standard frequency of every three days. Whereas changing the media less frequently than normal 
(every five or six days) resulted in even slower phenotypic changes. Regular supply o f fresh media 
may give the cells an advantage over cells grown predominantly in old media containing cell debris 
and other degradants, but it also seems that the depletion o f A T R A between media changes has an 
effect on cell growth and development. In high density cultures the frequency o f media changes and 
therefore presumably fluctuations in retinoid concentration are an important factor in differentiation 
efficacy. Synthetic retinoids that are less labile than A T R A may provide a more consistent source o f 
differentiation induction. 
During all differentiation experiments the cultures were continuously exposed to the test retinoid. At 
every media change the appropriate concentration o f retinoid was mixed thoroughly into the 
replacement media. In studies that used concentrations o f less than 10 ^ M , the retinoids were added to 
media immediately before use, as stability studies have demonstrated degradation o f the natural 
retinoids to be first order^"'' and, consequently, lower concentrations o f retinoid are expected to show 
elevated degradation kinetics. It was not investigated whether continuous exposure was necessary for 
optimal or terminal differentiation, though this has been demonstrated in other cancer cell lines.^'^ 
Human EC and ES cells tend to differentiate and/or grow poorly at low cell densities due to the loss o f 
cell-cell contacts,"*^* mediated through the NOTCH pathway.^"'^'^ In accordance with these 
observations, TERA2.cl.SP12 EC cells are also maintained at high density.'''^ To l imit and control for 
the effects of spontaneous differentiation during experiments, TERA2.cl.SP12 cells were seeded at a 
density o f 20 000 cells/cm^ in every experiment for which data are presented. Cultures seeded at lower 
densities were observed to respond differently to treatment (data not shown), which is consistent with 
other studies.^"' Unfortunately, high density seeding coupled with the relatively fast doubling time and 
slow initiation o f differentiation (and consequent late exit o f cell cycle) led to cultures quickly 
attaining and surpassing confluency. High culture densities made morphological and 
immunocytochemical features d i f f icul t to record photographically. 
Phenotypic observations 
The vehicles ( 0 . 1 % 7 , DMSO, D M F and ethanol), 5 mol% acetone, LGl00268 and the three 
"conjugated rigid rod" compounds (Table 3-2) induced no changes in culture appearance compared to 
a TERA2.cl.SP12 control culture throughout the experiments. The tolans and BPEB have some 
structural similarities to retinoid ligands but they appear to be unable to bind and transactivate the 
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RAR receptors to induce differentiation. It is essential that the vehicle has no effect on cell behaviour. 
The eight-week old DMSO culture that had been trypsinised, then replated at a lower density and 
maintained for longer than before may have behaved differently to a culture grown undisturbed in 
DMSO enriched media for eight weeks. The putative neuronal colony observed under these conditions 
may be due to spontaneous differentiation independent o f the presence o f DMSO. This concentration 
o f DMSO ( 0 . 1 % 7v, 14 m M ) has previously been demonstrated to be non-toxic and not induce 
differentiation in other EC cell l i n e s . H o w e v e r , other studies suggest that DMSO can affect cell 
behaviour down to 0.1%.^'^ Neuronal differentiation was reported in TERA2 huEC cells in response to 
a higher concentration, 1% DMSO.''^' The same concentration o f DMSO should be used in all 
experiments to negate any effect on cell behaviour. 
The three natural retinoids, A T R A , 9-CJ5-RA and 13-C/5-RA, three synthetic retinoids prepared by the 
author (CEB16, C E B l 7 and C E B l 8 ) and the commercial retinoids Am580 and TTNPB all induced 
phenotypic changes consistent with differentiation. CEB16, CEB17 and CEB18 were less efficacious 
than the other compounds at this concentration (10 ^iM). These compounds are all known in the art: 
C E B l 8 has been used in a number o f i n vitro studies,"^'" '^"' ' '" '" ' and C E B l 7 binds to RAR-p and 
RAR-Y,'"^ but no biological data have been published for C E B l 6 . C E B l 8 shows no activity towards 
the RXRs but does bind all three RAR isotypes weakly. It shows a preference for RAR-P and RAR-y 
for which the binding affinities have been measured at 9.5 and 19 times weaker than A T R A 
respectively. C E B l 8 is consequently unable to transcriptionally activate RAR-a , but activates RAR-P 
and RAR-y similarly to A T R A (Table 3-7)."'* Whilst these data are specific to the cell type and assay 
used in this study, they are believed to be indicative o f relative binding aff ini ty. Conversely, C E B l 8 
was found to be more than ten times as active as A T R A in the reversal o f keratinisation in hamster 
tracheal organ culture, but up to 70% less active than A T R A in another assay.'''^ 
Table 3-7: Comparison o f retinoid receptor transcriptional activation and competitive binding activity 
for A T R A and C E B l 8. Extracted f rom Gambone, 2002."* 
Compound 
Competitive binding activity, /Cd(nM) Receptor transcriptional activation, 
EC5o(nM) 
RAR-a RAR-P RAR-y RAR-a RAR-P RAR-y 
ATRA 14 11 16 240 38 6 
CEBl 8 600 103 301 >1000 103 301 
Radial arrangements o f columnar cells, described as rosette-like features, are observed in the 
differentiating cultures, as noted previously in this cell type and reported in human and mouse ES 
cells.^°^'" ' These rosettes are described as the developmental signature o f neural progenitors; they are 
nestin positive (see Section 3.6 and literature^"^) with broad differentiation potential towards CNS and 
PNS fates." ' " " Under appropriate conditions, rosettes derived f rom huES cells develop into neural 
tube-like structures,'"' but in the absence o f these signals, isolated neural rosette cells rapidly lose 
rosette organisation and progress to a more restricted stage o f differentiat ion." ' Induction of 
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differentiation in TERA2.cl.SP12 huEC cells by natural and synthetic retinoids as described herein 
therefore appears to mimic a stage o f the normal neuro-ectodermal development that takes place in the 
human embryo."^ 
Quantification of stem cell and neural antigens by flow cytometry 
Differentiation was monitored and quantified by measuring the levels o f characteristic cell surface 
markers: stem cell specific markers are down-regulated, whilst other markers o f more differentiated 
phenotypes are induced. A number o f markers are well established in studying EC cell 
differentiation.''"' Two stem cell markers, SSEA-3 and T R A - l - 6 0 , were chosen to assess loss o f 
pluripotency,''^*'''^'' and two neural associated markers, VrN-IS -53 and A2B5,'''' ' ' '*^ were measured to 
quantify differentiation towards neural lineages. 
Flow cytometric analysis o f these four extracellular antigens clearly distinguished between the 
compounds that were morphologically observed to induce differentiation and those that failed to affect 
these cells. The stem cell markers were rapidly down-regulated and neural associated antigens were 
concomitantly up-regulated. The small standard deviations in the data demonstrate the reproducible 
effects o f the compounds on TERA2.cl.SP12 cells. Analysis o f the kinetics o f suppression/acquisition 
o f immunophenotypic markers, in combination with the calculated statistically significant differences 
between conditions, can be used to quantify the relative potencies of the test compounds. From day 7 
data, the order o f loss o f pluripotency markers and acquisition o f neural antigens in response to 
retinoid treatment can be summarised as: 
13-c /5-RA>9-cz5-RA=ATRA>CEB 18>CEB 1 7 » C E B 16 
This trend is in good agreement with the morphological data, although no tangible differences were 
observed between the phenotypes o f the A T R A , 9-c/<r-RA and H-cw-RA treated cultures. The 
enhanced differentiation-inducing ability o f 9-cw-RA and 13-C/5-RA compared to ATRA has also 
been noted in the neuroblastoma cell line SH-SYSY.^*" A T R A is only able to bind to the RARs, while 
9-c/j-RA is able to bind strongly to both the RARs and RXRs, and 13-C/5-RA shows moderate affinity 
for both receptor families. '*'" '" The differential effects o f these isomers is believed to be due to 
additional or alternative mechanisms o f action compared to A T R A . The RXR-binding affinity o f 9-
c « - R A may enable it to induce activity through additional pathways and \3-cis-RA is believed to act 
as a prodrug for A T R A . ^ " " * 
Flow cytometry data o f the DMSO cultures show some changes typical o f cells undergoing slight 
differentiation, particularly after 28 days (Figure 3-11). This would seem to confirm the appearance of 
morphologically identifiable neurons in one mature culture. However, it is interesting to note that the 
data for LG100268 (dissolved in DMSO) is comparable to the control culture. 
100 
Proliferation 
A tetrazolium colourimetic assay was employed to quantify the observed differences in proliferative 
capacity o f TERA2.cl.SP12 cells undergoing retinoid induced differentiation. The MTS compound (3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt) 
is reduced by viable cells into a soluble coloured product which is measured by U V absorbance, and 
can thus be used to compare the effects of compounds on cell toxicity or prol iferat ion. '" " ' Although 
it has been suggested that mitochondrial activity w i l l be affected in cells undergoing differentiat ion, '" 
others report that tetrazolium reduction capacity o f a cell line are not altered by differentiation." ' 
Preliminary studies determined that MTS absorbance results were in good correlation with total 
protein content o f culture undergoing retinoid-induced differentiation (data not shown); furthermore, 
the MTS assay results were also more reproducible than protein measurement. 
Dose response curves o f cultures growing in 10 | i M retinoid were produced using the MTS assay data 
(Figure 3-14). The vehicle (DMSO) had no effect on the growth o f TERA2.cl.SP12 huEC cells for the 
duration o f the experiment and provides further confirmation o f the morphological and flow 
cytometric data. This is important since DMSO can have anti-proliferative effects on cells, and may 
itself induce differentiation at higher concentrations.''*"''" '^'' 
A t the first time point (3 days), treatment with CEB16, CEB17 and CEB18 was found to have slightly 
increased the number o f viable cells in the culture whilst A T R A , 9 -c«-RA and 13-c;>RA had all 
suppressed cell proliferation. After this initial period, when the CEB compounds appear to have 
promoted enhanced cell survival or mitosis, retinoid treatment resulted in reduced numbers of cells 
compared to the control. The CEB compounds and the natural retinoids formed two groups that were 
distinct in their effects on proliferation at all time points, though large standard deviations in the data 
(predominantly due to biological variation between batches) resulted in statistically insignificant 
differences. 
In older and highly confluent cultures, particularly the controls, cells were easily dislodged during 
media changes and the PBS-wash prior to addition o f MTS reagent. This increased the variation 
between samples at later time points. Further errors were introduced by the presence of cell debris in 
some samples, which affected the absorbance readings. Once this effect was noted, further samples 
were centrifuged briefly and the UV absorbance o f the supernatant was measured. The solution o f 
MTS reagent + culture media removed from cells after 4 hours' incubation was diluted 1:19 with 
dH20 to ensure that the absorbance reading was within the linear range o f the spectrophotometer. This 
dilution was performed in triplicate for ail samples, at all time points for consistency. 
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Flow cytometric data showed that differentiation was induced more slowly in cultures treated with the 
synthetic CEB retinoids than in cultures treated with the natural retinoids. The maintained or even 
enhanced proliferation observed in the MTS assay appears to confirm that cells treated with the CEB 
compounds were slower to exit the cell cycle and hence remained proliferative for longer than the 
natural retinoids. Alternatively, the CEB compounds may be less toxic than the natural retinoids at this 
concentration, or may otherwise promote differentiation in TERA2.cl.SP12 cells. Natural and 
synthetic retinoids are known to exert their biological effects through a number o f pathways and 
mechanisms. In addition to mediating differentiation, anti-proliferative and apoptosis-inducing effects 
are also being harnessed in retinoid therapy.'" 
This study would be complemented by an analysis o f the expression o f Ki-67 during differentiation o f 
different retinoids. This antigen is expressed only in proliferating cells and is lost when cells exit the 
cell cycle (GO), i.e. when cells have reached an end stage in their development, for example 
commitment to development o f differentiated phenotype. This data would provide an authentic 
indication o f the induction potential o f the different retinoids. 
Immunocytochemical analysis of neural and non neural antigen expression 
The expression o f genes known to be involved in the formation o f the vertebrate nervous system was 
examined during retinoid-induced differentiation o f TERA2.cl.SP12 cells. Immunocytochemical 
localisation permits the positive identification o f cells that were previously only putatively labelled 
from their characteristic morphology. A qualitative assessment o f the intensity and maturity o f the 
patterns o f expression o f each antibody provides another indication of the maturity o f each of the 
cultures. 
Cultures induced to differentiate by all active retinoids expressed neuron-specific genes in a 
developmentally controlled manner. Nestin was expressed at an early stage o f differentiation but was 
down-regulated as the cultures matured. Young neurons expressed TUJ-1 and then NSE and MAP2 as 
they matured. NF68 and NF200 staining further established that the neurons in these retinoid-
differentiated cultures were mature and similar in structure to naturally occurring neurons.''^' "^ 
Non-neural antigens were also expressed, consistent with the heterogeneous pattern o f differentiation 
typically observed in response to A T R A . CEB16, CEB17 and CEB18 induced the formation o f a 
greater number o f cytokeratin 8-positive epithelial colonies than was observed in the other cultures. 
These compounds may promote epithelial differentiation, be less effective at inducing neuronal 
differentiation or these colonies may develop as a consequence o f the higher cell density. Low levels 
o f fibronectin expression were detected in the undifferentiated culture, opposing previous reports that 
human EC cells in culture do not synthesize fibronectin until they differentiate."" Western blot 
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analysis did not detect fibronectin in cells that had always been maintained at optimal culture 
densities. The immunocytochemical detection of fibronectin may therefore indicate that these EC cells 
were slightly sub-optimal after being seeded at 20 000 cells/cm'. 
The strength o f immunocytochemistry (ICC) as a technique for studying gene expression lies in its 
ability to detect and localise a specific antigen in a cell. Whilst other methods such as real-time PCR 
or f low cytometry are better suited to the accurate measurement o f expression levels, for which ICC 
can only be semi-quantitative, the additional information about localisation within a cell can 
distinguish between different gene isotypes with potentially different funct ional i ty ." ' For example a 
number o f different C8-positive cell types were observed which w i l l not be distinguishable by western 
blot analysis. 
Western blot analysis 
Western blot analysis supported the qualitative assessments o f antigen expression determined by 
immunocytochemical staining and also examined expression of the retinoic acid receptors and 0CT4. 
Although data are only presented for one sample o f protein for each retinoid/time point, further 
batches o f some samples were analysed during preliminary experiments and were found to have 
similar levels of expression. Protein samples were collected from cells grown under the same 
conditions as previous experiments and all cultures that were analysed developed in a manner that was 
phenotypically identical to other batches. It is therefore believed that the western blot data presented is 
representative o f retinoid induced differentiation o f TERA2.cl.SP12 cells. 
Western blot analysis confirmed the absence o f differentiation in the control and LG 100268 cultures. 
Expression o f the pluripotency marker 0CT4 was maintained and antigens associated with 
differentiation were not significantly up-regulated in these cultures. Conversely, the retinoid treated 
cultures suppressed 0 C T 4 and this was accompanied by increases in expression of neural and non-
neural antigens. Protein expression levels o f the differentiated phenotypes are consistent with 
immunocytochemical data, the previously observed order o f differentiation-inducing efficacy and 
previously published data for this cell line."^' ''"^''''* 
The control cultures showed some changes in protein expression from the day 0 undifferentiated 
TERA2.cl .SPl2 EC cells. Cells were seeded at a lower density for the retinoid experiments compared 
with routine propagation o f the cell line, and were maintained beyond confluency (which was attained 
approximately 5 days into an experiment). The resulting cells are therefore sub-optimal and this is 
reflected in altered antigen expression by the cells. 
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Retinoic acid receptor expression 
This study demonstrates for the first time that retinoid receptors are expressed in TERA2.cl.SP12 
huEC ceils and that treatment with retinoids can modulate their expression. The protein expression 
profiles for RAR-a and RAR-y are not easily explained f rom these data and may reflect a complicated 
response to retinoid treatment. RAR-a was not detected in undifferentiated EC cells but was up-
regulated in some o f the retinoid cultures; however, protein levels are too low for a clear analysis o f 
relative expression. RAR-y is expressed at high levels in the control cultures and appears to be down-
regulated in the retinoid cultures, but not in a manner consistent with the stage o f differentiation. The 
levels o f both RAR-a and RAR-y appear to fluctuate between time points, which may suggest multi-
phasic expression of the receptors during differentiation, or indicate high levels of biological variation. 
Changes in the expression o f the retinoid receptors intimates at their involvement in the differentiation 
o f these cells with the retinoids tested. There is extensive evidence to suggest that ATRA is able to 
directly modulate the expression of its own receptors.'^^ A l l retinoids in the western blot study except 
CEB16 and LG100268 are known to bind to the RARs. Although it is feasible that the RARs may be 
regulated indirectly by other processes related to CEB16 differentiation, it seems highly probable that 
this compound is also a bona fide RAR agonist and is activating the classical retinoid pathway. 
RAR-a , RAR-p and RAR-y are differentially expressed in different cell types and differentially 
regulated during ATRA-induced differentiation, suggesting that they may regulate different sets o f 
g e n e s . G e n e expression studies in a number o f EC cell lines have revealed some differences in the 
regulation o f RAR transcripts during ATRA-induced differentiation. Broadly speaking, A T R A 
treatment induces moderate up-regulation"'""' or no change''•^'"''^''^ in the level o f RAR-a mRNA 
transcripts, rapid and dramatic increases in RAR-P mRNA^' ''*"^'^"""'''" and either suppression"^ or 
elevation'^* "''^^""'"'' o f RAR-y m?M\. Underlying this generalisation is a more complex regulation of 
the RAR isoforms, which was not investigated in this study, but further adds to the multiplicity of the 
retinoid pathway. Specifically, RAR-Uy is induced by A T R A treatment whilst RAR-ai expression is 
unaffected." ' RAR-fti is the major isoform o f this receptor to be activated and RAR-fti and RAR-jSj are 
not modulated.''*' Furthermore, induction o f RAR-P2 has been reported to occur in a temporary'*** or 
biphasic manner, suggesting that multiple factors and/or different mechanism are involved in 
controlling its expression."* Finally, RAR-yy mRNA is strongly induced while RAR-yi can act as a 
transcriptional repressor and antagonise expression.''*'''''''' ' ' " '''* Maintained expression o f RAR-
y2 may require continuous exposure to retinoid.'''* These primary target genes for A T R A are unified by 
the presence o f retinoic acid-responsive elements within their promoters which permit rapid and 
specific gene regulation.''''* ' ' " • ' " 
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The western blot data for retinoid differentiated TERA2.cl.SP12 cells appear to be in good agreement 
with the reported expression behaviour for RAR-a, which was moderately up-regulated. Similarly, 
because the RAR-y antibody only recognises the RAR-y: isoform, the results are as expected and agree 
with one report o f suppression o f RAR-y. Almost all reports of A T R A regulation o f the retinoic acid 
receptors analyse the regulation o f mRNA transcripts while only a few measure protein expression, the 
real biological effector. While gene expression is correlated to protein expression, it is not directly 
related and cannot be used to predict protein levels. '" Furthermore, western blot analysis o f RAR 
expression has been reported to not always detect these proteins, even when mRNA regulation has 
been observed."' The above data should therefore be interpreted carefully. It is unfortunate that RAR-
P was not detected using this protocol as RAR-P2 is o f particular interest given its strong association 
with tumour suppression''* '^ '^ and its expression can be used as a cellular marker of retinoid activity. 
Synergism with a rexinoid 
LG100268 (2-[ 1 -(5,6,7,8-tetrahydro-3,5,5 ',8,8'-pentamethy 1-2-naphthaleny 1) cyclopropy l]-5-
pyridinecarboxylic acid) is an RXR-P specific agonist with 3-4-fold higher affinity and 10-fold greater 
transactivation activity for the RXR receptors compared to 9-c/5-RA.^°''^" As observed in the 
TERA2.cl .SPl2 cells, RAR ligand-mediated physiological responses are separable and distinct from 
RXR ligand activation functions. '" Rexinoid agonists are able to induce co-activator recruitment to 
RXR but cannot dissociate co-repressors from the transcriptional complex, a phenomenon known as 
RXR subordination. "'•^°°''°^ Consequently, in common with other RXR agonists, LG 100268 is unable 
to induce differentiation a l o n e . H o w e v e r , numerous reports have demonstrated that RXR ligands 
have the ability to synergistically increase the potency o f RAR ligands.'**'^""'^"'-*"'"'-"^ Two 
explanations for this observation have been proposed: RAR/RXR heterodimerisation is significantly 
improved when ligands for both receptors are available^" and secondly that when both RAR and RXR 
ligands are present, stability o f the RAR-P promoter occupancy is increased.^"' 
RXR-selective ligands have favourable therapeutic potential, being less toxic and more active in 
animal breast cancer prevention studies and less toxic than RAR ligands in clinical trials.^°°' '" " * Rat 
studies have demonstrated the ability o f LGl00268 to prevent and treat breast cancer, both as a single 
treatment agent and to synergistically enhance the efficacy o f Arozoxifene® (Eli L i l l y ) . " ' Similar 
behaviour and effects have been reported for LGD1069, a pan-RXR agonist (Targretin®, 
bexarotene, E).^' ' ' '^" '^' 
A key feature o f the RXR receptors is that they are able to heterodimerise and consequently activate a 
number o f different signalling pathways, including the RAR receptors,'*" thyroid hormone 
receptors,"' '*^ '** vitamin D receptor'*' and peroxisome proliferator-activated receptor y (PPAR-y). '" 
It is proposed that the mechanism(s) o f action in preventing and treating breast cancer may involve the 
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concerted activation o f several signalling pathways, including enhanced RAR/RXR activation and 
activation o f TGF-P signal l ing. '" 
Previous studies in EC , ' ' ' cervical carcinoma cells'^' and neuroblastoma cells'^'' have demonstrated 
strong synergistic effects on cell differentiation and inhibition o f proliferation respectively by 
combining an RXR selective ligand with an RAR selective ligand. The activity o f LG100268 was 
therefore investigated in combination with the other retinoids in Table 3-1 (Section 3.8). These 
compounds were either known RAR agonists, or were believed to be RAR agonists based upon their 
differentiation-inducing ability. TERA2.cl.SP12 cells were cultured with either 5 | i M o f the RAR 
agonist or LG 100268 alone, or with a combination o f 5 ^ .M RAR agonist and 5 ]iM L G 100268. The 
concentration o f D M S O in the control culture and all retinoid treated cultures was maintained at 
0 .1% "/w, consistent with previous experiments. 
The induction o f cell differentiation using a concentration o f 5 [iM was less efficient than 10|J.M 
retinoid, as shown by comparing the phenotypic observations and f low cytometric antigen analysis o f 
this experiment with previous studies (Sections 3.3 and 3.4). Although synergistic modulation o f gene 
expression has been observed in other studies without translation into promotion o f differention, 
it was found that co-administration o f LG 100268 with RAR agonists synergistically enhanced 
differentiation in all cultures, as predicted. The effects were greatest in the cultures treated with 
CEB18 + LG 100268 and less apparent in combinations o f LG 100268 with the natural retinoids. RXR 
synergism has previously been shown to have the greatest effect when compounds are used at sub-
optimal concentrations.""' The data presented here suggest that l O f i M of the natural retinoids and 
CEB16 is sufficient to induce optimal differentiation under these conditions, whereas CEB17 and 
CEB18 may demonstrate superior efficacy at a higher concentration. Preliminary experiments were 
performed in an attempt to define dose-response curves for these compounds but a satisfactory method 
could not be established within the available time. Developing an experiment to measure changes in a 
rapid-response antigen or gene (for example suppression o f OCT4) would provide an improved 
indication of retinoid efficacy compared to long-term analysis o f phenotypic changes and slowly 
acquired markers. This would enable retinoid compounds to be rapidly and efficiently screened over a 
range o f concentrations. 
SH-SY5Y studies 
Studies using the SH-SY5Y human neuroblastoma cell line provide evidence o f the ability o f CEB16, 
CEB17 and CEB18 to activate differentiation in a second cell type of clinical relevance. Both 
experiments reveal the same order of activity, which is the complete opposite to that observed in 
TERA2.cl .SPl2 cells. A l l compounds are also significantly less effective than A T R A at inducing 
neurite outgrowth and resisting the apoptosis inducing effects o f fenretinide. These data confirms the 
retinoidal activity o f the three synthetic compounds and highlights the different responses o f different 
cells. 
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3.11 Conclusions 
A T R A is used extensively by molecular biologists to investigate differentiation in a large array o f cell 
models and this ability is well characterised in the TERA2.cl.SP12 EC cell line. 9-cw-RA and \ 3-cis-
RA bind strongly to the RXR family of receptors in addition to the RAR binding activity of ATRA," ' ' " 
which enables these molecules to act via alternative additional molecular pathways. A number o f 
RXR agonists have been identified as potent inducers o f growth arrest and apoptosis in some cancer 
cells.'*' A l l three isomers are approved for the treatment o f dermatological disorders and have also 
been investigated extensively in pre-clinical and clinical studies, primarily in chemotherapy and 
prevention, to utilise their differential pharmacological profiles (Section 1.5).'^'' A l l three of the 
"natural" retinoids effectively and reproducibly induced morphological differentiation in this 
investigation. Subtle differences in antigen expression suggest that the three compounds possess 
different efficacies that may be attributable to different mechanisms o f action, mirroring the 
contrasting efficacy, toxicity and pharmacokinetics observed in clinical studies.'**' 
Morphological features present in retinoid and control cultures were identified based on their 
characteristic morphology, for example neurons are distinctive in having a round dark soma with 
extending processes. Flow cytometric analysis of stem cell and neural cell type markers was used to 
analyse the differentiation biochemically, complementing and substantiating the observed 
morphological differentiation. Differentiation was further characterised by a proliferation study and 
the analysis o f neural and non neural antigen expression by immunocytochemistry and western blot. 
The three CEB synthetic retinoids are all known. Extensive data pertaining to CEB18 (TTNM) and its 
retinoidal activities have been published, whereas information on CEB 16 and CEB 17 is restricted to 
their structures and potential activities. (See references in Table 3-1.) It was therefore expected that 
these compounds should have differentiation inducing effects, so it was gratifying to confirm that this 
preparation o f these compounds was effective in the cell line of interest. A l l three compounds induce 
neural differentiation, but with different potencies: C E B l 8 » C E B 1 7 > C E B 1 6 . In common with 
A T R A , 9-C/5-RA and 13-c/5-RA, epithelial colonies are also observed; large numbers are observed in 
CEB16 cultures. Cultures grown with CEB16-18 continue to be proliferative for longer and result in 
very confluent, multi-layered growths with high media demands. This might be due to a lower 
potency, relative to A T R A and its stereoisomers, lower toxicities or alternative mechanisms promoting 
mitosis. 
Two commercially available synthetic retinoids, Am580 and TTNPB were also investigated that were 
both found to induce high levels o f neural differentiation. To date, all compounds known to possess 
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RAR activity have successfully effected the morphological differentiation o f TERA2.cl.SP12 cells. 
The nature o f these synthetic retinoids w i l l affect their potency: they are expected to show greater 
physical stability, so are likely to persist in cultures for longer. It is also known that TTNPB and 
Am580 are not metabolised by the CYP26 enzymes that are primarily responsible for the removal o f 
A T R A from cel ls . ' " ' " 
The structures o f arotinoids such as CEB 16, CEB 17 and CEB 18 were designed by cyclising elements 
o f the labile polyene chain present in A T R A with the aim o f improving retinoid receptor binding 
selectivity and also to improve compound s t a b i l i t y . S p e c i f i c a l l y the trimethylcyclohexenyl group 
has been replaced by a tetrahydro-tetramethyl naphthalane moiety, and the carboxylic acid end o f the 
polyene chain made rigid by substituting an acrylic acid group (CEB 16 and CEB 17) or a naphthalene 
carboxylic acid group (CEB 18). 
The effect o f media-changing frequency appears to significantly affect differentiation, presumably due 
to a rapid loss o f active retinoid in the media, and merits further investigation. These data, together 
with preliminary stability results,"" ''"' highlight the need to appreciate the instability of A T R A and its 
isomers, and the effects that this may have on cell behaviour. CEB 16, CEB 17 and CEB 18 were stable 
during synthesis and the extensive manipulation involved in purification. This was confirmed in a 
unique stability study which also highlighted the moderate instability o f the acrylic acid group present 
in C E B l 6 and C E B l 7 under U V light.'*°^ These synthetic retinoids are considerably more stable than 
their natural counterparts. 
It is anticipated that CEB 16, CEB 17 and CEB 18 w i l l also be significantly more stable to store, handle 
and under culture conditions. The use o f stable pharmacological agents w i l l lead to more reproducible 
and reliable biological activity, which may facilitate superior cell culture and, ultimately, provide 
reliable entities suitable for therapeutic applications. Furthermore, stable synthetic retinoids offer 
easier handling and storage properties over A T R A , removing a variable from biological experiments. 
They are also likely to persist longer during cell culture, through a combination o f increased stability 
and inferior cellular metabolism. Taken together, these factors w i l l enhance and prolong the exposure 
of cell cultures to the retinoid, with reduced exposure to metabolites and other degradants that may 
have a heterogeneous affect on cell behaviour. 
Stable synthetic retinoids offer further advantages to in vivo studies. The profile o f metabolic products 
to be analysed during A D M E studies would be simpler and biological samples would not require the 
laborious and scrupulous procedures required to limit isomerisation o f A T R A and other labile 
retinoids after collection, during storage and sample preparation. 
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These improvements seem to offer a significant advance in cell culture techniques. However, ATRA 
has been extensively studied and its effects have been characterised in numerous cell lines, animal 
models and in clinical studies; substituting an alternative differentiation-inducing agent introduces an 
unknown - researchers have no standards to compare against. Careful validation o f the effects of 
synthetic retinoids in this context is therefore required. An additional consideration in the adoption of 
stable retinoids is safety: these compounds possess similar ( i f not greater) toxicity than A T R A , yet 
their stability w i l l prolong this hazard. 
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CHAPTER 4: INVESTIGATING THE 
MOLECULAR MECHANISM OF 
SYNTHETIC AND NATURAL RETINOID 
ACTION 
n o 
4.1 Introduction 
Endogenous retinoids are small hydrophobic molecules that associate in vivo w i th a number o f soluble 
proteins wi th high selectivity and aff ini ty. Taken together these components comprise a pathway that 
transports retinoids to their nuclear receptors in order to effect gene transcription, whilst 
simultaneously regulating cellular exposure to these potentially toxic molecules. It is becoming clear 
that biologically active synthetic retinoids, o f interest for potential therapeutic applications, do not 
necessarily invoke the same mechanism o f activation. It is necessary to identify and understand the 
effect o f retinoids on the body, and i f they interact wi th the classical retinoid pathway, in order to 
responsibly harness the therapeutic promise that retinoids offer. 
This chapter presents the results o f a study undertaken to define the role o f the molecular components 
o f the classical retinoid signalling pathway that are involved in synthetic retinoid-induced 
differentiation o f TERA2.cl.SP12 cells. 
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Figure 4-1: Schematic representation o f the extra-visual retinoid signal transduction pathway. 
Abbreviations: ROL = retinol, R A L = retinal, RBP4 = serum retinol-binding protein, RolDH = retinol 
dehydrogenase, RalDH = retinaldehydrogenase, CRBP-I = cellular retinol-binding protein I , CRABP-
I + I I = cellular retinoic acid-binding proteins I and I I , RE = D N A response element. Adapted f rom 
Klaassen and Braakhuis, 2002.'"* (Figure also presented as Figure 1-3 in Section 1.4, but included here 
to illustrate text.) 
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4.2 Retinoid-binding proteins: mediators of retinoid activity 
Vitamin A is absorbed in the intestine, stored primarily in the liver and transported to target cells in 
blood, bound to serum retinol-binding protein (RBP4).'' Within the cell, retinol binds to cellular 
retinol-binding proteins (CRBPs) and undergoes a two-step oxidation process: first it is converted 
reversibly to retinaldehyde by retinol dehydrogenases and then irreversibly oxidised by retinaldehyde 
dehydrogenases to al l- /ra«j-ret inoic acid ( A T R A ) . The CRBPs possess a low affini ty for A T R A , the 
major biologically active metabolite o f vitamin A and it instead binds with cellular retinoic acid-
binding proteins (CRABPs) which transport their ligands to two families o f specific receptor within 
the nucleus, the retinoic acid receptors (RARs) and retinoic X receptors (RXRs). After binding with 
ligands, the RARs heterodimerise with the RXRs and together they bind to retinoic acid response 
elements (RAREs) in the promoter regions o f primary target genes. This initiates a cascade o f gene 
activation or repression that ultimately leads to a particular developmental or homeostatic event.^ The 
cellular retinoid-binding proteins, in combination with the cytochrome P450 A T R A hydroxylases, are 
also responsible for the control o f A T R A catabolism, thus regulating cellular exposure to this essential 
vitamin. (Figure 4-1) 
4.2.1 Cellular retinol-binding proteins 
Retinol and A T R A circulate in the blood bound strongly to RBP4, whereas 9-cis-retinoic acid {9-cis-
RA), 13-c/5-retinoic acid (13-c/5-RA) and synthetic retinoids are transported bound to serum 
albumin.'* Retinol may then be transferred into target cells via STRA6 a specific glycoprotein cell 
membrane receptor,'"' while all other retinoids can presumably only enter cells by passive diffusion."" 
Four human cellular retinol-binding proteins are currently known: CRBP- l ' °" and CRBP-ll*" have 
been thoroughly characterised and extensively investigated, while C R B P - l I l ' ° ' (distinct from murine 
CRBP-lIl) '*" and CRBP-1V"° have been identified as putative members o f the CRBP sub-family. 
They are the cytoplasmic receptors o f all- /ra«5-retinol.*° '"° ' '"" '* ' The CRBPs are monomeric proteins 
o f approximately 15.5 kDa, that possess a sequence homology o f approximately 50% between any two 
CRBP. '° ' ' '^* However each protein has significantly different affinities for all-rram-retinol: CRBP-1 
binds -100 times more strongly than C R B P - I I , " ' -600 times more strongly than CRBP-111,'°' and 
-2000 more strongly than C R B P - I V . " ° Considering that each protein also possesses distinct tissue 
expression patterns, these properties imply different roles for the different CRBP types. In humans, 
CRBP-l is found at low levels in a wide range o f tissues with high levels o f expression present in 
ovary, adrenal and pituitary glands, and testis.'^' CRBP-II is localised to the enterocytes of the small 
intestine,*' where it absorbs retinol and facilitates its estrification by lecithin-retinol acyltransferase 
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( L R A T ) ; it is also able to bind retinal, which suggests that this protein may serve as a receptor for 
retinal formed during cleavage o f P-carotene in the enterocyte. CRBP-III is expressed mainly in liver 
and kidney,"" while CRBP-IV is expressed primarily in kidney, heart and transverse colon."" 
The CRBPs possess both high specificity and binding aff ini ty for retinol, their endogenous ligand, but 
discriminate against A T R A and cis forms o f r e t ino l . ' ° ' " ° The CRBPs facilitate the enzymatic 
oxidation o f retinol to either retinyl esters, for storage, or to retinal and subsequently A T R A . The 
CRBPs are involved in delivering retinol to microsomal NADP-dependent retinol dehydrogenase 
(RolDH), which it uses to form al l-frans-ret inal , '""" and protect retinol f rom oxidation by other 
enzymes."^' Furthermore, the CRBPs facilitate the synthesis o f A T R A by NAD-dependent cytosolic 
retinal dehydrogenases (Ra lDHs) . ' " - " ' 
4.2.2 Cellular retinoic acid-binding proteins 
The cellular (or cytoplasmic) retinoic acid binding proteins, CRABP-I and C R A B P - I I are two 
homologous low molecular weight (-15 kDa) intracellular proteins that are found in all vertebrates 
and are highly conserved across species."*'"' As with the CRBPs, there is accumulating evidence to 
suggest that the two CRABP proteins perform different and potentially complimentary roles. 
In the adult CRABP-I is almost ubiquitous, whereas CRABP-II is expressed only in skin, uterus, ovary 
and choroid plexus. '" During embryonic development both proteins are widely expressed although 
not in the same cel ls . ' " The two proteins bind A T R A strongly, but wi th different affinities: CRABP-I 
binds almost twice as strongly as CRABP-I I . ' " ' The CRABPs bind only very weakly with 9-c/5-RA 
and 13-cw-RA, ' " • " ' ' " ' presumably owing to their non-linear conformat ion , ' " ' ' " and the A T R A 
metabolites 4-oxo-ATRA and 4-hydroxy-ATRA also only bind weakly with the CRABPs.'^' They can 
also bind with a number o f active synthetic retinoids with varying binding affinities, for example 
CD367 (compound R in Appendix 1) has a greater affinity than A T R A , ' ' ' TTNPB (D) binds with 
similar aff ini ty as A T R A and Am80 (O) has only a weak affinity. '^" As with A T R A , CRABP-I and 
CRABP-II have different binding affinities for individual synthetic retinoids.''" 
Traditionally, these proteins were viewed simply as transport proteins, stabilising and protecting their 
lipophilic ligand f rom non-enzymatic oxidation and isomerisation.^ However, the CRABPs are also 
believed to play important roles in modulating the intracellular levels o f A T R A in both the adult and 
developing embryo."* ' " ' " Upon treatment with A T R A , CRABP-II , but not CRABP-I , translocates to 
the nucleus to deliver the ligand directly to the nuclear bound RARs.'^°"'"^ This movement is 
facilitated by a conformational change upon retinoid binding, which permits the holo-form o f 
CRABP-II to target the nucleus.'" CRABP-I is closely associated with regulating the metabolic fate o f 
A T R A since differentiation rate, ATRA-degradation and rate of formation o f polar metabolites have 
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all been shown to be proportional to the expression o f Q R A B P - I . ' * ' '^^•'^''•"* " ' Furthermore, crystal 
structure studies have revealed that when A T R A is bound to the CRABPs the p-ionone ring o f A T R A 
is accessible to solvent in a suitable orientation for presentation to metabolising enzymes."* 
Elevated levels o f CRABPs have been shown to be co-incident with the induced hypercatabolism 
observed during therapeutic application o f retinoids, which leads to reduced drug sensitivity and 
resistance.'""'-'^^ However, it may be that CRABP regulation is a secondary factor in reducing 
plasma levels o f A T R A during therapy, as indicated by a difference in the time-course o f CRABP 
induction and reduction in A T R A levels, and that catabolic enzyme induction is more significant (see 
section 4.2.3) ." ' 
However, the biological ftinctions o f the CRABPs are not completely clear since they are not 
absolutely essential to the retinoid signalling pathway. The knockout o f either one or both CRABP 
isoforms in mice resulted in essentially normal adult animals,'™'^*' yet mutant embryonal carcinoma 
(EC) cell lines that have little or no CRABP activity are differentiation-defective.'*" ' " Furthermore, 
despite low binding affinity to CRABP, synthetic retinoids Am80 (O), Am580 (P) and Ch55 (Q) 
regulate morphogenesis in the chick limb bud.'*" Additionally, CRABP-I binding is also not required 
for retinoid reversal o f keratinisation in hamster trachea,'*' and HL-60 human promyelocytic 
leukaemia cells are induced to differentiate in response to A T R A but lack CRABP-1.'** 
4.2.3 CYP26: A family ofretinoic acid specific P450 enzymes 
In addition to the spatio-temporal regulation o f all-^ra/u-retinoic acid synthesis, co-ordinated by the 
CRBPs, CRABPs, RolDHs and RalDHs, the cellular concentration o f A T R A is also controlled by 
metabolism and, it is proposed, isomerisation into its constitutional isomers 9-cis-RA and 13-C/5-RA. 
A T R A is metabolised and subsequently deactivated by the specific and non-specific activity of 
cytochrome P450 (CYP) enzymes,'^^ a diverse super-family of haemoproteins found in every class of 
organism that catabolise a wide range o f both exogenous and endogenous compounds via mono-
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oxygenase enzymatic reactions. ' 
The major CYP enzymes involved in the degradation o f A T R A in vivo are the A T R A hydroxylases, 
C Y P 2 6 , ' " currently divided into three isoforms in humans: CYP26A1, '"*• ' ' ' CYP26Bl ' ^ ° and 
CYP26C1.'^ ' A fourth member o f the family, Cyp26Dl , has also been identified in zebrafish.'*' The 
CYP26 enzymes play essential roles in the regulation o f A T R A exposure during embryogenesis and in 
adult t i s s u e s . T h e CYP26 genes share extensive sequence similarity but differential spatial and 
temporal distribution suggesting individual roles in the catabolism o f ATRA.'^* ' ^ ' " ° ' " A l l CYP26 
enzymes catabolise A T R A in the adult and embryo to more polar metabolites."' CYP26A1 is also 
able to oxidise retinol to 4-oxo-retinol, ' ' '° whilst CYP26C1 is more efficient at metabolising 9-c/5-RA 
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than CYP26A1 or CYP26B1. '^ ' Cyp26Dl can also metabolise 9-c/i-RA and 13 -C/5 -RA," ' however a 
range o f other cytochrome enzymes have been identified that are more effective at metabolising these 
isomers."" The metabolites o f A T R A formed by CYP26A1 include 4-hydroxy-ATRA, 4-oxo-ATRA, 
18-hydroxy-ATRA and 4-oxo-retinol 129,138-140 These intermediates can be further hydrolysed before 
they are converted to glucuronides and eliminated.^ ' '" The majority of these polar metabolites are 
inactive in the retinoid cycle, however exceptions include 4-oxo-retinol,'''"'''"' 4-oxo-ATRA,^* '''^ "^ ' ' ' ' ' 
4-hydroxy-ATRA, 18-hydroxy-ATRA and retinoyl p-glucuronide.-*'"''"^ 9- and 13-c/5-RA are 
similarly metabolised to their respective 4-hydroxy- and 4-oxo-metabolites (Figure 4-2).'''^ 
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Figure 4-2: Metabolism o f A T R A , 9-cw-RA and 13-c/5-RA. Figure adapted from Bruon, 2007.'"* 
(Figure also presented as Figure 1-4 in Section 1.4, but included here to illustrate text.) 
Expression o f the CYP26s is induced by RAR/RXR heterodimer activation and can be blocked by 
RAR antagonists.^"'^'^ Up-regulation o f CYP26 mRNA is consequently observed in response to RAR 
agonists that are not metabolised by these enzymes, including Am580 (P) and CD367 (R) , and results 
in a longer-lived up-regulation than is observed in response to ATRA."^ '^ ' ' 
Altered retinoid metabolism has been observed in a wide variety o f human cancers, both in cell lines 
and in tumour tissue samples, which is thought to result in tumour cells that are ATRA-deficient."* 
The up-regulation o f CYP26A1 accelerates the metabolism o f A T R A in patients undergoing retinoid 
therapy and is likely to be a major factor in the development o f reduced sensitivity or resistance to 
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retinoid therapy.^"''^"'•"^"* Significant intra-patient variations in CYP26A1 expression are observed 
that correlate with efficacy of treatment. It is therefore proposed that pharmacokinetic monitoring 
during retinoid therapy may identify potentially receptive patients.^'" Employing a high-dose, 
intermittent regimen, rather than continuous low-dose treatment is one way to improve clinical 
outcomes.^'""' 
A very promising alternative therapeutic area currently attracting a lot of research interest is the 
development of inhibitors of the CYP450 metabolism of endogenous and exogenous compounds.'"* "' 
Retinoic acid metabolism blocking agents (RAMBAs) specifically block CYP26 activity, permitting 
an increase in endogenous retinoid levels for therapeutic benefit,"' or alternatively act synergistically 
with A T R A or 13-<:/.?-RA to inhibit the development of ATRA-resistance."^ This approach may yield 
effective agents for the treatment and/or prevention of cancers and dermatological diseases and will 
hopefully circumvent the extreme toxicities and resistance to traditional retinoid therapy. 
Liarozole (Liazal® Johnson and Johnson Pharmaceutical Research and Development, S) is an 
imidazole derivate that has been clinically evaluated for dermatological disorders and prostate cancer, 
with further positive activity in cancer cell lines. Liarozole has been approved for the treatment of 
congenital ichthyosis; however it is a relatively weak and non-specific inhibitor of CYP26 and has 
consequently ceased anti-neoplastic clinical development."" '"'*"" A large number of more specific 
azolyl R A M B A s have been developed, including Rambazole® (Talarozole, R l 15866, Barrier 
Therapeutics, T)*"' and RII6010 (Barrier Therapeutics, U)*" '^*°^  which have been investigated for 
clinical dermatological effects*"" and in vitro anti-cancer properties respectively."*'*"' Other novel 
inhibitors have been developed as potential anti-cancer agents."''*"* 
The atypical retinoid fenretinide is unusual in that CYP26A1 is involved in its metabolism,"* while 
other synthetic retinoids including CD367 (R) , Tamibarotene (AmSO, O), Am580 (P) and T T N P B (D) 
are not substrates for the CYP26 enzymes."^''*^'"*'"' Retinoids that are not recognised and hence not 
metabolised by this enzyme may therefore be more effective inhibitors of growth in susceptible cancer 
cells.'*' This is one feature that enabled Tamibarotene to reintroduce complete remission in patients 
with acute promyelocytic leukaemia (APL) that had previously developed resistance to A T R A -
treatment.'"'"" Tamibarotene is also unable to bind to the C R A B P s , yet is less toxic than A T R A 
partially because of the lack of binding affinity to RAR-y.^*'''" Poor metabolism is also a major factor 
in the remarkable toxicity of TTNPB, which also possesses reduced affinities for the C R A B P s and 
prolonged nuclear receptor activation.'*^ Other enzymes may be involved in the metabolism of 
synthetic retinoids, for example Tamibarotene is metabolised by CYP3A4."*' 
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4.2.4 Retinoic acid receptors 
The retinoic acid receptors (RARs) play a pivotal role in the activation o f retinoid-responsive genes. 
Regulation o f receptor expression has consequently been extensively studied in an attempt to delineate 
the specific roles o f the individual receptors and how they are modulated by retinoid treatment. For 
example, aberrant expression or regulation o f the RARs is associated with various types o f cancer,''^'"* 
while expression o f RAR-P2 is of particular interest as it is strongly associated with tumour 
suppression.''*''^''**" The general structure, features and functions o f the two families of retinoid 
receptors, the RARs and the RXRs have been described previously (Section 1.5). 
Crucially, the binding o f ligand-bound RAR/RXR heterodimers to the response elements o f a number 
o f components o f the retinoid pathway is responsible for inducing the transcription of these genes. 
This has been shown to be true for both A T R A and a number o f synthetic retinoids."* Furthermore, 
RAR-a, RAR-P and RAR-y are differentially expressed in different cell types and are differentially 
regulated during ATRA-induced differentiation, suggesting that they may regulate different sets o f 
genes.'^^•*°* For example, in some EC cell lines RAR-a is required for the induction o f RAR-P, without 
which the cells fa i l to differentiate*"' and the activation o f the developmentally important homeobox 
//OA'genes has been shown to be dependent on the induction o f RAR-a^^° and RAR-p.^^^ Specific 
receptors are also believed to act cooperatively in order to signal terminal growth suppression and 
maturation o f NTERA2/D1 human EC (huEC) cells.*'^ 
Novel synthetic retinoids have traditionally been assessed by comparing the aff ini ty o f the new 
compounds with that o f A T R A for the retinoid receptors. It is also important to consider the ability o f 
compounds to transactivate the receptors in functional assays, since many isotype-binding specific 
retinoids have subsequently been found to be less selective at activating the receptors. 
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4.3 HOX gene expression 
The homeobox gene family are defined by the presence o f an eponymous short D N A sequence which 
encodes a DNA-binding protein domain known as the homeodomain.*''"^" The Hox gene family are 
the most studied and the most evolutionarily conserved group o f the homeobox genes and the Hox 
proteins that they encode are putative master regulators o f development, responsible for specifying the 
antero-posterior axis and controlling segmental patterning during embryogenesis.^" '"""'' 
The mammalian genome is currently known to contain thirty-nine Hox genes (designated HOX in 
humans*'^) that are organised into four different clusters (HOXA, HOXB, HOXC and HOXD) found at 
four distinct chromosomal loci (7, 17, 12 and 2 respectively).^'^"*" Each gene is also assigned to one 
o f thirteen paraloguous groups based on sequence homology, analogous expression domains and 
occupation o f similar positions along the chromosome (Figure 4-3)."' "^ 
Hox genes are activated and expressed in intricate spatial and temporal patterns during embryonic 
d e v e l o p m e n t . • " ' " ' * " ° During initial stages, these expression events demonstrate spatial collinearity in 
that they form a sequential pattern o f partially overlapping domains along the antero-posterior axis in 
coincidence with the 3' to 5' order o f the genes in the Hox cluster. Additionally the genes are activated 
one after the other in the 3' to 5' order, which is termed temporal collinearity (Figure 4.3) ' '-624-626 
regulatory mechanism(s) responsible for this precise control o f gene activation are poorly understood. 
It is believed that morphogenic signalling molecules including A T R A are responsible for the 
regulation o f Hox gene expression, through direct and/or indirect control, which may involve graded 
sensitivities to A T R A concentrations.^"'*^*'"* Furthermore, it is proposed that vertebrate Hox genes 
may synergistically co-operate in order to enhance or silence other Hox genes within the same 
622 complex. 
Aberration o f the normal pattern of Hox gene expression results in homeotic transformations 
(duplication of head-tail axial structures) and malformations.^'•"•''*"''*" Mutations in human HOX 
genes are observed to result in limb development defects; for example the duplication o f a digit 
(Polydactyly) occurs as a result o f mutations in the HOXD13 gene.*"'" HOX genes continue to be 
expressed in some normal adult tissues suggesting a role in maintenance,*^* however the expression o f 
HOX genes may be deregulated in cancers implicating the participation o f HOX genes during 
• 49-54 
carcinogenesis. 
Considerable experimental evidence strongly suggests that A T R A is an important modulator of Hox 
gene expression. Numerous in vitro studies have shown that homeobox genes are regulated during 
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ATRA-induced differentiation o f cultured cells;'""'"'"*'" / / O X gene expression may be induced during 
retinoid therapy and thus contribute to tumour progression, potentially l imiting its efficacy.*'*" Both a 
deficiency and excess of A T R A are observed to disrupt normal vertebrate development in a similar 
manner to Hox gene mutations."'''^'*'''''*'*'' Further evidence suggesting that A T R A has a normal role in 
embryogenesis comes from the restricted yet co-localised distribution o f retinoic acid receptors,*"'"*''' 
cytoplasmic retinoid binding proteins*"* and areas o f A T R A synthesis,-**"'"*" which overlap with 
many o f the sites in the embryo that are sensitive to ATRA.*''* The gene transcription site of Hoxal in 
F9 murine EC (muEC) cells contains an ATRA-inducible enhancer that contains an RARE.*'" Similar 
response elements have also been found in human and murine HOXBllHoxbf^^-^^'^ and 
HOXD4IHoxd4 genes,*"'**° suggesting that the expression o f these genes may be directly responsive 
to ATRA-signall ing via ligand-bound RAR-RXR heterodimers. This regulatory relationship is 
dynamic and has been shown to involve feedback regulation.*'"'**'"**" 
It is therefore suggested that endogenous retinoids may be vital for establishing the antero-posterior 
graded expression oi Hox genes and thus influence antero-posterior identification along the body axis. 
The net effect o f A T R A treatment can be said to recapitulate the differential Hox gene expression 
pattern seen in early embryogenesis and likely represents the posterior transformation signal in early 
central nervous system development.*'* 
O f particular note for the study described in this chapter, A T R A has been demonstrated to induce 
HOX genes with gene-specific kinetics in the NTERA2/D1 human teratocarcinoma cell 
line.'""'*""'*"' **' Detailed studies have established that within each cluster the gene located most 3' 
responds to low concentrations o f A T R A , while increasingly higher concentrations are needed to 
activate successively more 5' positioned genes. At a given concentration of A T R A , the 3' genes are 
induced very rapidly, while transcripts f rom genes positioned successively more 5' respond after a few 
daysoftreatment.'""'*""'*"' 
In perfect accordance with collinearity, paralogue group 1 are the first members o f their clusters to be 
activated and display the highest sensitivity to exogenous ATRA.*"''*** Hoxal is the first gene 
induced, and is required to initiate expression o f the Hoxbl gene.**' Other Hox genes located in more 
5' positions are not modulated directly by A T R A , it is hypothesised that they may be activated 
fol lowing expression of Hoxal and Hoxbl, presumably through the protein products o f these genes, 
leading to sequential activation o f Hox genes.* For example, activation o f both Hoxbl and Hoxb3 are 
regulated by //oxZ)/,*****' although knockout o f the murine Hoxal gene does not alter the A T R A -
induced expression o f other Hoxa cluster genes.*'" 
In addition to their general patterning role during embryogenesis, specific functions for some o f the 
Hox genes have been reported. For example, the Hoxb gene cluster is expressed in the developing 
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hindbrain and spinal cord, and may help to establish pattern and positional identity in neural 
development.^'^^'"*'"^ Hoxbl is required for the specification o f facial motor neurons and disrupting this 
gene results in facial paralysis in mice, a phenotype that resembles the human conditions o f Bell 's 
Palsy or Moebius Syndrome.^''' Hoxbl also plays a critical role in the antero-posterior axis patterning 
o f the gut."^ 
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Figure 4-3: Conservation between the Drosophila melanogaster Hom-C and Homo sapiens HOXgene 
clusters. The four mammalian Hox gene clusters are conserved f rom the Hom-C complex in terms o f 
sequence and co-linear expression. During embryonic development and ATRA-induced 
differentiation, the genes are expressed in a pattern that correlates with chromosomal positioning, 
namely the 3' genes are expressed both earlier and more anteriorly than the 5' genes. Figure prepared 
by combining and modify ing figures from Lappin et ai, 2006 and Maconochie et al, 1996.^^''^^^ 
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4.4 P0U5F1 (0CT4) transcription factor 
P0U5F1 (PouSfl in species other than Homo sapiens, previously known as 0 C T 4 or 0CT3) is known 
as the "guardian o f pluripotent phenotype".*'' It is the earliest transcription factor, a DNA-binding 
protein required for the activation and regulation o f expression o f genes, known to be expressed 
during embryonic development. P0U5F1 belongs to the sub-group o f octamer-binding proteins which 
bind by the POU (Pit-Oct-Unc) domain to promote and enhance regions o f various genes;^ ^*'**^ it is a 
key component in the molecular control o f stem cell pluripotency and orchestrates the expression o f 
genes associated with stem cell character, including NANOG^^^'^^'^ and S0X2,^^^ and represses genes 
that promote developmental processes.^^^ Although the roles o f these factors have not been fu l ly 
elucidated, it is clear that their down-regulation correlates with the loss of pluripotency and self-
renewal, and the initiation o f differentiation.**'^'*^' 
High expression o f the PouSfl gene is found in the blastocyst and epiblast o f the developing mouse 
embryo but is subsequently restricted to primordial germ cells and silenced in all somatic cell 
lineages.*"'**''*'°'*'' During human development POU5F1 mRNA is continuously expressed between 
the time o f fertilization and 10+ cell stages.*'" Precise control o f PouSfl expression is essential for 
normal embryonic development.^"^ *" '*" '*" PouSfl is also associated specifically with undifferentiated 
EC cells, embryonic germ cells, and embryonic stem (ES) cells*^°'**''*""*'^ and is rapidly down-
regulated during differentiation of these cells, recapitulating in vivo observations.**"'*'*"*'* 
Furthermore, knockdown o f P0U5F1 leads to differentiation o f EC and ES cells.*" PouSfl has 
consequently become widely used as an important marker o f undifferentiated pluripotent stem cells 
and has been identified as a potential marker in developmental toxicity testing.™" 
Two different isoforms have been identified: POUSFl i A , or OCT3A/OCT4A and POUSFI J B , or 
OCT3B/OCT4B.™' POUSFl iA is required for pluripotency, but the function o f the POUSFI J B 
isoform has yet to be identified.™"'™' A number o f pseudogenes are also known, these non-functional 
genes or gene fragments may be mistakenly identified as functional transcripts.™'' POUSFl expression 
has also been demonstrated in terminally differentiated cells, suggesting that the presence of POUSFl 
is not sufficient to define a cell as pluripotent."^'™''™^ However these data contradict previously 
published work and it has been proposed that the authors detected POUSFIJB, not POUSFlJA.^°^-'^°'' 
The POUSFl gene is expressed in a number o f adult stem cells, suggesting that these cells are 
potential pluripotent stem cells and could be the target cells for the initiation o f the carcinogenic 
process.™* POUSFl is also expressed in human tumours, which may provide an opportunity for 
targeted cancer treatment.^"' 
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4.5 Experimental objectives 
The aim o f the study described in this chapter was to investigate the effects o f A T R A and two 
synthetic retinoids, selected from those studied in the initial in vitro experiments (Chapter 3), on 
components o f the retinoid pathway in TERA2.cl.SP12 human EC cells. The two cinnamic acids 
CEB16 and CEB17 were chosen to compare the effect o f the position o f the terminal carboxylic acid 
group on activity. In CEB17, the CO2H group is in a para position to the tetrahydrotetramethyl 
naphthalene group, mimicking the configuration o f all-fmm-retinoic acid, whilst CEB16 is its meta 
isomer, bearing a similarity to 13-c/5-retinoic acid. Both compounds were found to induce 
differentiation in TERA2.cl.SP12 cells, but at a slower rate than A T R A , and with moderately different 
proportions o f terminal cell types. 
C O j H 
CO2H 
C E B 1 6 C E B 1 7 
TERA2.cl.SP12 cells were grown in the presence o f either 10 [iM or 0.1 |AM o f A T R A , CEB16 or 
CEB17 for up to 14 days. Cells were also grown with 0 .1% Vv DMSO (14 m M ) to control for the 
effects o f the vehicle. The media was replaced with fresh retinoid- or DMSO-enriched media after 3 
and 5 days' culture and then subsequently every day. Phenotypic changes in the cultures were 
observed and phase microscope images recorded after 7 and 14 days' culture. RNA was extracted 
f rom the cultures at ten time-points and the expression o f eleven genes quantified by real-time reverse 
transcription-polymerase chain reaction. The expression o f mRNA relative to a housekeeping gene 
(glyceraldehyde-3-phosphate dehydrogenase, GAPDH) was profiled for POU5F1, CRBP-I, CRABP-I, 
CRABP-II, CYP26A1, RAR-a, RAR-/3, RAR-y, HOXBl, H0XB2 and HOXB3 genes. P0U5F1 was 
analysed in order to correlate the differentiation status o f the cultures with the other genes o f interest. 
The three genes located at the 3' end o f the H O X B cluster were analysed to provide a further 
functional characterisation of the effects o f synthetic retinoids. 
Due to time limitations the data presented are from unique biological samples. 
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4.6 Results and discussion 
4.6.1 Observation of changes to cell phenotypes 
TERA2.cI.SP12 huEC cells were seeded at the standard density o f 20 000 cells/cm^ and allowed to 
adhere for 24 hours before the normal media was replaced with media supplemented with either 
0 . 1 % 7v DMSO or freshly prepared solutions of 10 or 0.1 o f A T R A , CEB16 or CEB17. The 
delayed addition o f retinoid relative to the experiments reported in Chapter 3 was a practical necessity 
in such a large experiment. The cultures in this investigation were therefore slightly more confluent 
than in previous studies (compared to Section 3.3) and may consequently have developed at a slightly 
slower or different rate. 
Phase images were recorded after 7 and 14 days' culture with retinoids to document the phenotypic 
changes that occurred during the experiment (Figure 4-4 and Figure 4-5). The DMSO cultures became 
significantly overgrown but did not develop the heterogeneity associated with cultures undergoing 
retinoid-induced differentiation nor develop any identifiably differentiated phenotypes. The cultures 
treated with 0.1 | i M CEB16 developed identically to the control cultures: it would appear that the cells 
failed to differentiate. A l l other cultures underwent some phenotypic changes consistent with the 
induction o f differentiation. As previously noted (Section 3.3), 10 |nM A T R A induced differentiation 
in the TERA2.cl.SP12 cells more effectively than either 10 ^iM CEB16 or 10 CEB17. Treatment 
with 0.1 | j .M A T R A produced minor changes in the cells after 14 days' culture, including a reduction 
in cell number compared to the control and the development o f several small epithelial colonies. The 
0.1 CEB17 cultures became moderately heterogeneous by the end o f the experiment and a number 
o f epithelial colonies developed. 
The effects o f lower concentrations of A T R A and other retinoids on TERA2.cl.SP12 cells have not 
previously been reported. Concentrations o f only 0.1 f i M o f A T R A and 0.1 [ i M CEB17 induced a 
degree o f differentiation in the cells, although the changes were slower to appear than in the 
corresponding 10 | j ,M cultures. Morphological observations suggest that 0.1 ^ M CEB16 was 
ineffective, which is consistent with this compounds previously observed low level o f relative 
potency. No neuronal cells were observed in the 0.1 |a.M A T R A and C E B l 7 cultures at the 14 day time 
point but these cultures contained more epithelial colonies than their 10 |j .M counterparts. Different 
concentrations of retinoids may affect the differentiation propensity o f these cells. Alternatively these 
phenotypes may have developed as a consequence o f the increased cell density, which may also partly 
explain why the CEB compounds, in particular l O ^ M C E B l 6 , induce the formation o f a greater 
number o f epithelial colonies than the natural retinoids. 
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Figure 4-4: Phase images of 7 day old TERA2.cl.SP12 huEC cultures treated continuously with 0.1% % DMSO 
or either 10 j i M or 0.1 nM of ATRA, CEB16 or CEB17. The DMSO control shows no phenotypic changes 
indicative of differentiation. Al l cells are EC-like (EC), possessing the typical high nuclear to cytosol ratio, and 
are starting to over-grow (O) as the culture has surpassed confluency. Cultures grown with 10 faM retinoid are 
less dense than the control and consist of heterogeneous cell types. The 10 ^ M ATRA culture is most developed; 
a few putative neurons (N) and a developing rosette (R) are visible. The 10 |uM CEB17 culture is slightly more 
developed than the 10 (iM CEB16 culture, consistent with previous efficacy observations. Of the lower 
concentration cultures, only the 0.1 |.iM ATRA culture shows slight signs of heterogeneity, the other cultures 
resemble the DMSO culture and remain phenotypically undifferentiated. Scale bar represents 50 ^m. 
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Figure 4-5: Phase images of 14 day old TERA2.cl.SP12 huEC culmres treated continuously with 0.1% 7v 
DMSO or either 10 |aM or 0.1 of ATRA, CEB16 or CEB17. The control culture is very overgrown (O) but 
there are no differentiated phenotypes visible. The 10 | i M ATRA culture is the most differentiated: highly 
heterogeneous with a number of rosettes (R) and developing putative neuronal colonies (N). The cultures grown 
with 10 (xM of either synthetic retinoid are also undergoing morphological changes consistent with 
differentiation. Epithelial colonies (EF) and putative neurons are visible in the very dense cultures. The 0.1 |aM 
CEB 16 culture is indistinguishable from the DMSO control culture. EC-like cells are visible amongst very 
overgrown areas. The 0.1 |xM ATRA and CEB 17 cultures are heterogeneous and present a number of 
differentiated phenotypes but are significantly less developed than the 10 ^ M cultures. Scale bar represents 
50 |im. 
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4.6.2 Induction of differentiation - P 0 U 5 F 1 expression 
The transcription factor POUSFl is expressed in undifferentiated TERA2.cl.SP12 cells and down-
regulated as the cells undergo differentiation, both in response to retinoid treatment and as a 
consequence o f the sub-optimal culture conditions o f highly confluent cultures (Figure 4-6). 
Expression o f POUSFl mRNA in the control culture is suppressed after the time-point at 3.5 days' 
culture, gradually reaching basal levels between 7 and 14 days. These observations correspond with 
the culture reaching confluency (four days after the start o f the experiment, five days after seeding) 
and beginning to overgrow. This process appears to have reduced the stem cell potential o f the cells 
though the cells remain somewhat proliferative and no phenotypic features consistent with 
differentiation are observed. Changes in the expression o f other genes investigated in this study are 
also observed in cells grown in control conditions, confirming that over 14 days these cells have 
geneotypically changed from TERA2.cl.SP12 huEC cells. These observations must be considered 
when analysing the gene expression profiles o f cells treated with retinoids; especially, the cultures 
grown in 0.1 i^M CEB16 and 0.1 [iM CEB17 that become significantly overgrown during the 
experiment. 
The cultures treated with 1 0 | i M o f retinoid down-regulated POUSFl faster than the lower 
concentration o f the same retinoid, consistent with phenotypic observations o f differentiation. 
However, in contrast to phenotypic observations, the three retinoids modulated POUSFl at 
approximately similar rates, although A T R A was slightly more effective than CEB16 or CEB17. The 
10 )j.M C E B I 6 and CEB17 cultures responded at approximately the same rate, but the CEB16 0.1 |aM 
culture lost pluripotency at a similar rate to the control, whilst the CEB17 0.1 |a.M expression profile 
was very similar to that o f 0.1 | i M A T R A . A l l retinoid cultures, but not the control condition, showed 
an increase in POUSFl expression f rom the first time-point. This transient elevation has also been 
reported during the ATRA-induced differentiation o f F9 muEC cells, but without explanation."" 
The 10 i^M A T R A result is consistent with previously published data for TERA2.cl.SP12 cells'*"^ and 
the 10 \iM results for all retinoids correlate well with the levels o f OCT4 protein detected by western 
blot (Section 3.7). The kinetics o f POUSFl regulation are comparable to those observed in PCC7 
muEC cell l i ne , " ' but slower than many other cultured cells. For example, the expression o f PouSfl 
mRNA in PI9 muEC cells treated with 1 |.iM A T R A is significantly decreased within 24 hours and 
undetectable after 72 hours.*"'"' NTERA2/D1 huEC cells also respond faster, wi th complete down-
regulation, as detected by northern blot, within 72 hours."" In F9 muEC cells protein levels are 
substantially suppressed after 48 hours' treatment.*^* PCC7 cells have also been used to demonstrate 
the down-regulation o f PouSfl protein levels during synthetic retinoid induced differentiat ion." ' 
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Figure 4-6: Concentration and time-dependent regulation of POU5FI expression in TERA2.cl.SPI2 huEC cells by ATRA and two synthetic retinoids (n = 1). 
It is suggested that some published studies may have erroneously identified the expression of POUSFl 
pseudogenes, rather than POUSFl itself, by relying solely on reverse transcription-PCR analysis.*" 
Whilst protein was not extracted f rom these cultures, other experiments conducted under identical 
conditions have demonstrated the presence o f POUSFl protein by positive immuno-labelling with 
POUSFl specific antibodies (Section 3.7). It therefore seems reasonable to infer that the mRNA 
detected in this qRT PCR assay is translated into functional protein. It is hoped that analysis o f more 
samples would smooth the POUSFl expression profiles whilst establishing the biological variation of 
this gene in TERA2.cl.SP12 cells. 
4.6.3 Regulation of retinoid-binding protein expression 
Expression of CRBP-I 
Cellular retinol-binding protein {CRBP-I) transcripts are expressed at low levels in undifferentiated 
TERA2.cl .SPi2 cells (Figure 4-7) and are only moderately up-regulated with retinoid treatment. This 
low level o f expression was confirmed by the detection of only a faint band when a PCR product was 
analysed by electrophoresis (Figure 4-17). The fluctuations in the low levels o f expression o f this gene 
in the control culture during the first seven days highlights the limit o f detection, such that f rom just 
one biological repeat the variations in expression observed for the majority o f cultures can only be 
described as insignificant. Treatment with A T R A induced elevated levels o f CRBP-I mRNA and this 
was the only retinoid for which a clear response was observed at 0.1 |aM. This data is supported by the 
observation that CRBP-I protein is also up-regulated in these cells in response to A T R A treatment."' 
The kinetics o f CRBP-I expression fo l low a complicated pattern, which may be partly explained as a 
response to the provision o f fresh retinoid when the media was changed. Examining the lO juM 
retinoid graph (Figure 4-7), an increase in gene expression is observed at the 3.S day time-point in all 
retinoid conditions (after a media change at 72 hours) and a further increase is observed in the 10 | i M 
CEB16 culture at the 7 day time-point (168 hours) after a media change at 120 hours. Depletion of 
retinoid in the culture media between media changes may have affected expression o f this gene, which 
then responds in a magnified manner when new retinoid is supplied to the culture. Expression of 
CRBP-1 in the 0.1 f i M A T R A and CEB17 cultures appears to transiently increase at the initial time-
points o f the experiment before returning to basal levels after 5 days' culture. The A T R A 0.1 yiM 
culture then appears to respond to the supply o f fresh retinoid at 120 hours, before returning to low 
levels by the end o f the experiment. A biphasic expression pattern has also been reported in A T R A -
treated NTERA2/D1 huEC cells, without further explanation or correlation with culture conditions.'''^ 
Ostensibly the up-regulation o f CRBP-1 is intriguing: the protein is unable to bind to either A T R A or 
the synthetic retinoids and A T R A cannot be reduced to retinol in vivo so this modulation is unable to 
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have a direct effect. It is proposed that CRBP-I is a component o f a feedback mechanism that is 
initiated by the presence o f high cellular levels o f retinoid; CRBP-I may be up-regulated to sequester 
excess retinol, the in vivo precursor o f A T R A , and control cellular exposure to retinoids. The 
expression o f CRBP-I is up-regulated by RAR activation of a functional RARE-related sequence 
within its promoter""""^ and cannot be blocked by cycloheximide, a protein synthesis inhibitor.^" 
This is therefore a direct response to A T R A treatment. 
ATRA-induced up-regulation of CRBP-I is also observed in F9 muEC cells,"* P19 muEC cel ls , ' " 
NTERA2/D1 huEC cells'''^ and rats,"^^ however in all cases significant responses were observed 
within hours of treatment compared to the moderate changes that occur in TERA2.cl.SP12 over 
several days. Published data corroborate the modulation of CRBP-I in TERA2.cl.SP12 cells by 
synthetic retinoids. Treatment with 9-c/j-RA (B) and synthetic retinoids Am80 (P) and Ch55 (Q) 
induces a strong up-regulation o f CRBP-I in rats, comparable to the response observed with A T R A . " " 
The apoptosis-inducing atypical retinoid fenretinide promotes a marked up-regulation in human 
ovarian tumour cells,^'* which is o f particular interest as dysfunctional regulation o f CRBP-1 may be 
observed in human cancers."'^^ 
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Figure 4-7: Concentration and time-dependent regulation of C/?5P-/expression in TERA2.cLSP12 huEC cells by ATRA and two synthetic retinoids (n = 1). 
Expression of CRABP-I 
Regulation o f the intracellular A T R A carrier proteins, cellular retinoic acid-binding proteins 1 and I I 
(CRABP-I and CRABP-II ) was also investigated in response to A T R A , CEB16 and CEB17 (Figure 
4-8 and Figure 4-9). CRABP-I and CRABP-II mRNA are both constitutively expressed in 
TERA2.cI.SPl2 cells and are strongly up-regulated by all three o f these retinoids, furthermore a 
moderate gradual increase is also observed in the DMSO control cultures over 14 days. 
C/i/iS/'-/transcripts in the 10 f i M A T R A culture respond quickly reaching a maximum response after 
96 hours before declining to basal levels; however the magnitude o f this up-regulation is less than any 
o f the other morphologically differentiating cultures (Section 4.6.1, i.e. excluding the CEB16 0.1 
culture). This unusual response is in good agreement with analysis o f ATRA-treated A B l muES cell 
line, in which CRABP-I mRNA and protein levels are induced at low concentrations o f A T R A but 
diminished at higher concentrations."' 
The expression pattern of CRABP-I in the cultures treated with 10 |aM CEB16, 10 \iM CEB17, 0.1 
CEB17 and 0.1 |aM A T R A are all very similar. Levels o f mRNA initially increase very slowly for the 
first 48 hours and then, after a media change, rapidly accumulate high levels o f transcripts to attain 
maximal expression at the seven day time point before levels decline to the same level as the control 
cultures at the end o f the experiment. Except for the A T R A cultures, stronger responses are observed 
in the 10 j i M cultures compared to the 0.1 | i M cultures o f the same retinoid. 
The genes encoding CRABP-1 are regulated by A T R A treatment in a number o f different cell lines 
including P19 and F9 muEC cells and A B l muES cells. CRABP-I is strongly induced in human 
keratinocytes, P19 and A B l cells within 24 hours ," '" '" '" whereas ATRA-treatment of F9 cells causes 
a 2-3 fo ld reduction in the expression o f CRABP-I mRNA. '"° " ' A number of active synthetic retinoids 
including Am80 (O) and TTNPB (D) bind to C R A B P - I ; " ' " " it is also known that CRABP-I binds 
retinoids with a higher aff ini ty than CRABP-I I . ' " ' ' "* These data are believed to demonstrate that a 
high intracellular concentration o f CRABP-I is able to modulate the effects o f excess retinoid in the 
cell by sequestering both natural and synthetic retinoids to facilitate enhanced metabolism by CYP450 
enzymes and simultaneously impede transport o f retinoids into the nucleus by CRABP-II. '"^ '^ ' ' •"^ 
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Figure 4-8: Concentration and time-dependent regulation of C/?^^P-/expression in TERA2.cl.SP12 huEC cells by ATRA and two synthetic retinoids (n = ! ) . 
Expression of CRABP-II 
CRABP-II, the gene encoding the cellular retinoic acid-binding protein involved in the transport o f 
A T R A to the nuclear receptors, is expressed in undifferentiated TERA2.cl.SPI2 cells at a very low 
level and is strongly up-regulated in all retinoid cultures except for those treated with 0.1 |a,M CEB16 
(Figure 4-9). The 10|J.M A T R A culture exhibits the fastest induction o f gene expression; this 
expression is also biphasic in profile, unlike the synthetic retinoid 10 |^M cultures, wi th a second rapid 
accumulation of transcripts immediately after the first media change. This biphasic pattern has also 
been reported in human NTERA2/D1 EC cells.'''" Interestingly, the maximum response achieved in all 
three retinoid cultures is identical although only A T R A induces a sustained response; this may 
represent the maximum response of these cells. As with all the genes investigated in this study all 
fluorescence readings, except very low results which were effectively un-detectable, were within the 
standard curve generated during each assay. The maximum observed response is therefore not the 
upper l imit o f detection for this assay. 
The 0.1 ]xM retinoid cultures o f A T R A and CEB17 also present biphasic temporal expression profiles. 
Although this cannot be directly associated with the media change, both of these compounds present a 
similar pattern suggesting that it is a genuine response in these cells. Furthermore, the levels of 
CRABP-II mRNA in the 0.1 nM CEB16 culture show excellent agreement with the results of the 
DMSO culture lending a high degree o f confidence to the data for this gene. 
The gene encoding huCRABP-II is directly regulated by A T R A via an RARE that mediates the 
differential transcriptional transactivation by the RARs and R X R s . ' " The rapid response of CRABP-II 
observed during these experiments is consistent with its identification as an early downstream target of 
A T R A during the commitment o f NTERA2/D1 huEC cells to differentiation.™ CRABP-II transcripts 
are rapidly and strongly up-regulated by A T R A in F9, PI9, neuroblastoma, N T E R A 2 / D 1 , muES and 
human fibroblasts cells.""' ' ' '"' ' ' '*'"' '"' ' ' ' ' ' '^^ A number active synthetic retinoids, including Am80 and 
TTNPB have been shown to bind to CRABP-I I , "^ and up-regulate CRABP-II m R N A , ' * ' ' " ' ' ' ' ^ ' ' " 
leading to the proposal that regulation o f CRABP-II mRNA can be used as a retinoid bioassay."**'''"^ 
A f f i n i t y for the CRABPs may actually impede transport o f A T R A to the nucleus compared with 
retinoids that cannot bind to these proteins, such that some low affini ty synthetic retinoids may induce 
a faster genomic response.'"' However, although active retinoids are able to induce a concentration 
dependent response to the levels o f CRABP-II, the magnitude o f response does not correlate with 
potency in some cell systems.'"" '"* Furthermore, whilst up-regulation o f CRABP-II was been observed 
in response to CD271 (adapalene, L ) and LGD1069 (Targretin®, E ) this was not accompanied by 
induction o f biological ac t iv i ty . ' " '"^ 
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Figure 4-9: Concentration and time-dependent regulation of CRABP-II expression in TERA2.cl.SP12 huEC cells by ATRA and two synthetic retinoids (n = 1). 
Expression of CYP26A1 
CYP26A1 mRNA is also rapidly and strongly up-regulated in TERA2.cl.SP12 huEC cells after 
treatment with retinoids (Figure 4-10). Transcript levels in the DMSO culture remain unchanged 
throughout the 14 day experiment and demonstrate the consistency o f the results o f this gene assay, 
even though the data only represents one biological repeat. A l l three retinoids potentiate the 
expression o f this A T R A 4-hydroxylase, a member o f the family o f CYP26 enzymes believed to be 
primarily responsible for the specific degradation o f A T R A in vivo. 
The fastest and strongest response is observed in the 10 |a.M A T R A culture, which again presents a 
biphasic temporal expression profile consistent with hypothesis that a supply o f fresh retinoid at 72 
hours stimulates a further induction o f gene expression. The results o f the 10|a.M A T R A culture 
suggest that initial exposure to A T R A (during the first 48 hours) has primed the cells to respond to 
further stimulus with an augmented induction in a comparable manner to the development o f clinical 
resistance in retinoid therapy. In addition to in vivo data,"'"'^^''^"^ this hyper-catabolism has previously 
been reported in cultured cells""'^''' and explains the decreased half-life o f A T R A observed in pre-
exposed c e l l s . A T R A sensitivity is inversely correlated to the rate o f A T R A metabolism. CYP26A1 
is part o f a feedback loop involved in the auto-regulation o f retinoid levels, such that when normal 
physiological levels are exceeded, induction of CYP26A1 acts to normalise retinoid levels."' 
There are numerous reports o f A T R A and a small number o f reports of synthetic retinoid induced 
expression of CYP26A1 in v/fro.^"'^-*'"' ' '^^ " ^ - " ' The magnitude and speed of CYP26AI induction 
observed in the TERA2.cl.SP12 cultures is generally consistent with observed phenotypic 
differentiation. However ATRA induces a notably greater induction o f this gene than the synthetic 
retinoids compared to any o f the other genes investigated in this study. Given the lower sensitivity o f 
CYP26A1 to C E B l 6 and C E B l 7, this may indicate that CYP26A1 is not an important metabolic 
enzyme for these compounds, particularly as it is known that other enzymes may be involved in the 
metabolism o f other synthetic retinoids.'*' "^ Multi-phasic expression is observed in all the cultures 
suggesting that this gene is very sensitive to retinoid levels. 
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Figure 4-10: Concentration and time-dependent regulation of CYP26A1 expression in TERA2.cl.SPl2 huEC cells by ATRA and two synthetic retinoids (n = I). 
4.6.4 Analysis ofretinoic acid receptor mRNA expression 
The three retinoic acid receptors, R A R - a , RAR-P and RAR-y, are the Hgand-activated transcription 
factors responsible for mediating the biological response of natural and synthetic retinoids. Expression 
of these proteins is regulated in direct response to exogenous A T R A and changes in the expression of 
RAR transcripts can also be measured,"* enabling the use of rt qPCR as a sensitive quantitative 
method to determine the ability of compounds to modulate the classical retinoid pathway. 
The primers used in these assays amplify the DNA of all isoforms of each specific receptor. Low 
levels of each of the three RAR isotypes were detected in undifferentiated TERA2.cl .SP12 cells 
(Figure 4-11, Figure 4-12 and Figure 4-13). Culturing cells in media enriched with the same 
concentration of DMSO that was used as a vehicle in all retinoid cultures (0.1% 7v, 14 mM) had no 
effect on the expression of retinoic acid receptor transcripts, the 14 day DMSO time-point for RAR-y 
appears to be anomalously high in comparison to all other cultures. 
RAR-a expression 
RAR-a expression is strongly modulated by all three retinoids except in the generally unresponsive 
0.1 C E B 1 6 culture for which the results show very close agreement with the control data. RAR-a 
transcripts respond rapidly to retinoid treatment, generally within 12 hours of initial exposure. This is 
particularly notable given the generally slow response of this cell line observed in other gene assays 
(Figure 4-11). 
The temporal expression profiles of the 10 | iM A T R A culture and to a lesser extent the 0.1 | J . M A T R A 
culture appear to respond to the supply of fresh retinoid on two occasions: after approximately 72 and 
120 hours' culture. After this time the retinoid enriched media was replaced daily, providing a more 
consistent supply of retinoid. Further experiments are required to confirm this observation; analysis of 
additional biological samples and a specific investigation into the effect of the timing of media 
changes. Early transient accumulation of RAR-a transcripts is also observed in the cultures exposed to 
10 )iM CEB16 , 10 i^ M CEB17 and 0.1 fiM CEB17. All cultures show a trend towards a slight increase 
in mRNA levels by the 14 day time-point, which may be a consequence of the extreme confluence of 
the cultures at this late stage of the experiment. The magnitude of response of RAR-a to 0.1 |j,M 
retinoid follows the previously observed trend of differentiation-inducing efficacy, namely 
ATRA>CEB17>CEB16 . Unexpectedly, the amount of gene up-regulation observed in the 10| iM 
cultures is comparable for all three retinoids, although the elevated expression attained in the C E B 1 6 
and C E B l 7-treated cultures is short lived. This may indicate that RAR-a transcription is a general 
event that occurs in the early stages of differentiation of TERA2.cl .SP12 cells. Fluorescence levels of 
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RAR-a gene expression transcripts are the lowest of any of the genes examined in this study, however 
this is a function of primer efficiency and should not be confused with the level of gene regulation. 
Multiple S Y B R green dye molecules may bind to single amplified products, though the amount is 
consistent for each gene. This has the major advantage of increasing sensitivity at low levels of gene 
expression, but the fluorescence signal is consequently dependent on the mass of the DNA product. 
The intensity of fluorescence is therefore only relative within single gene analysis and cannot be 
compared between genes. 
Unlike RAR-p and RAR-y, R A R - a is expressed ubiquitously,™ " ' intimating a more general role in 
mediating the biological effects of A T R A . The expression of RAR-a mRNA correlates with the 
observed levels of R A R - a protein detected by western blot under identical experimental conditions 
(Section 3.7). R A R - a protein was undetected in undifferentiated TERA2.c l .SPI2 cells and its 
expression was not induced in the control cultures, consistent with the lack of transcript regulation 
measured by rt qPCR. R A R - a protein levels increased slightly in all retinoid cultures over 28 days, 
consistent with the synthesis of mRNA, however the sustained expression of RAR-a in response to 
10 i^ M A T R A did not have a measurable effect on protein levels. 
Gene expression studies in other cell lines have previously been reported to induce moderate up-
regulation^""' or no c h a n g e ' " i n the level of RAR-a transcripts during ATRA-induced 
differentiation, in good agreement with the data presented here. Furthermore, the different RAR-a 
isoforms are differentially regulated: RAR-a^ is induced by ATRA-treatment whilst RAR-a/ 
expression is unaffected."' RAR-a modulation was observed in all cultures that also demonstrated 
CRABP-II activation consistent with the observation that this specific receptor is required to control 
CRABP-Il}^^ Given that RAR-a is unresponsive to ATRA-treatment in a number of E C cell lines, it is 
un-surprising that RAR-a is also un-affected by synthetic retinoids in the same cell lines."""'"^"' 
Am580 (P) and fenretinide (J) have both been shown to up-regulated RAR-a transcripts in responsive 
murine and human cells respectively.^''* " ' 
RAR-/3 expression 
Analysis of RAR-P expression following retinoid treatment is of particular interest given the rapid and 
dramatic increases in transcript levels that have been previously reported in response to 
y^i^ 3^i.157,198,487,538.540-542 ().cis-KA^^^ which havc led to the proposal that RAR-P cm be used as a 
biomarker for retinoid activity."*'''"* ''''' Specifically, the expression of the RAR-P2 isoform, rather than 
RAR-Pi or RAR-Ps variants, is up-regulated,'"' although up-regulation of RAR-/?; has also been shown 
to be redundant in F9 muEC cells."*' Alteration of RAR expression or function has been observed in a 
variety of cancers. Hypermethylation of the RAR-P gene, and specifically the RAR-pi promoter, is 
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strongly associated with aberrant retinoid signalling and the development of numerous different 
tumour types including lung, squamous cell carcinoma, breast, stomach and prostate." '^'"" 
Pharmacological reactivation of the RAR-P2 promoter has been demonstrated in vitro, offering hope 
for novel chemotherapeutic strategies.''^ 
All three retinoids induced an up-regulation in RAR-fi, though 0.1 \xM of C E B 1 6 was insufficient to 
amplify transcription of this gene (Figure 4-12). Interestingly, gene expression in a number of the 
experimental conditions was very similar, both in terms of magnitude and profile, as observed in 
response to 10 and 0.1 \xM CEB17 , 0.1 |aM A T R A and (to a lesser extent) 10 i^ M CEB16. Levels of 
RAR-P mRNA were elevated almost immediately upon treatment (an increase is observed within 8 
hours) and this moderate expression remained constant for the first five days' culture, whereupon 
transcription increased in an approximately exponentially manner to a very high level (to a maximal 
200-fold increase upon control conditions), which was maintained for the remainder of the 
experiment. This response may be explained by a number of factors, which given the complex nature 
of the retinoid pathway may well operate in combination to achieve this fine level of control over gene 
expression. 
The supply of fresh retinoid-enriched media at approximately 72 hours into the experiment did not 
have an immediately observable effect on the 3.5 day sample data, but may be responsible for 
initiating the large increase in expression visible in most of the cultures after 5 days' treatment. 
Further media changes after 120 hours and at 24-hour intervals thereafter could then be seen to permit 
the continued accumulation of RAR-P transcripts to a maximal level which is maintained by the 
continuous supply of retinoid. As was observed in the CYP26AI assay, TERA2.cl .SP12 cells may 
become sensitised to the presence of retinoid during the initial stages of the experiment and then 
respond more strongly upon further exposure to the retinoid. The cells may be said to be primed 
towards a magnified response and subsequent induction, which may itself cause cellular effects, or 
permit an opportunity for synergistic therapeutic activity. 
Furthermore, the kinetics of the RAR-ft response bears similarity to the CRABP-I and CRABP-II 
expression profiles and their maximal response. Given the co-dependence on these binding proteins 
with the retinoid receptors it is highly likely that regulation of all three factors are tightly related. 
However, according to the above hypothesis, the data presented for the 10 [M A T R A conditions are 
anomalous. As might have been predicted, the 10 )a.M A T R A culture shows the fastest response of any 
of the treatment conditions in this assay and the multi-phasic expression appears to correlate very well 
with retinoid supply, yet the maximal response of RAR-P transcripts is considerably less than both 
concentrations of CEB17 . It was expected that the retinoid that induced the greatest amount of neural 
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differentiation {i.e. 10 i^ M A T R A ) would also induce the highest levels of transcription, given 
that several RAR-P isoforms are particularly abundant in the developing nervous system."*^ However 
the expression of R4R-P in this assay does not prescribe to this relationship. The observed expression 
of this receptor is likely to be regulated by feedback mechanisms of other components of the retinoid 
pathway and the obvious candidate for this behaviour in 10 A T R A is CYP26A1. Indeed these two 
genes are observed to be co-ordinately controlled in PI 9 E C cells.'"^ 
With respect to synthetic retinoids, the retinoid-related molecules (also known as atypical retinoids) 
ST1926 (K) and CD437 (I) as well as 13-C/5-RA (C), Ch55 (Q), Am80 (Tamibarotene, O), T T N P B 
(D), "acyclic retinoid" (V) and fenretinide (J) have all been demonstrated to induce a strong up-
regulation in the levels of RAR-P expression." '^"""'-''*''''^ -"*'""' In good agreement with the data 
presented here, it has also been observed that synthetic retinoids may cause a slower accumulation of 
RAR-p, but ultimately significantly greater levels than the maximal mRNA levels induced by 
A T R A . ' ' * 
expression 
Finally, the third retinoic acid receptor to be discovered, RAR-y, is also modulated in TERA2.cl.SP12 
cells by retinoid treatment (Figure 4-13). Aside from the 14 day time-point, which appears to be 
erroneously high, the expression of RAR-y is un-affected by the control conditions. Both 
concentrations of all three retinoids regulated the expression of RAR-y: the kinetics may be generalised 
to a rapid and intense response in the early stages of the experiment, followed by a rapid decline to a 
low level of stable transcript expression for the remainder of the study. A similar regulation has 
previously been observed in NTERA2/D1 huEC cells.'"^ 
Interestingly, the fastest and most intense response was measured in the C E B 1 6 10 |iM culture; indeed 
expression in response to 10 A T R A was also surpassed by \Q \xM C E B 1 7 and 0.1 | j M A T R A . In 
vivo, RAR-y is confined to lung and skin'" and is believed to mediate the pharmacological activities 
of retinoids in the skin.'"*' It is therefore proposed that the expression of RAR-y in response to 10 |aM 
C E B 1 6 correlates with the observation that this compound induces a high proportion of epithelial cell 
types (Chapter 3). Furthermore, RAR-y over-expression in NTERA2/D1 cells inhibits neuronal 
maturation, another characteristic of cultures grown in CEB16.*'^ Conversely, this theory would also 
explain the low proportion of epithelial differentiation observed in response to 10 i^ M A T R A . Western 
blot analysis of RAR-y protein (Section 3.7), where higher levels of protein were observed in response 
to treatment with the synthetic retinoids than either A T R A or its geometric isomers, corroborates the 
rt qPCR data. However, the high level of RAR-y observed in the control cultures does not appear to 
require active transcription of RAR-y. 
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Modulation of RAR-y expression in TERA2.cl .SP12 cells was expected, given that terminal 
differentiation of NT2/D1 and F9 cells in response to A T R A has been reported to be triggered by an 
RAR-y dependent pathway.^'^**' '"* In agreement with the results discussed for TERA2.c l .SPI2 cells, 
A T R A treatment has been reported to either suppress"* or elevate"*"''"^''"" RAR-/ mRNA. 
Specifically, beyond the scope of this experiment, RAR-y2 mRNA is strongly induced while RAR-yi 
can act as a transcriptional repressor and antagonise RAR-P expression.'"' '""'"''"* Furthermore, 
induction has also been reported in response to a range of synthetic retinoids including ST1926 (K), 
CD437 (I), fenretinide (J) and AmSSO (p) 244,246,539,542 j^ g^gygp^ once again, transcript accumulation is 
reported in other cell lines at a much faster rate, for example RAR-y2 mRNA is strongly up-regulated 
in NTERA2/D1 cells within 3 hours of treatment.'"^ These data do not support the suggestion that 
maintained expression of RAR-y2 may require continuous exposure to retinoid.'"* 
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Figure 4-11: Concentration and time-dependent regulation of /?/</?-a expression in TERA2.cl.SPI2 huEC cells by ATRA and two synthetic retinoids (n = 1). 
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Figure 4-12: Concentration and time-dependent regulation of expression in TERA2.cl.SP12 huEC cells by ATRA and two synthetic retinoids (n = 1). 
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Figure 4-13: Concentration and time-dependent regulation of RAR-y expression in TERA2.cl.SP12 huEC cells by ATRA and two synthetic retinoids (n = 1). 
4.6.5 Analysis of H O X B expression 
The mammalian HOX proteins are a large family of transcription factors that control cell identity, 
differentiation, and patterning in animal embryonic development. Given the important role that 
endogenous A T R A appears to play in controlling HOX expression, it is clearly important to 
understand if synthetic retinoid-induced differentiation affects HOX gene expression. Regulation of 
HOX genes also plays a role in modulating the expression of components of the retinoid pathway, as 
was recently demonstrated in muES cells: induction of HoxbJ resulted in a strong up-regulation of 
CRABP-I and CRABP-II.^^^ 
The three HOXB genes analysed in this study, HOXBl, H0XB2 and H0XB3 (previously known as 
HOX2I, HOX2H and H0X2G respectively, and corresponding to the murine genes previously known 
as Hox2.9, Hox2.8 and Hox2.7) are barely detectable in undifferentiated TERA2.cl .SP12 cells. All 
three genes are strongly up-regulated in a co-linear and concentration dependent manner in response to 
A T R A and both synthetic retinoids, providing further evidence of the similarity of genotypic effects 
induced by C E B 1 6 and CEB17 compared to the natural retinoid (Figure 4-14, Figure 4-15 and Figure 
4-16). Once again, 0.1 C E B 1 6 fails to modulate expression of these genes, mirroring the results of 
the DMSO treated culture. 
Examining the HOXBl results in detail (Figure 4-14) reveals that transcript accumulation started to 
increase at approximately the same time in response to both A T R A and the synthetic retinoids and that 
expression levels appear to be un-related to the potency of the compounds. Gene expression appears to 
be a multi-phasic; this might be explained in the 10 fiM cultures by a direct response to the provision 
of fresh retinoid, most notably in the 10 |a,M A T R A culture, consistent with its rapid degradation in 
culture. Accumulation of mRNA is slower in the 0.1 |j,M cultures, although interestingly treatment 
with 0.1 )iM CEB17 results in sustained accumulation of HOXBl (seemingly in response to retinoid 
supply), producing the greatest expression of all cultures by the 14 day time-point. The least potent 
differentiating agent, CEB16 , initially induces a slow response, but gradually accumulates mRNA 
throughout the study resulting in a higher level of gene expression than either of the other 10 |iM 
conditions by 14 days. 
The HOXB2 and H0XB3 expression profiles (Figure 4-15 and Figure 4-16 respectively) present 
simpler responses of TERA2.cl .SP12 cells to exogenous retinoid treatment. 10 [iM A T R A induces the 
fastest and ultimately strongest expression of both genes; however both 10)aM CEB16 and ]0)a.M 
C E B 1 7 modulate HOXB2 accumulation similarly to lOjaM A T R A , whereas HOXB3 expression 
follows the expected pattern of potency. At the lower concentration, 0.1 ]xM A T R A and 0.1 laM 
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C E B 1 7 also induce very similar responses in both genes, which is of a lower intensity than the 
corresponding 10 |aM data. Induction of HOXBl and H0XB2 appears to commence at approximately 
the same time in these cells, i.e. between 8 and 24 hours, at both concentrations and in response to all 
retinoids; however, the rate of transcript accumulation is fastest during these initial stages in H0XB2. 
Collection and analysis of more time points during this window would be expected to show an earlier 
induction of HOXBl. H0XB3 is clearly regulated more slowly than either of the more 3' genes, in true 
co-linear fashion. 
The co-linear induction of HOXB expression during ATRA-induced differentiation has previously 
been reported in a number of murine and human cell lines,''"''" '^^ '" and although this expression has 
not been reported as phasic, it has been established that a continual supply of retinoid is required for 
maintained expression."^"' Gene regulation was faster in NTERA2/D1 cells compared to 
TERA2.cl .SP12 cells, for example an up-regulation oi HOXBl was observed in NTERA2/D1 cells 
within just one hour in response to 10 | j . M A T R A , although the expression of this gene in response to 
0.1 iiM A T R A is more c o m p a r a b l e . H u m a n HOXB genes have previously been noted to require a 
longer induction period (up-regulation of H0XB9 was observed after six days compared to just 24 
hours for than the corresponding murine Hoxb gene) which have led to the suggestion that the 
induction may be directly linked to cellular differentiation rather that activation by A T R A . " ^ 
The gene transcription site of Hoxal in F9 muEC cells contains an ATRA-inducible enhancer that 
contains an RARE.^^'' Similar response elements have also been found in human and murine 
HOXBl/Hoxb 1^^^'^^^ and HOXD4IHoxd4 genes,*"'*^° suggesting that the expression of these genes 
may be directly responsive to ATRA-signalling via ligand-bound R A R - R X R heterodimers. Indeed, 
murine Hox expression has been demonstrated to probably be dependent upon the activation of RAR-
a and f^ R.p '^98,6io,662,664 p i^^  ^ feedback circuit to ensure the correct expression of these 
powerful transcription factors.^ ^" 
This study is believed to present the first investigation into the effects of synthetic retinoids upon 
human HOX gene expression. The synthetic retinoids ST1926 and CD437 have previously been 
shown to up-regulate Hoxal in muF9 E C cells, but at a slower rate than ATRA.""'' Interestingly, 
expression of the HOXB genes investigated in this study do not appear to be strictly related to the 
differentiation-potency of the retinoids. 
146 
H0XB1 e x p r e s s i o n in A T R A c u l t u r e s H0XB1 e x p r e s s i o n in C E B 1 & c u l t u r e s 
exposure' hours 
|-*-ATRA 101.M -^^^A0.1^M OMSo| 
H0XB1 e x p r e s s i o n in C E B 1 7 c u l t u r e s 
e » p o s i « ; h o * « exposure / hours 
|-*-CeBl6iaiM -•-CCBlSQUiM DMSO| -CEBl71CtjM -W-Cgai^OliiM OMSOl 
H0XB1 e x p r e s s i o n in 1 0 p M r e t i n o i d c u l t u r e s H0XB1 e x p r e s s i o n in O . l p M re t ino id c u l t u r e s 
exposure / hoirs exposure I hows 
I - * - A T R A IOMM -»-CirBie lOfcjM X CEBViCyU DMSO I l-e-ATRAQIuM -*-CEB16 0.1uW X CEBITaiuM DMSO | 
-1^  
Figure 4-14: Concentration and time-dependent regulation of HOXBI expression in TERA2.cl.SP12 huEC ceils by ATRA and two synthetic retinoids (n = 1). 
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Figure 4-15: Concentration and time-dependent regulation of HOXB2 expression in TERA2.cl.SP12 huEC cells by ATRA and two synthetic retinoids (n = 1). 
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Figure 4-16: Concentration and time-dependent regulation of HOXB3 expression in TERA2.cl.SP12 huEC cells by ATRA and two synthetic retinoids (n = 1). 
4.6.6 /Agarose gel electrophoresis ofrt qPCR products 
The major disadvantage of using S Y B R green chemistry for real-time quantitative PCR analysis 
(rt qPCR) is that S Y B R green binds non-specifically to double stranded DNA formed during the PCR 
reaction. However, if primers are well designed the AmpliTaq Gold® DNA polymerase in the 
mastermix will only amplify the target sequence, there will be no primer dimerisation and non-specific 
products will not be formed. 
Initially, all primer sequences for the genes of interest were obtained from published sources (Table 
6-4) and preliminary experiments were performed to test the performance of these primers. After each 
rt qPCR reaction, a final step in the analysis programme generated a disassociation curve. If only one 
peak is observed, and no peaks are visible in the no target control (NTC, sample DNA is replaced by 
H 2 O to act as a blank), this demonstrates that a single product has been formed. Secondly, a PCR 
product from each gene was run out on a 1.5% "/v agarose gel and detected using ethidium bromide 
under UV light. Each PCR product produced a unique disassociation curve and was composed of only 
one band when run out on an agarose gel, which eluted at the correct molecular weight for the 
expected product (Figure 4-17). 
The fidelity of transcription could be un-equivocally established by extracting the PCR products and 
sequencing. For three of the genes analysed in this chapter {RAR-a, RAR-y and H0XB3) the initial 
choice of primer was either non-specific or failed to generate any product. Three pairs of additional 
primers for each problematic gene were sourced from either the literature or designed using Primer 
Express 3.0 (Applied Biosystems) software, tested as described above, and the best performing 
primers selected for use in rt qPCR analysis. 
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Figure 4-17: Images of PGR products eluted on 1.5% agarose gels, stained with ethidium bromide and 
visualised by UV. Each gene product produced only one band of the expected size confirming its 
identity. 
151 
4.7 Conclusions 
The mechanistic pathway by which vitamin A exerts its activity has been studied extensively for more 
than f i f t y years and with renewed interest since the nuclear receptors for its major metabolite, all-
trans-retinoic acid, were identified twenty years ago. It is o f significant clinical interest to investigate 
whether synthetic retinoids also interact with the same retinoid proteins and receptors and to compare 
this behaviour to the activity o f exogenous ATRA. The previous chapter demonstrated that some 
synthetic retinoids are able to induce differentiation in TERA2.cl.SP12 human EC cells in a 
phenotypically and seemingly genotypically analogous manner to A T R A . To date, limited data haVE 
been published on the effects o f synthetic retinoids on the retinoid pathway during differentiation o f 
human cells and no human studies have examined the activity o f synthetic retinoids on the HOX 
genes. Delineating the biological behaviour o f this powerful group o f compounds to understand the 
fundamental mechanisms and signalling pathways that control and accompany the early stages o f 
retinoid-induced differentiation should result in more effective therapies. 
Studies o f the ATRA-induced differentiation of cultured stem cells have permitted the detailed 
dissection o f the differentiation pathway, such that more than 500 genes have been identified as 
regulatory targets o f A T R A . Control may be exerted directly, driven by the binding of ligands to 
RAR/RXR heterodimers, or indirectly through intermediate factors or even more distant 
mechanisms.'^^ The speed of gene response can vary f rom hours to weeks, and may be up-regulated, 
down-regulated or variable in their regulatory direction. However, few reported gene expression 
studies analyse the modulation of transcripts o f the retinoid pathway in any detail or over an extended 
period; most arbitrarily select a small number of time-points to provide a simple snapshot. The data 
presented in this chapter suggest that gene modulation within the retinoid system is more complex 
than has previously been reported and highlights the limitations o f other studies. This investigation 
was designed to measure these changes thoroughly over an extended period of differentiation and 
attempt to capture transient expression. It has also demonstrated the significant importance o f t iming 
o f addition o f inductive agent {i.e. retinoids), and an apparent unexpected consumption or degradation 
o f "stable" synthetic compounds. 
TERA2.cl.SP12 huEC cells were treated continuously with 0 .1% 7v DMSO or either 10 | i M or 0.1 ^ M 
o f A T R A , CEB16 or C E B l 7 for a total o f two weeks. After 8, 24 and 48 hours and 3.5, 5 ,7 ,10 and 14 
days' culture mRNA was isolated from each o f the different culture conditions and used to determine 
the expression o f eleven transcripts involved in retinoid transport, activation and metabolism by 
quantitative real-time PCR (rt qPCR). A large number o f time-points over an extended period of 
differentiation were analysed in order to try to capture the detailed fluctuations in mRNA expression 
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that previous studies have detected. The vehicle did not modulate the expression o f any o f the genes in 
this study, at the concentration used to deliver the retinoids, although it may interact with alternative 
pathways. These data confirms the results presented in Chapter 3 and further validates the use o f this 
concentration o f DMSO in TERA2.cl.SP12 cells. 
As previously observed, A T R A , CEB16 and CEB17 induced phenotypic differentiation in this cell 
line (Section 4.6.1). At 10 the order o f efficacy o f morphological development towards mature 
neural cultures was A T R A » CEB17 > CEB16. Evidence o f differentiation was also observed in 
cultures grown with 0.1 ]xM A T R A and CEB17, but CEB16 was ineffective at this lower 
concentration. However, 0.1 | i M CEB16 did modulate the expression o f three o f the genes 
investigated in this study: CRABP-I, CYP26A1 and RAR-yiF\guvQ 4-8, Figure 4-10 and Figure 4-13). 
CRABP-1 is involved in the transport o f A T R A to the major specific metabolising enzyme CYP26A1 
so it is perhaps unsurprising that this pair o f transcripts are modulated. Furthermore, activation o f 
RAR-y is consistent with the apparent propensity o f CEB16 to induce epithelial differentiation. 
A l l o f the retinoic acid inducible genes examined in this study were found to be modulated in 
TERA2.cl.SP12 cells in response to both A T R A and two synthetic retinoids. It may therefore be 
inferred that these compounds are activating the same pathway as the natural metabolite in these cells 
and that this is responsible for at least some o f the observed effects. The cellular behaviour o f these 
synthetic retinoids may be largely analogous to the well studied actions o f A T R A in vitro and in vivo. 
Gene up-regulation was typically greater in response to 10|a.M compared to 0.1 |aM o f the 
corresponding retinoid, although the modulation does not always demonstrate a similar but 
concentration dependent profile. Furthermore, the order o f phenotypic efficacy described above and in 
Chapter 3 is not observed as clearly in the gene expression assays. This final observation is consistent 
with the theory that geometrically constrained synthetic retinoids may function in a subtly differently 
manner compared to A T R A . 
The induced retinoid-regulated genes show a range o f different kinetic and temporal expression 
profiles. While the large fluctuations in gene expression were observed during the experiments do not 
represent the technical accuracy o f the experiment (as exemplified by the consistent expression levels 
o f the DMSO culture in many o f the gene assays and a number o f very similar results obtained with 
different retinoids, for example the 10 j ^ M CEB16 and 10 i^M CEB17 CRABP-11 expression profiles, 
Figure 4-9), they may be less significant i f further biological samples had been analysed. 
O f the eleven genes analysed in this study, f ive have been established as direct targets o f A T R A 
treatment: CRABP-II, HOXBl, RAR-a, RAR-p and RAR-y}''^ Whereas the other genes are controlled 
indirectly. The quickest up-regulation o f mRNA (within 8 hours o f treatment) was observed in RAR-/3, 
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CRABP-I, CRABP-II and CYP26A1, genes which are involved in the modulation/attenuation o f the 
retinoid signal."'' 
The large variations o f individual gene expression during the course o f these experiments, as a 
function of both retinoid concentration and retinoid structure, reveal an underlying complexity to the 
differentiation pathway(s). In vivo, it is well established that a fine spatial and temporal control o f 
genes is required for cell growth, differentiation and development. Minor aberrations to the activity o f 
the molecular signals and induction factors that underlie this control can cause lethal abnormalities. 
The developmental landscape is extremely complicated; whilst the scientific community understands 
only a small proportion o f it, each new discovery provides a therapeutic potential. 
The patterns o f gene regulation observed in this study were compared with other published reports for 
cultured cells and in vivo data, where available. The multipotent murine embryonal carcinoma cell 
lines F9 and PI9 have been used extensively as models o f early embryonal differentiation.""'"' ' ' 
However, human EC cells appear distinct f rom murine EC cells in terms o f genetic, phenotypic and 
biological markers,"'' making human EC lines the best comparator for observations in TERA2.cl.SP12 
cells. The TERA2.cI.SP12 and NTERA2/D1 (NT2) human embryonal carcinoma cell lines were both 
clonally derived f rom the human teratoma line TERA2 and have both retained the capacity for 
differentiation into diverse somatic lineages.''"'"' However, differences in the method o f isolation or 
simply as a consequence o f each cell line originating from two different clones have led to previously 
observed differences between the cell lines.""^'"^ The data in this chapter further exemplifies the 
disparity between these cells. 
A preliminary experiment determined that no significant changes in the expression o f any o f the genes 
occurred prior to 8 hours' retinoid exposure. The fu l l gene analysis study presented in this chapter did 
not therefore examine any earlier time-points. Compared with the other cell lines discussed, which use 
similar retinoid concentrations and seeding densities, gene expression in TERA2.cl.SP12 cells respond 
relatively slowly to natural and synthetic retinoid treatment. Whilst it seems unlikely, it is possible that 
this discrepancy is somehow related to the protocol employed. In order to investigate this hypothesis it 
would be necessary to analyse other cell lines in the same manner and compare the results obtained 
with those in the published literature. Alternatively, these cells may be unusually inefficient at taking 
up retinoids from the media. This could be tested by comparing the intracellular concentrations o f 
retinoids with those o f other cell types treated similarly. 
As with many previous studies, supra-pharmacological concentrations o f the retinoids were applied to 
the cells, and may therefore not represent the in vivo behaviour o f the retinoid molecular pathway 
under realistic therapeutic regimens. Furthermore, cultured cells are a simple but artificial model 
biological system, whereas animal models and the human body are likely to respond in a more 
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complicated and un-predictable manner. For example, in vivo the retinoids may differ in rate o f 
cellular uptake and metabolic transformations. A large number o f positive in vitro retinoid studies 
have promised effective treatments for a wide range of cancers; however, with the exception of acute 
promyelocytic leukaemia and neuroblastoma, clinical results have thus far been disappointing.^"' 
However, the up-regulation o f mRNA observed in this study does not necessarily correlate directly 
with protein expression, the real effector in many biological processes, but does suggest that these 
genes are involved in the mediation o f retinoid effects in v / r ro ." ' Conversely, genes may be actively 
transcribed with measurable protein expression, but without accumulating high levels o f R N A . " ' " * 
The mRNA o f different genes have widely ranging half-lives such that observed levels wi l l vary 
significantly between genes and may not be detected i f they are particularly transient. 
The expression profiles o f a number o f the genes appear to respond to media changes, which are 
believed to demonstrate a direct response to the provision o f fresh retinoid at these time-points. For 
example, expression o f HOXBl in cells grown with 10 f i M A T R A declines just before the media is 
changed at approximately 72 and 120 hours and then increases rapidly immediately after this time 
(Figure 4-14). A more consistent level o f expression thereafter is proposed to be a response to the 
subsequent supply o f retinoids at daily intervals, providing a more consistent stimulus. Although 
further biological samples need to be analysed to confirm these observations, these results appear to 
represent a concentration dependent response to the amount o f retinoid available to the cells. This 
relationship is rarely mirrored at both concentrations o f the same retinoid as might be expected from 
this hypothesis, but the overall temporal expression profiles are more complicated and do not typically 
show a concentration dependent relationship. Similar responses are seen in some o f the synthetic 
retinoid cultures (for example expression of RAR-/3 in response to 0.1 | i M CEB17, Figure 4-12), 
however these patterns are not clearly observed in response to all retinoids for a given gene analysis. A 
specific study to investigate the effect o f the timing o f media changes on gene expression is required 
to investigate this hypothesis. 
AII-/raA75-retinoic acid is notoriously unstable towards a range o f physical, chemical and enzymatic 
triggers o f oxidation, isomerisation, and metabolism. A small number o f studies have examined the 
degradation o f A T R A under cell culture conditions and although they highlight experiment-specific 
differences, such as cell type and presence o f certain media supplements, they clearly demonstrate that 
the initial concentration o f A T R A rapidly declines in c u l t u r e . A T R A is predominantly 
isomerised into its 9- and \3-cis geometric i s o m e r s . I n some instances these isomers induce 
phenotypically similar effects to A T R A (Chapter 3), but they are distinct in mechanism o f action and 
in a clinical setting.^*' "^' 
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Stability studies need to be performed under typical TERA2.cl.SP12 culture conditions to determine 
the specific retinoid degradation kinetics of A T R A and the apparently more stable synthetic analogues 
under investigation. An almost complete loss o f A T R A within 24 hours' culture has been reported,^^° 
while two independent reports are in good agreement that after 24 hours 75% o f the original 
concentration of A T R A remains, declining to 40-50% after 48 hours and 35-40% after 72 hours.^ **''"** 
Specific stability study results should be used to define a standard protocol on the frequency o f media 
changes, to constrain retinoid concentrations within a defined range. Furthermore, given the 
dependence of effect on concentration, this parameter should be reported in all retinoid studies. 
Although a number o f synthetic retinoids are more stable than A T R A outside the cell culture 
environment,^" ""^ their stability in vitro has yet to be tested. 
The pleiotropic effects o f retinoids may be explained by the existence o f complex signal transduction 
pathways involving multiple forms o f specific binding proteins, nuclear receptors and metabolic 
enzymes. These proteins have different expression patterns in the adult and during vertebrate 
embryogenesis suggesting that they have particular complementary functions that permit them to 
carefully control the concentration and effects o f retinoids in vivo. Aberrations in the normal retinoid 
pathway have been identified in tumour cells, thus confirming the importance o f timely regulated 
expression o f components o f the retinoid cycle and presenting the opportunity to use exogenous 
retinoids in clinical therapy. As further components o f the retinoid cycle are identified and their 
physiological roles defined, it is anticipated that synthetic retinoids may be used to bypass non-
essential parts o f the system permitting the design o f more efficacious and tolerable drugs. 
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CHAPTER 5: FINAL CONCLUSIONS & 
RECOMMENDATIONS FOR FUTURE 
WORK 
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6.1 Conclusions 
Detailed conclusions have been presented at the end o f Chapters 2, 3 and 4; the fo l lowing is an 
overview o f the key findings o f this work. 
Human EC stem cells have been used to screen and characterise the ability o f a small library o f 
synthetic retinoids to induce differentiation. Two isomeric compounds (CEB16 and CEB17) were 
further investigated to examine the capacity o f synthetic retinoids to modulate the retinoid pathway. 
Three o f these compounds, CEB16, CEBI7 and CEB18 were prepared by the author using emerging 
C-H activation methodologies. Significant progress was also made towards the complete synthesis of 
two further series o f compounds. 
The retinoid and retinoid-like compounds shown in Table 3-1 and Table 3-2 were screened at a 
concentration o f 10 |j.M for the ability to induce differentiation in TERA2.cl.SP12 human EC cells. 
Phenotypic changes consistent wi th differentiation were observed in response to some o f the 
compounds, in agreement with published data for a number o f the compounds or as might be expected 
from comparison o f the pharmacophore o f previously un-tested compounds with that o f bona fide 
retinoids. However prior to this study, the production o f different proportions of cell types in response 
to alternative retinoid compounds had not been reported. Not only did the proportion o f neuronal cell 
types observed vary, but CEB16, CEB17 and CEBI8 induced a greater proportion o f epithelial cell 
types to develop f rom TERA2.cl.SP12 cells than was observed with A T R A , 9-cis-RA, 13-C/5-RA or 
two commercially available synthetic retinoids. The importance o f subtle changes in ligand structure, 
in this case f rom meta to para substitution (CEB16 vs. CEB17), has subsequently been reported by 
our group for another isomeric pair o f retinoids."^ Flow cytometric analysis o f stem cell and neural 
cell antigens confirmed the morphological observations and permitted the fol lowing order o f 
differentiation efficacy to be established: 
1 3 - C i j - R A > 9 - C ( 5 - R A = A T R A > C E B 1 8 > C E B 1 7 » C E B 1 6 . 
Differentiation was further characterised by immunocytochemical and western blot analysis of 
antigens associated with neural and non neural markers, proliferation studies and co-culture with a 
rexinoid. Data are also presented that demonstrate, for the first time, the expression o f retinoid 
receptors in TERA2.cl.SP12 huEC cells and that treatment with both natural and synthetic retinoids 
retinoids can modulate this expression. These data validate the use of this cell line for the study o f 
retinoid effects. The synthetic retinoids are shown to induce the expression o f RAR-a, RAR-/3 and 
RAR-y and to have their efficacy potentiated by co-administration with an RXR ligand: two pieces of 
evidence that suggest these compounds are RAR ligands. 
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A further study was designed to investigate the effects of A T R A and two synthetic retinoids on 
components o f the retinoid pathway. Real time PGR analysis was used to construct detailed temporal 
expression profiles o f eleven genes involved in retinoid transport, metabolism and activation 
{P0U5F1, CRBP-I, CRABP-I, CRABP-II, CYP26A1, RAR-a, RAR-p, RAR-y, HOXBl, HOXBl and 
H0XB3). Although the data requires confirmation through analysis o f further biological samples, 
CEB16 and CEB17 were clearly found to regulate the expression o f a number o f key components o f 
the classical retinoid pathway, in a similar manner to A T R A . In many cases, gene expression patterns 
were complex, confirming the need for detailed expression analysis when comparing compounds o f 
differ ing efficacy and emphasising the complicated nature o f gene regulation in the retinoid pathway. 
Both CEB16 and CEB17 also induced the expression o f three HOX genes. These results show that 
these synthetic retinoids are able to emulate some o f the essential roles o f A T R A in embryonic 
development. 
Despite this similarity to A T R A and the observation of phenotypic changes consistent with neural and 
non-neural differentiation, it is unlikely that any o f the other synthetic retinoids discussed in this thesis 
are able to offer the f u l l differentiation potential and range o f biological effects that are attributable to 
A T R A . However, this may actually be an advantage in the therapeutic application of retinoids: it is 
hoped that synthetic retinoids w i l l induce specific biological effects and circumnavigate the toxicity 
associated with the pleiotropic nature of A T R A . 
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5.2 Further work 
Complete and extend retinoid gene analysis 
1. Analyse further independent biological samples for the expression of genes o f the retinoid 
pathway to hopefully confirm the results presented in Chapter 4 and eliminate biological variation. 
2. Investigate the effect o f t iming o f media changes/supply o f fresh retinoid on gene expression to 
validate the hypothesis that the temporal expression o f a number o f genes correlates with the 
strength o f retinoid in the media. 
Develop methods to measure changes in retinoid concentration in vitro 
1. Develop suitable assay(s) to extract and then quantify natural and synthetic retinoid concentrations 
in culture media. A number o f HPLC methods have been published which should provide a good 
starting point."*^-^"' 
2. Investigate the stability o f natural and synthetic retinoids under TERA2.cl.SP12 culture conditions 
and the effect that this has on cell behaviour. Are "stable" synthetic retinoids as un-labile in vitro 
as on the laboratory bench? 
3. Attempt to correlate the expression o f sensitive retinoic acid inducible genes (e.g. CYP26A1 and 
RAR-P) with retinoid concentration in culture. 
4. Define optimal media-changing protocol. 
Develop retinoid screening assay 
1. Develop a rapid and efficient method for screening synthetic retinoids in TERA2.cl.SP12 human 
EC cells. 
2. Select appropriate marker(s): for example suppression o f the sensitive stem cell marker SSEA-3 to 
investigate differentiation-inducing ability, or up-regulation o f TUJ-1 to compare efficacy of 
neuronal differentiation induction. Construct dose response curves and calculate the EC50 o f novel 
and previously tested synthetic retinoids to provide a better analysis o f retinoid efficacy in this 
system. 
3. Use the determined optimal concentration(s) to differentiate TERA2.cl.SPI2 stem cells. 
4. Receptor binding assays w i l l not capture non-retinoidal activation, so may be less appropriate than 
functional assays. However, this information would complement and extend the characterisation 
o f retinoid ability and permit comparison with published aff ini ty ( K j ) data. Pharmacological 
antagonism of individual receptors could be alternatively or additionally used. 
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CHAPTER 6: EXPERIMENTAL SECTION 
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6.1.2 General 
A l l reactions were performed under dry nitrogen or argon atmospheres using either standard Schlenk 
techniques or in an Innovative Technology, Inc. System 1 glove box, except for compounds 12, 13, 14 
and 17. Once the reactions were complete, further procedures were carried out without any precautions 
against oxygen. Where appropriate, solvents were dried before use with appropriate drying agents. 
Reagents used in synthesis were purchased from commercial suppliers and used without further 
purification. B2pin2 was generously donated by Frontier Scientific Inc. TLC was performed with 
Merck Kieselgel 60 F-254 plates. Silica gel chromatography was conducted using 40 - 63 | i M silica 
gel (Flurochem). Evaporations were carried out at 20 mmHg using a Buchi rotary evaporator and 
water bath, followed by evaporation to dryness (< 2 mmHg). 
N M R spectra were obtained using a Bruker 400 Ultrashield, Varian Mercury-200, Varian Unity-300 
or Varian Inova-500 M H z Varian spectrometer. C D C I 3 , CeDe and c?6-DMS0 solvents were used, the 
' H and '^C chemical shifts are recorded in ppm using partially deuterated solvent signals as the 
internal standards, and coupling constants are given in Hz. 
GC-MS analysis was performed on a Hewlett Packard 5890 Series I I chromatograph equipped with a 
5971A mass selective detector and a fused silica capillary column (10 m, 5% cross linked 
phenylmethylsilicone), using UHP helium as the carrier gas and under operating conditions similar to: 
163 
injector temperature 250 °C, detector temperature 300 °C, oven temperature ramped from 50 °C to 
280 °C at a rate o f 20 °C/min. 
Mass spectra were obtained on a Micromass AutoSpec (El) and Micromass-LCT (ES) spectrometers. 
The elemental analyses were performed using an Exeter Analytical Inc. CE-440 Elemental Analyser. 
FT-IR spectra were recorded as KBr discs using a Perkin-Elmer 1615 FT-IR spectrometer operating 
f rom a Grams Analyst! 600. Melting point determinations were made using a Mel-Temp (Laboratory 
Devices) apparatus, using an external thermometer. 
X-ray diffraction experiments were performed at 120 K on Bruker S M A R T 3-circle diffractomers with 
CCD area detectors, using graphite-monochromated Mo-Ka radiation {X = 0.71073 A) . The low 
temperature o f the crystals was maintained by Oxford Cryosystems Cryostream open-flow nitrogen 
crytostats. A l l structures were solved by direct methods and refined by f u l l matrix least squares against 
o f all reflections using S H E L X T L software. A l l non-H atoms were refined in anisotropic 
approximation; all H atoms were refined in isotropic approximation. Crystal data and experimental 
details are listed in Appendix 2. 
6-Pinacolboron-1,1 ',4,4'-tetramethyl-1,2^,4-tetrahydronaphthaiene (7). 
A solution o f l,2,3,4-tetrahydro-l,r,4,4'-tetramethylnaphthalene (3.00 g, 16.0 mmol) in dry hexane 
(1ml) was added to B j p i n j (8.09 g, 32.0 mmol, 2.0 equiv.), I rCI(C0E)2 (1.42 g, 3.20 mmol, 20 mol%) 
and 4,4'-di-/m-butyl-2,2'-bipyridine (0.86 g, 3.20 mmol, 20 mol%). Dry hexane (24 ml) was added 
and the mixture shaken thoroughly, though the solids did not ful ly dissolve. The reaction was heated 
to 80 °C with stirring in a sealed tube. After 46 hours all starting material had been consumed (as 
determined by GC-MS). The solvent was removed in vacuo to give a dark-orange solid that was 
purified by silica gel chromatography (hexane:DCM, 1:1 as eluent)to afford 5.17 g (103%) o f an off-
white solid, which was shown by ' H N M R to contain 10% o f COE-Bpin by-product. Small-scale 
recrystallisation from hot hexane gave 7 as a white crystalline solid. Mp 116-118 °C; ' H N M R 
(400 MHz, CfiDa): 5 1.14 (s, 12H, pinacolato C(C//3)2), 1.18 and 1.22 (2s, 12H, C(CHi)2), 1.55 (s, 4H, 
CH2CH2), 7.28 (dd, I H , J = 1.3 and 8.1 Hz, Av-CH), 8.01 (dd, I H , J = 1.3 and 8.1 Hz, Ar-CH), 8.23 
(d, 1 H , J = 1.3 Hz, AT-CH); ' H N M R (400 MHz, CDCl3):6 1.26 (s, 12H, pinacolato C(C//3)2), 1.30 (s, 
6H, C{CHi)2), 1.31 (s, 6H, C(C//3)2), 1.66 ( s ,4H, C / / 2 C / / 2 ) , 7.75 (d, l H , y = 1.2 Hz, Ar-CH); '^C { ' H } 
N M R (101 MHz, CeDe): 5 25.0 (C(CH3)2), 31.8, 31.9, 34.3, 34.6, 35.6 (ring Cs o f I ,r ,4,4'-tetramethyl 
ring), 83.5 (C(CH3)2), 126.4, 132.7, 134.0, 144.2, 148.3 (C6H3-Bpin); " B { ' H } N M R (128 MHz, 
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CaDft) 5 31.19 (Spin); IR ( K B r disc): v (cm"') inter alia 2966, 2926, 2855, 1609, 1364, 1145; GC-MS 
(EI) m/z: 314 [ M ] " , 299 [ M - C H j ] " ; Anal, calcd. (%) for C20H31BO2: C, 76.44; H, 9.94; found: C, 76.64; 
H, 10.13. 
Method 1: 6-Isopropenyl-l,r,4,4'-tetrainethyl-l,2,3,4-tetrahydronaphthalene (8). 
A solution o f 2-bromopropene (260 ^ l , 354 mg, 2.90 mmol), 7 (996 mg, 3.20 mmol, 1.1 equiv.), 
Pd(dppf)Cl2 (121 mg, 0.16 mmol, 5.0 mo\% w.r.t. 7) and potassium phosphate dihydrate (2.01 g, 
8.10 mmol, 2.5 equiv.) in D M F (15 ml) was heated to 80 °C in a sealed tube. After 17 hours the 
reaction mixture was cooled to room temperature and analysis by GC-MS showed total consumption 
o f starting material. The reaction mixture was added to purified water (20 ml) in a separating funnel. 
Ether (20 ml) and brine (20 ml) were added, but the phase boundary could not be seen in the dark 
liquid. Further brine and ether were added, without improvement. The mixture was left to settle over 
weekend, and the layers separated. The organic layer was combined with ether washings (3 x 20 ml) 
o f the aqueous phase, dried over Mg2S04 and concentrated in vacuo to give a cloudy dark orange o i l . 
To ensure all salt had been removed, the oi l was dissolved in ether (10ml) and washed again with 
water ( 3 x 1 0 ml) . Drying over Mg2S04 and concentrating in vacuo gave a dark orange oil that was 
purified by silica gel chromatography (DCM:hexane, 1:9 as eluent)to give 8 as a yellow oil (approx. 
0.35 g, 45% yield). ' H N M R (400 MHz, CsDe): 5 1.18 (s, 12H, C(CHi)2), 1.22 and 1.23 (2s, 4H, 
CH2CH2), 1.53 (s, 3H, CH2=CC//3), 4.98 (t, 1H, 7 = 1.2 Hz, =CH2 cis to ring), 5.37 (t, 1H, J = 0.8 Hz, 
=CH2 trans to ring), 7.09 (d, l H , y = 5.7 Hz, Ar-CH), 7.19 (d, I H , J = 3.8 Hz, Ar-CH), 7.46 (d, I H , 
J= 2.2 Hz, Ar-CH); '^C { ' H } N M R (101 MHz, CsDs): 5 22.0 (CH2=CCH3), 32.0, 32.0, 34.2 (C(CH3)2 
andC(CH3)2), 35.5, 35.6 ( C H 2 C H 2 ) , 111.6 (CH2=CCH3), 123.6, 123.9, 126.7, 128.5, 129.3, 139.1 
(C6H3-C(CH3)=CH2), 144.2 (s, CH2=CCH3); GC-MS (EI) m/z: 228 [ M ] ' , 213 [M-CH3T. 
Method 2: 6-Isopropenyl-l,r,4,4'-tetrainethyl-l,2,3,4-tetrahydronaphthalene (8). 
A flask containing 7 (800 mg, 2.50 mmol), Pd(PPh3)4 (282 mg, 0.24 mmol, 10 mol% w.r.t. 7) and 
Ba(OH )2 .8H20 (2.01 g, 6.40 mmol, 2.6 equiv.) was evacuated / f i l led with nitrogen (x 3). A solution 
o f 2-bromopropene (300 ^ i l , 410 mg, 3.40 mmol, 1.5 equiv.) in 25 ml o f a 5:1 mixture of A',yV-
dimethylacetamide : purified water was freeze / thaw degassed (x 3) and transferred via syringe to the 
flask. The reaction mixture was heated at 80 °C for 65 hours, when analysis by GC-MS showed 
complete consumption o f 7. The reaction was quenched with dilute hydrochloric acid (2 ml). The 
resulting mixture was extracted with DCM ( 3 x 1 0 ml) ; the organic phase was washed with dilute 
165 
hydrochloric acid (3 x 10ml), dried over MgS04, filtered and concentrated in vacuo. Purification by 
silica gel chromatography (hexanes : D C M , 1:1 as eluent) gave) 8 (0.62 g, 95% yield, >95% purity by 
GC-MS). 
(2-(5,5',8,8'-Tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyI)-I-propenyl]pinacolboron (10). 
i5< 
Dry toluene (3 ml) and dry acetonitrile (1ml) were mixed together and used to dissolve 8 (250 mg, 
1.10 mmol), B jp in , (278 mg, 1.10 mmol) and [frara-Rh(CI)(CO)(PPh3)2] (23 mg, 33 ^mol , 3 mol%). 
The reaction was heated to 80 °C with stirring, in a sealed tube, for 20 hours, when analysis by GC-
M S showed complete consumption o f the starting material. Water (5 ml) was added, and the aqueous 
layer washed with ethyl acetate ( 3 x 5 ml). The combined organic phases were dried over MgS04 and 
concentrated in vacuo to give a dark orange o i l . The crude product was purified by silica gel 
chromatography (hexanes:DCM, 1:1 as eluent), solidified by washing with hot methanol and re-
crystallised from hot hexane to give 10 as an impure o f f white solid (91 mg, 77% purity by 
' H N M R = 18% yield). M p 134-137 °C; ' H N M R (400 MHz, CDCI3): 8 1.25 and 1.26 (2s, 12H, 
C{CHi)2), 1.29 (s, 12H, pinacol C{CHi)2), 1.53 (s, 4H, CH2CH2), 2.37 (d, 3H, J = 0.8 Hz, CH=CCHi), 
5.71 (q, I H , J = 0.8 Hz, CH^CCHj), 7.23 (s, I H , Ar-CH), 7.23 (s, I H , Ar-CH), 7.45 (t, I H , 7 = 
1.3 Hz, Ar -C / / ) ; " B { ' H } N M R (128 MHz, CDCI3) 5 30.42 (s, l B , 5 p i n ) ; GC-MS (EI) m/-: 354 [ M ] " , 
339 [M -CH3]^ 
2,5-Dichloro-2,5-dimethylhexane (12) 394,750 
In a large conical flask 2,5-dimethyl-2,5-hexanediol (11) (33.5 g, 230 mol) was dissolved in c. HCI 
(450 ml) with stirring; a large quantity o f white precipitate was formed immediately. The mixture was 
stirred for a further 2 hours and then poured carefully into ice-water (500 ml), filtered, and the white 
solid washed with more ice-water (2 x 250 ml). The aqueous filtrate was split into three and each 
portion was extracted by washing with ethyl acetate (2 x 75 ml). The white solid was dissolved in the 
combined organic washings, concentrated and dried in vacuo to give 12 as a white solid (24.8 g, 59%). 
M p 63-65 °C (L i t . 63-65 ° C " " ) ; ' H N M R data were identical to those reported in the literature;"' '^C 
{ ' H } N M R (101 MHz, CDCI3): 5 32.5 (s, C(CH3)2), 41.2 (s, CH.CH,) , 70.3 (C(CH3)2). 
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l,2,3,4-Tetrahydro-l,r,4,4',6-pentaniethylnaphthalene (13). 395,751-753 
Compound 12 (20.1 g, 110 mol) was dissolved in HPLC grade toluene (20.3 g, 220 mol, 2.0 equiv.) 
and D C M (95 ml) and the apparatus flushed with nitrogen. The resultant pale yellow solution was 
stirred vigorously as AICI3 (202 mg, 1.50 mmol) was added in portions over 10 minutes to give a dark 
orange solution. The reaction was stirred at room temperature for 30 minutes, refluxed for 15 minutes, 
then allowed to cool to room temperature. Additional AICI3 was added (110 mg, 0.82 mmol) and the 
solution was stirred at room temperature for a further 30 minutes; the colour o f the solution became 
dark orange-red and analysis by GC-MS showed that all the starting material had been consumed. 
Hydrochloric acid (20%, 20 ml) was added to the stirred solution, and the reaction mixture changed to 
a clear, pale yellow solution. The organics were extracted with hexane (3 x 100 ml), washed with 
purified water (100 ml) and brine (100 ml) , then dried over MgS04, filtered and concentrated in 
vacuo. The resultant pale yellow oil crystallised overnight when stored at -20 °C to give 13 as a pale 
yellow solid (23.4 g, 84% yield). Mp 27-28.5°C (Li t . 29 ° C " ' ) ; all spectroscopic and analytical 
properties were identical to those reported in the literature.'" 
l-(5,6,7,8-Tetrahydro-3,5,5',8,8'-pentamethyl-2-naphthyl)ethan-l-one(14). 
AICI3 (14.3 g, 110 mmol, 2.2 equiv.) was added slowly to a stirred D C M solution (50 ml) o f 13 
(10.0 g, 49.0 mmol) and acetyl chloride (10.0 g, 130 mmol, 2.7 equiv.). The reaction was refluxed for 
15 minutes. Additional AICI3 (2.0 g, 15 mmol) was added to ensure the reaction was complete, and 
stirred for 15 minutes at room temperature. The reaction mixture was poured into vigorously stirred 
ice-water (200 ml) , acidified with 20% hydrochloric acid (50 ml) and EtOAc added (100 ml) . Stirring 
was continued until the organic layer was yellow (15 min). The organic layer was separated, and the 
aqueous layer extracted with ethyl acetate (2 x 100ml). The combined organic extracts were washed 
with water (100 ml) and brine (50 ml), then dried over MgS04, filtered and concentrated in vacuo to 
give an off-white solid (11.5 g, 47.0 mmol). This was purified by Kugelrohr distillation to give 14 as 
white crystals (10.0 g, 83% yield). Mp 55-58 °C; ' H N M R (400 MHz, CDCI3): 5 1.26 and 1.28 (2s, 
12H, C(C//3)2), 1.67 (s, 4H, CHjCHj), 2.47 (s, 3H, ArCHi), 2.55 (s, 3H, 0=CCH,), 7.12 (s, I H 
ArCH), 7.64 (s, I H ArCH); '^C { ' H } N M R (101 MHz, CDCI3): 8 21.4 (ArCH3), 29.3 (0=CCH3), 
31.5, 31.8 (C(CH3)2), 33.9, 34.3 (C(CH3)2), 34.9, 34.9 (CH2CH2), 128.1, 130.1, 135.2, 135.3, 142.3, 
149.0 (Ar-Cs;, 201.3 (s, C = 0 ) ; GC-MS (EI) m/z: 244 (46%, [ M ] ' ) , 229 (100%, [ M - M e ] ' ) ; Anal, calcd. 
(%) for C17H24O: C, 83.55; H, 9.90; found: C, 83.29; H, 9.91. 
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3-[3-(5,6,7,8-Tetrahydro-5,5',8,8'-tetramethyl-2-napthalenyl)phenyIl acrylic acid (3, C E B 1 6 ) . 
CO2H 
In a nitrogen atmosphere, 7 (534 mg, 1.70 mmol), 3-brorT\o cinnamic acid (406 mg, 1.80 mmol, 1.1 
equiv.), Pd(PPh3)4 (57.8 mg, 50.0 nmol, 3.1 mol% w.r.t. 7) and Ba(OH)2.8H20 (1.25 g, 4.00 mmol, 
2.4 equiv.) were dissolved in a degassed mixture o f yV,A^-dimethylacetamide / purified water (5:1, 
17 ml). The solids did not dissolve completely. The reaction was heated at 80 °C in a sealed tube for 3 
days when the reaction was quenched with dilute hydrochloric acid (2 ml) and extracted with D C M 
(3 X 20 ml) . The organic phase was washed with brine (10 ml) and dilute hydrochloric acid (5 x 
20 ml) ; the combined aqueous washings were back-extracted with D C M (2 x 20 ml). The combined 
organic layers were dried over MgS04, filtered and concentrated in vacuo. Purification by silica gel 
chromatography (hexane : D C M , 1:1 as eluant), and recrystallisation first f rom EtOAc then acetone 
gave 3 as a white crystalline solid (280 mg, 37% yield). M p 208-209 °C; IR (KBr disc) inter alia: 
3436, 3029, 2955, 2858, 2682, 2595, 1679, 1626, 1434, 1271, 1217, 987, 873, 807, 701, 593, 538 cm" 
'; ' H N M R (400 MHz, CDCI3): 5 1.31 and 1.34 (2s, 12H, C(CHi)2), 1.71 (s, 4H, C//2C//2), 6.50 (d, 
1 H , J = 15.9 Hz, CH=C//-C02H), 7.34 (dd, 1H, 7 = 2.0 and 8.1 Hz, 1-Ar-CH), 7.39 (d, 1 H , J = 8 . 1 Hz, 
8-Ar-C/f ) , V.45 (t, I H , 7 = 7.7 Hz, 4/6-cinnamic-/f), 7.49 (d, I H , y = 1.8 Hz, 5-Ar-C//) , 7.50 (dm 
overlapping 7.49, I H , 5-cinnamic-//), 7.60 (dt, I H , J = 1.5 and 7.6 Hz, 4/6-cinnamic-//), 7.71 (broad 
s, I H , 2-cinnamic-/f), 7.84 (d, I H , 7 = 16.2 Hz, CH^CH-COjH); ' H N M R (400 MHz , de-DMSO): 5 
1.31 and 1.36 (2s, 12H, C{CHi)2), 1.71 (s, 4H, C//2C//2), 6.68 (d, I H , J = 16.4 Hz, CH=C//-C02H), 
7.44 (d, 1H, y = 8.3 Hz, S-Ar-CH), 7.48 (dd overlapping 7.52, 1H, J = 1.6 and 8.6 Hz, 1-Ar-CH), 7.52 
(t overlapping 7.48, 1H, J = 7.7 Hz, 5-Ar-C//) , 7.67 (dm, 2H, 7 = 17.7 Hz, cinnamic-//), 7.73 (d, 2H, 
J = 16.2 Hz, cinnamic-//), 7.96 (broad s, I H , CH^CH-COjW), 12.44 (s, I H , CH=C//-C02H); "C { ' H } 
N M R (101 MHz, CDCI3): 31.9 and 31.9 (C(CH3)2), 34.2 and 34.4 (C(CH3)2), 35.1 and 35.2 (CH.CHj) , 
117.3 (CH=CH-C02H), 124.4, 125.3, 126.7, 127.2, 129.3, 129.5, 134.4, 137.5, 142.6, 144.7, 145.5 
and 147.2 (Ar-C and cinnamic acid-Q, 171.5 (CO2H); '^C { ' H } N M R (101 MHz, dg-DMSO): 32.0 
and 32.1 (C(CH3)2), 34.2 and 34.5 ( ^ C H j ) . ) , 35.0 and 35.2 (CH2CH2), 120.0 (CH=CH-C02H), 124.6, 
125.2, 126.9, 127.2, 127.5, 128.8, 129.8, 135.3, 137.2, 141.6, 144.4 and 144.5 (Ar-C and cinnamic 
acid-Q, 168.1 (CO2H); MS (EF) m/z: 334 ( 2 1 % , [ M ] " ) , 333 (100%, [ M - H ] " ) ; HRMS (EF) calcd. for 
C23H26O2 - H: 333.18600; found: 333.18582. 
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4-(4-(5,6,7,8-Tetrahydro-5,5',8,8'-tetrainethyl-2-napthalenyl)phenyll acrylic acid ( C E B 1 7 , 4). 
,C02H 
In a nitrogen atmosphere, 7 (515 mg, 1.60 mmol), 4-bromocinnamic acid (396 mg, 1.70 mmoi, 1.1 
equiv.), Pd(PPh3)4 (58.7 mg, 51.0 ^mo!, 3.1 mol% w.r.t. 7) and Ba(OH)2.8H20 (1.26 g, 4.00 mmol, 
2.5 equiv.) were dissolved in a degassed mixture o f A'jN-dimethylacetamide / purified water (5:1, 
17 ml) . The solids did not dissolve completely. The reaction was heated at 80 °C in a sealed tube for 3 
days when the reaction was quenched with dilute hydrochloric acid (2 ml) and extracted with EtOAc 
(50 ml) . The organic phase was washed with brine (10 ml) and dilute hydrochloric acid (3 x 20 ml) ; 
the combined aqueous washings were back-extracted with EtOAc (2 x 50 ml) . The combined organic 
layers were dried over MgS04, filtered and concentrated in vacuo. The crude off-white product was 
purified by flash silica gel chromatography (THF as eluent), and recrystallisation first from hot THF 
then acetone at approximately -20 °C (freezer) to give 4 as a white crystalline solid (360 mg, 66% 
yield). Mp 276-278 °C; I R (KBr disc) inter alia: 2957, 2920, 1674, 1626, 1426, 1313, 1184, 1107, 
821, 700, 500 cm"'; ' H N M R (400 MHz, C D C I 3 ) : 5 1.31 and 1.33 (2s, I 2H , CiCH})2), 1.71 (s, 4H, 
CH2CH2), 6.46 (d, I H , y = 15.9 Hz, CH=CH-C02H), 7.37 (broad m, 2H, A r - C H ) , 7.52 (broad m, I H , 
AT-CH), 7.60 (s, 4H, cinnamic acid Ar-CH), 7.79 (d, I H , 7 = 15.9 Hz, C//=CH-C02H); ' H N M R (400 
MHz, d6-DMSO):5 1.31 and 1.35 (2s, \2H, C(.CH^)2), 1.71 (s, 4H,CH2CH2),6.60 (d, 1 H , J = 16.0 Hz, 
CH=CH-C02H), 7.46 (s, I H , 5-Ar-CH), 7.46 (m, I H , 1-Ar-CH), 7.63 (bs, I H , Ar-CH), 7.65 (d, I H , 
J = 15.7 Hz, C / / = C H - C 0 2 H ) , 7.72 (d, 2 H , y = 8.1 Hz, cinnamic-//), 7.80 (d, 2H, J = 7.6 Hz, cinnamic-
H), 12.44 (s, I H , CO2H); '^C { 'H} N M R (101 MHz, ds-DMSO): 8 32.4 and 32.5 (C(CH3)2), 34.7 and 
35.0 ( Q C H j ) . ) , 35.4 and 35.6 (CH2CH2), 119.8, 124.9, 125.4, 127.8, 128.0, 129.7, 133.9, 137.4, 
143.0, 144.4, 145.2 and 145.9 (Ar-C and cinnamic acid-Q, 168.5 (CO2H); MS ( E f ) m/z: 334 (23%, 
[ M ] " ) , 333 (100%, [M-H]^ ) ; HRMS ( E I ) calcd. for C23H26O2 - H: 333.18600, found: 333.18586. 
6-(l,l',4,4'-Tetramethyl-l,2,3,4-tetrahydro-6-naphthyl)-2-napthaiene carboxylic acid ( C E B 1 8 , 
496 
5) 
CO2H 
In a nitrogen atmosphere, 7 (532 mg, 1.70 mmol), 6-bromo-2-naphthoic acid (439 mg, i .70 mmol, 1.0 
equiv.), Pd(PPh3)4 (58.9 mg, 51.0 nmol, 3.0 mol% w.r.t. 7) and Ba(OH)2.8H20 (1.25 g, 4.00 mmol, 
2.4 equiv.) were dissolved in a degassed mixture o f A'.A^-dimethylacetamide / purified water (5:1, 
17 ml). The solids did not dissolve completely. The reaction was heated at 80 °C in a sealed tube for 3 
169 
days when the reaction was quenched with dilute hydrochloric acid (15 ml) and extracted with EtOAc 
(3 X 50 ml). The organic phase was washed with water (3 x 20 ml); the combined aqueous washings 
were back-extracted with EtOAc (2 x 50 ml). The combined organic layers were dried over MgS04, 
filtered and concentrated in vacuo. The crude product was filtered through a silica gel pad (eluent = 
EtOAc). Re-crystallisation f rom acetone at -20 °C gave four crops o f 5 as a white crystalline solid 
(250 mg, 4 1 % yield) as colourless crystals. Mp 279-280 °C (Li t . 287.5-288.5 °C ' '^ ) ; all spectroscopic 
and analytical properties were identical to those reported in the literature.'"* 
6-Bromo-l ,r,4,4'-tetramethyl-l ,2,3,4-tetrahydronaphthalene(17)/"'^' ' ' '"^ 
A solution of 6 (25.0 g, 130 mmol) and Br2 (38.1 g, 240 mol, 1.8 equiv.) in dry D C M (150 ml) under 
nitrogen was stirred in an ice-bath while boron trifluoride diethyl etherate (19.9 g, 140 mmol, 1.1 
equiv.) was added drop-wise over 2 hours. Analysis by GC-MS showed no 6 remained. A 40% ethyl 
acetate / hexane mixture was added (350 ml), and the resultant solution washed sequentially with 
saturated aqueous sodium Na^S^Os, NaHCOs and brine. The organic extracts were dried over MgS04, 
filtered and concentrated in vacuo to give a pale brown soMd. The crude product was re-crystallised 
from methanol at approximately -20 °C (freezer) overnight to yield 17 as white needle-shaped crystals 
(27.9 g, 79%). Mp 47-48 °C (Li t . 35-36 "C"") ; all spectroscopic and analytical properties were 
identical to those reported in the literature;"' MS (EI) m/z: 268 and 266 (24% and 24%, [ M ] " ) , 253 
and 251 (98% and 100%, [M-CH3]"), 172 (49%, [ M - M e B r ] ^ . 
5,6,7,8-Tetrahydro-5,5',8,8'-2-naphthaleneboronic acid (18) 357 
B(OH)j 
n-BuLi (15.5 ml o f a 1.6 M solution in hexanes, 25.0 mmol, 1.3 equiv.) was added dropwise to a 
stirred solution o f T M E D A (3.70 ml , 25.0 mmol) in dry THF (65 ml) at -78 °C under Ar. After 30 
minutes a THF solution (35 ml) o f 17 (5.00 g, 18.0 mmol) was added dropwise to the mixture and 
stirred for a further 75 minutes. The resultant yellow solution was treated with trimethylborate (5.30 
ml, 47mmol, 2.6 equiv.) dropwise over 10 minutes. The solution was allowed to warm to RT and left 
to stir at RT for 15 hours under Ar. 3 M HCl was added slowly until the pH was \ . The organic and 
aqueous layers were separated and the aqueous layer washed with ethyl acetate/hexane (9:1, 3 x 
75 ml). The combined organic fractions were dried over MgS04, filtered and concentrated in vacuo to 
give a dark orange o i l . The crude product was purified in three stages by silica gel chromatography 
(ethyl acetate : hexane 1:4, then 1:1; 10% MeOH/90%) C H C I 3 as eluent) to give 18 as a white 
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crystalline product (1.21 g, 19%). Mp 188-190 °C (Lit . 190-192 ° C " ' ) ; ' H N M R d a t a were identical to 
those reported in the literature;^" '-^ C { H } N M R (101 MHz, dDe): 6 31.7 and 31.9 (C(CH3)2), 34.2, 
34.7,35.1 ( r i n g C s o f l ,r ,4,4 '- tetramethyl ring), 126.2, 132.4, 134.2, 144.3, 149.8 (Ar-CH); " B { 1 H } 
N M R (128 MHz, CeD^) 5 29.7 (s, 5(OH)2). 
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6.2 Biological testing 
6.2.1 Cell culture techniques 
TERA2.cl.SP12 cell culture 
TERA2 clone SP12 (TERA2.cl.SP12) human EC stem cells were maintained in Dulbecco's Modified 
Eagle's media ( D M E M , Sigma or Gibco) supplemented with 10% heat deactivated foetal bovine 
serum (Gibco), 2 mmol L-glutamine (Cambrex), 1000 lU /ml penicillin and streptomycin (Gibco) 
( D M E M - F G A ) at 37 °C in a humidified atmosphere o f 5% CO2 in air. TERA2.cl.SP12 cells were 
grown at high confluency as monolayers in tissue culture plastic flasks (Nunc), changing the medium 
every 2-3 days as necessary and passaging when fu l ly confluent using acid-washed glass beads, 
typically in a 1:3 split. These conditions have previously been demonstrated to maintain the 
undifferentiated phenotype o f this cell line.''^^ 
In preparation for differentiation induction, confluent cultures o f TERA2.cl.SP12 cells were gently 
disassociated by incubating wi th 2 mg/L trypsin-EDTA (Cambrex) for up to 2 minutes to produce a 
suspension o f single cells. The number o f cells harvested was counted using a haemocytometer and 
then seeded at a density o f 20 000 cells/cm^ into an appropriate vessel for the experiment with 
D M E M - F G A containing 10'' M retinoid or an equal volume o f vehicle ( 0 . 1 % 7v DMSO). Media was 
refreshed every 2-3 days with retinoid or DMSO-enriched media and the cultures maintained for up to 
4 weeks. 
Differentiated cells were harvested by disassociating with 2 mg/L trypsin-EDTA, however it was 
noted that while some cell types were loosely attached to the tissue culture plastic, some cells 
(particularly epithelial cells) adhered strongly. To capture the whole population in the best condition it 
was found that an initial wash with PBS prior to trypsinisation aided disassociation; i f necessary the 
cells should be harvested in two stages. Cultures should be treated with trypsin-EDTA for up to 2 
minutes, the trypsin neutralised and all suspended cells removed f rom the flask. The flask should be 
washed with PBS (and added to harvested cells), and the culture trypsinised again. 
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Compound Synonym(s) 
al\-trans- . ATRA 
retinoic acid 11 tretinoin 
9-as- 9-C/5-RA 
retinoic acid 
C07H 
alitretinoin 
13-c«- 13-c/i-RA 
retinoic acid isotretinoin 
CEB16 CD2908 
CEBIT X ^ X J — 
CEB18 
TTNN 
AGN 191650 
TTNPB TTNPB Ro 13-7410 
AmSSO CD366 
LG100268 ccca — 
Compound Synonym(s) 
NMej tolan " ^ — ( ^ = 
OMe tolan 
BPEB 
Table 6-1 contains lists of the retinoids and other compounds tested during in the project. M\-trans-
retinoic acid ( A T R A ) , 9-c/>retinoic acid (9-C/5-RA), 13-c/5-retinoic acid (13-cw-RA), (£)-4-[2-
(5,6,7,8-tetTahydro-5,5',8,8'-tetramethyl-2-naphthalenyl) propen-l-yl] benzoic acid (TTNPB) and 4-
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(5,6,7,8-tetrahydro-5,5',8,8'-tetramethyl-2-naphthalenecarboxamido)-benzoic acid (Am580) were 
purchased from Sigma-AIdrich. Compounds CEBI6 , CEB17 and CEB18 were prepared by the author, 
Jonathan Barnard prepared additional samples o f CEB16 and CEB17. A sample o f LG100268 ( 6 - [ l -
(3,5,5',8,'8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-cyclopropyl]) was kindly provided by Dr. 
Chris Redfern. Compounds identified as OMe tolan, NMe2 tolan and BPEB were prepared by Dr. Tolu 
Fasina. Samples were dissolved in sterile dimethylsulfoxide (DMSO, Sigma) to a concentration o f 
10 m M , protected from light and stored in aliquots at -18 °C. The stock solutions were diluted in 
D M E M - F G A to give a final concentration o f approximately 10 | i M o f retinoid or control substance, 
and filter sterilised through a 0.22 | im membrane filter (Mi l l ex -LG, Mill ipore) . 
The effects induced in the TERA2.cl.SP12 cells were studied by: 
1. Morphological observation over 28 days, recorded by phase microscopy; 
2. Changes in expression o f established immunophenotypic antigens by indirect f low cytometry after 
7, 14 and 28 days' culture; 
3. Immunocytochemical (ICC) localisation o f neural and non-neural antibodies after 14 and 28 days' 
culture on glass coverslips; 
4. Investigating the effects on cell proliferation, measured by tetrazolium dye reduction assays for up 
to 14 days' culture; 
5. Western blots were used to profile the protein expression o f samples harvested after 7, 14 and 28 
days' culture; 
6. Temporal variations o f selected components o f the retinoid pathway was measured using real-time 
PCR analysis over 14 days' culture. 
SH-SY5Y culture 
Experiments using SH-SY5Y neuroblastoma cells were performed by Dr. Chris Redfern's research 
group (Northern Institute for Cancer Research, Medical School, Newcastle University). The SH-SY5Y 
cells were kindly supplied by Professor Robert Ross (Fordham University, N Y , USA). SH-SY5Y cells 
were grown in Dulbecco's modified Eagle's medium ( D M E M , Sigma or Gibco) supplemented with 
heat-deactivated foetal bovine serum (10% 7 v ) , L-glutamine (2 m M ) and antibiotics (penicillin and 
streptomycin, 1000 lU/ml) at 37 °C in a humidified atmosphere (5% CO2 in air). 
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6 . 2 . 2 Morphological changes 
Cell cultures were monitored carefully for the duration o f each experiment, using a Nikon Eclipse 
TSlOO phase-contrast microscope. Typical observations for a culture, in isolation and in relation to 
other cultures, included: 
1. Colour o f phenol red indicator in medium; 
2. Using the naked eye: opacity o f the culture, areas o f the flask where cells are clumping, absent, or 
adopting other notable features; 
3. Amount o f cell debris; 
4. The level o f culture confluence; 
5. Individual cell and colony morphologies. 
Representative phase photographs were captured during this time using Nikon Coolpix 5000 and 
Nikon DMX1200 digital cameras. 
6 . 2 . 3 Immunofluorescent flow cytometry 
Cell surface antigen expression was determined on TERA2.cl.SP12 stem cells and their retinoid-
induced derivatives by indirect immunofluorescence using an EPICS X L cytometer (Coulter). Primary 
monoclonal antibodies specific to the antigens associated with pluripotent stem cells (globoseries 
glycolipid SSEA-3 and keratan sulfate-related TRA-1-60) and neural cell types (VrN-IS-53 and 
A2B5) were used to investigate the differentiation status o f EC cells and their derivatives grown in 
media enriched with test retinoids. Undifferentiated TERA2.cl.SP12 cells were analysed before 
treatment and after 7, 14 and 28 days' treatment with retinoids. 
Cell cultures were disassociated with 2 mg/L trypsin-EDTA trypsin EDTA to create a single cell 
suspension and the number o f cells counted using a haemocytometer. A l l subsequent procedures were 
performed on ice to preserve cell viability. An appropriate number o f cells were washed twice in 
chilled wash buffer ( W B ) consisting o f PBS supplemented with 0 .1% bovine serum albumin 
(BSA, Sigma) and 200 000 cells for each antibody were transferred into one well o f a 96-well round-
bottomed plate (Nunc). The plate was centrifuged and supernatant removed. 
Cell pellets were re-suspended in 50 p.1 o f one o f the fol lowing primary antibodies diluted in WB: P3X 
(IgG, a generous gif t o f Prof P. Andrews, University o f Sheffield, 1:10), SSEA-3 ( I g M , 
Developmental Studies Hybridoma Bank, 1:5), TRA-1-60 ( I g M , a generous g i f t o f Prof P. Andrews, 
University o f Sheffield, 1:6), VIN-IS-53 (IgG, Developmental Studies Hybridoma Bank, 1:5), A2B5 
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( I g M , R & D Systems, 1:100) and incubated for between 20 and 40 minutes. Excess antibody was 
removed with three washes of W B . The cells were re-suspended in 50 | i l o f the appropriate FITC-
conjugated secondary antibody diluted in W B : a-mouse IgG (Cappell, 1:100) or a-mouse I g M 
(Cappell, 1:100) and incubated shielded f rom light for a further 20 to 40 minutes. The cells were 
washed with W B three times, then re-suspended in 800 |a.l WB and transferred to cytometer tubes for 
analysis. 10 |J.I propidium iodide solution (1.0 mg/ml, Sigma) was added to each sample to label dead 
cells. 
Single, live cells were examined by indirect immunofluorescence using a Coulter X L f low cytometer 
fitted with a 15 mW Ar ion air-cooled laser with a 488 nm excitation wavelength and a 10 mW HeCd 
air-cooled laser exciting at 325 nm. Dead cells and cell debris were excluded from the analysis by 
gating with forward scatter and side scatter. 
Data analysis 
Data were analysed using SPSS version 12.01 for Windows (SPSS Inc.). Data were normally 
distributed (one sample Kolmogorov-Smirnov, P > 0.05), but since the variance increased with the 
mean, and the SSEA-3 and A2B5 data sets were skewed, the % positive cells data was arcsin 
transformed for statistical analysis. Univariate analysis o f variance ( A N O V A ) was used to test for 
significant differences between compounds, followed by Bonferroni correction post-hoc analysis. 
Significance levels were set at: * P-value < 0.05, *• /"-value < 0.01 and *** P-value < 0.001. 
6 . 2 . 4 Tetrazolium proliferation assay 
TERA2.cl.SP12 cells were seeded at a density o f 20 000 cells/cm^ in 12-well plates (Nunc) in retinoid-
enriched media, media containing the vehicle (0 .1% 7v DMSO) or fresh proliferative media. Media 
was changed every two days, or more frequently as required, with fresh media containing the 
appropriate retinoid or control reagent. After 0, 3, 7, 10 and 14 days' exposure to the test conditions 
the cell cultures were subjected to a tetrazolium colourimetic assay to measure the number o f 
proliferative cells. 
Media was gently aspirated from the wells and replaced with fresh D M E M - F G A (1500 | i l ) and 300 nl 
MTS reagent (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium, inner salt, Promega).** An additional empty well was also prepared in this manner to act as 
a U V blank. The plates were incubated for four hours and the resulting solutions were mixed gently. 
^ Optimum volumes were determined in a preliminary experiment. These volumes provide an excess of MTS 
reagent at the greatest cell density expected in this experiment (data not shown). 
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50 \i\ o f each solution was diluted in 950 ^1 dH20** and the UV absorbance o f these solutions 
measured at 490 nm. The dilution and U V measurement step was performed in triplicate and the result 
averaged to control for pipetting accuracies. 
Data analysis 
Data were analysed using SPSS version 12.01 for Windows (SPSS Inc.). Data were normally 
distributed (one sample Kolmogorov-Smirnov, P > 0.05), but since the variance increased with the 
mean the % UV absorbencies were arcsin transformed for statistical analysis. Univariate analysis o f 
variance ( A N O V A ) was used to test for significant differences between compounds, followed by 
Bonferroni correction post-hoc analysis. Significance levels were set at: * P-value < 0.05, ** P-value 
< 0.01 and •** P-value < 0.001. 
6 . 2 . 5 Immunocytofluorescence 
Cells were grown on poly-D-lysine coated coverslips in 12-well plates (Nunc) or 8-well chamber 
slides ( B D Falcon) using culture techniques as previously reported. After 14 and 28 days' culture, the 
cells were fixed with either 4% "/v paraformaldehyde in PBS (20 minutes, RT) or 5% 7 ,^ glacial acetic 
acid in methanol (for MAP-2 staining: 20 minutes, -20 °C). Cells were blocked for 30 minutes in wash 
diluent ( W D : 5% normal goat serum (Invitrogen) and 0.2% Triton X-100 (Fisher Scientific) in PBS) 
to l imit background staining, then incubated for 60 minutes with one or two o f the primary antibodies 
shown in Table 6-2 diluted in W D . Cells were then washed three times in W D and subsequently 
conjugated with the appropriate secondary antibodies (a-mouse IgG-FITC conjugated, a-rabbit IgG-
Cy3 conjugated, a-mouse IgM-Texas Red conjugated, or a-rabbit IgG-FITC conjugated, all diluted 
1:600 in W D ) for 1 hour at room temperature. Unbound secondary antibodies were removed by three 
PBS washes. Control slides were also prepared for each retinoid: the slides were prepared as above, 
except W D alone was used in place o f the primary antibodies. 
Stained coverslips were inverted and mounted on microscope slides in Vectashield Mounting Medium 
(Vector Laboratories) containing 1% o f Hoechst 33342 (10 ng/ml aqueous solution. Molecular Probes) 
to retard photobleaching and the coverslips sealed using nail varnish. Stained cover-slips were 
examined using a fluorescence microscope (Axiovert 135). Phase contrast and corresponding 
fluorescence images were collected using a Nikon Coolpix 5000 digital camera. 
To give absorbencies within the linear range of the spectrophotometer. 
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Table 6-2; Antibodies used in immunocytochemical analysis. 
Antibody 
anti- Raised in Dilution Supplier 
P-Ul-tubulin (clone TUJ-1) rabbit 1:100 Covance 
nestin mouse 1:200 Chemicon 
neurofilament-68 (NF68) mouse 1:200 Sigma 
cytokeratin 8 (C8) mouse 1:300 Sigma 
fibronectin rabbit 1:500 Sigma 
Glial fibrillary associated protein 
(GFAP) mouse 1:500 Sigma 
Neuron specific enolase (NSE) mouse 1:200 Chemicon 
A2B5 mouse 1:200 R & D Systems 
Microtubule associated protein-2 (MAP-2) mouse 1:200 Sigma 
Growth associated protein-43 (GAP-43) mouse 1:400 Sigma 
178 
6 . 2 . 6 Western blots 
Protein samples were prepared from TERA2.cl.SP12 EC cells and their retinoid-induced derivatives 
by lysing harvested cells for 30 minutes on ice, in a lysis buffer prepared f rom six parts Igepal lysis 
buffer ( 1 % Igepal CA-630 (Sigma), 5% 1 M Tris (pH 8.0), 5% 3 M NaCl, 1% 1 M MgCh , 89.6% 
dH20) and one part protease inhibitors (Complete Min i protease inhibitor cocktail tablets, Roche 
Diagnostics). The resulting protein solutions were centrifuged at 14 500 rpm for 5 minutes to remove 
cytoskeletal debris. Protein concentrations o f the supernatants were quantified using the Bradford 
method,"^ then snap-frozen in liquid N2, and stored at -80 °C until required. 
Sodium dodecyl sulfate (SDS)-polyacrylamide gels were prepared according to the method o f 
Laemml i . ' " Using the Bio-Rad minigel system (Bio-Rad Laboratories), separating gel (10% or 5% 
polyacrylamide) with a loading gel (4% polyacrylamide) was poured to a thickness o f 0.75 mm. 
Samples were prepared as follows: \2 of each protein sample was diluted in dH20 to 12 | i l and 
denatured in 3 | i l o f reducing sample loading buffer (22% 1 M Tris-HCI (pH 6.8), 44% glycerol, 
63 m M sodium dodecyl sulfate, 1 1 % 0.5 M EDTA, 8% P-mercaptoethanol, 5% bromophenol blue, 5% 
phenol red and 5% xylene) at 95 °C for 3 minutes and vortex mixed. 
15 nl o f each sample and 3 | i l o f ECL Plex Fluorescent Rainbow Marker (GE Healthcare) were loaded 
onto the gels and electrophoresed at 70 V until the dye bands were compressed at the gel junction 
(approx. 12 minutes), then at 200 V until the coloured bands at the SDS front dropped o f f the bottom 
o f the gel (approx. 45 minutes). Resolved gels were immediately transferred onto Hybond-P (PVDF) 
membranes (GE Healthcare) using the Bio-Rad mini-gel transfer apparatus at 100 V, at 5 °C for 
1 hour. Confirmation o f protein transfer was achieved by staining blots wi th 0.2% "^ /^v Ponceau S in 5% 
acetic acid; however. Ponceau staining resulted in elevated background fluorescence when using the 
Typhoon scanner so this step was generally omitted. 
Membranes were blocked in 5% BSA in PBS, with rocking, for one hour at RT and subsequently 
incubated with the primary mouse and goat antibodies listed in Table 3-6 diluted in 0 ,1% Tween 20 in 
PBS (PBS-T) for 1 hr at RT or overnight at 5 °C. Blots were rinsed in PBS-T twice and washed for 
2 x 5 minutes in PBS-T rocking at RT. The membranes were then incubated for 1 hour at RT, 
protected f rom light and with rocking, with ECL Plex CyDye a-mouse and/or a-goat conjugated 
secondary antibodies as appropriate (1:2500, GE Healthcare) diluted in PBS-T. Unbound secondary 
antibodies were washed o f f by rinsing the membranes three times in PBS-T, followed by 4 x 5 
minutes in PBS-T with shaking at RT and finally rinsed three times with PBS. Blots were dried and 
viewed using a Typhoon 9400 Variable Mode Imager (Amersham Biosciences). 
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Table 6-3: Antibodies used in western blot analysis. 
Gel 
Antibody 
anti-
Predicted 
M W 
(kDa) 
Raised in Dilution 
Supplier & product 
code 
1 P-actin 42 mouse 1:10 000 Sigma A5441 
TUJ-1 50 rabbit 1:1000 Covance PRB-435P 
NF68 68 mouse 1:1000 Sigma N5139 
2 NSE 45 mouse 1:1000 Sigma MAB324 
RAR-P 51 rabbit 1:500 Santa Cruz sc-552 
NF160 160 mouse 1:1000 Sigma N2787 
3 C8 52.5 mouse 1:500 Sigma C5301 
OCT 4 43 rabbit 1:500 Abeam ab19857 
RAR-y 60 rabbit 1:500 Santa Cruz sc-550 
RAR-a 50/55 rabbit 500 Santa Cruz sc-551 
4 NF200 200 mouse 1:400 Abeam ab7795 
fibronectin 220-240 rabbit 1:500 Sigma F3648 
5 nestin 220-240 mouse 1:1000 Chemicon MAB5326 
MAP-2 2 X 280 & 70 mouse 1:1000 Sigma M9942 
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6.2.7 Real-time PCR 
RNA extraction and reverse transcription (RT) 
Cultures were washed gently with PBS prior to extracting total RNA with TRI reagent® (Sigma) 
according to the manufacturer's suggested protocol for monolayer cell extraction for rt qPCR. The 
RNA pellet was dissolved in DEPC-treated water (Sigma) and stored at -80 °C. Purified RNA was 
quantified and assessed for purity by U V spectrophotometry using a Nanodrop® ND-1000 (Thermo 
Fisher Scientific). 
Single stranded cDNA was synthesised f rom 4 |ag of total cellular RNA by reverse transcription in a 
20 10.1 reaction using oligo-d(T)i6-primers and MultiScribe™ reverse transcriptase (TaqMan® Reverse 
Transcription Reagents, Applied Biosystems) fol lowing the manufacturer's instructions. The RT 
reaction was performed in an Eppendorf Mastercycler gradient programmed with the parameters: 
incubation at 25 °C for 10 minutes, reverse transcription at 48 °C for 30 minutes followed by RT 
inactivation at 95 °C for 5 minutes. cDNA was stored at -80 °C until use. 
Absolute quantitative real-time PCR (rt qPCR) 
Quantitative PCR was used to measure the relative changes in R N A gene expression after treatment o f 
TERA2.cl.SP12 with retinoids. Real-time PCR (rt qPCR) was performed using Applied Biosystems 
7500 Fast Real-Time PCR Systems instrument, with Sequence Detection Software Version 1.4 
(Applied Biosystems) and SYBR® GREEN chemistry. 
PCR reactions were performed in a volume o f 10|u.l containing 1 fj.1 cDNA, forward and reverse 
oligonucleotide primers ( 1 5 0 n M o f each), SYBR® GREEN PCR master mix (x2. Applied 
Biosystems, 5 |j.l) and dH20. After incubating the plate at 50 °C for 2 minutes, rt qPCR amplification 
was performed in a two-step procedure: denaturation at 95 °C for 10 minutes and between 40-60 
cycles (as required for f u l l amplification o f the gene o f interest. Table 6-4) o f denaturation at 95 °C for 
15 seconds, annealing at 60 °C for 1 minute. Acquisition o f the fluorescent signal from the samples 
was carried out at the end o f annealing step. Finally, a disassociation programme was run: the plate 
was heated to 95 °C for 15 seconds, 60 °C for 1 minute and 95 °C for 15 seconds. 
Primer sequences (Table 6-4) were obtained from published references, some o f which were sourced 
from the Real Time PCR Primer and Probe Database ( R T P r i m e r D B ) , " ^ " ' or designed using Primer 
Express 3.0 (Applied Biosystems). A l l oligonucleotides were custom synthesised by V H Bio. Primer 
sequences were confirmed to be specific to only the sequence(s) o f interest using the Basic Alignment 
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Search Tool (BLAST, http://www.ncbi.nlm.nih.gov/blast/blast.cgi)'^" and Netprimer 
(http://www.premierbiosoft.com/netprimer/index.htmI) was used to assess the quality o f primer design 
and likelihood o f primer dimerisation. 
The purity and identity o f the PCR products was confirmed by establishing the presence o f a single 
peak in the disassociation curve, and subjecting a sample to electrophoresis on a 1.5% "'/v agarose gel 
stained with ethidium bromide and visualised by UV, to confirm a single product o f the expected size. 
Table 6-4: rt qPCR primer sequences 
Gene Primer Sequences (5' to 3') 
F , R 
Product 
length (bp) 
and 
position(s) 
N
u
m
b
er 
of cycles 
1 
S
eq
u
en
ce 
R
ef. 
S
tan
d
ard
 
C R B P - I TAGAGATGAGAGTGGAAGGTGTGGT 
GGGGTGGCTGGACATTTTTG 
151 
(628-478) 45 
761 5d 10^M 
ATRA 
CRABP-1 AGGTCGGAGAAGGCTTTGAG 
AGAAGAGTTTGCGTGCAGTG 
103 
(376-274) 40 
56 5d 10 ^M 
ATRA 
C R A B P - I I TGCAGGGTCTTGCTTTCTTT 
GGGCTAGGACTGCTGACTTG 
126 
(698-823) 40 
762 5d 10 nM 
ATRA 
CYP26A1 
(variants 1 & 2) 
GGAGGACACGAAACCAC 
TCAGAGCAACCCGAAACC 
221 (1143-923, 
1070-1290) 60 
763 5d 10 nM 
ATRA 
R A R - a 
(variants 1 & 2) 
GGGACAAGAACTGCATCATCAA 
CCTTGGACATGCCCACTTC 
90 (832-921, 
977-1066) 50 
self-
designed 
14d 10 \iM 
ATRA 
RAR-(3 
(variants 1 & 2) 
ATTCCAGTGCTGACCATCGAGTCC 
CCTGTTTCTGTGTCATCCATTTCC 
349 (722-1070, 
1079-1427) 60 
764 14d 10 nM 
ATRA 
R A R - y 
(variants 1 & 2) 
TGTGCGAAATGACCGGAAC 
CTAACTGAGGGCTCAGCTCATAGC 
83 (906-988, 
805-887) 50 
216 do 
POU5F1 
( O C T 3/4) 
(variants 1 & 2) 
GAGAACCGAGTGAGAGGCAACC 
CATAGTCGCTGCTTGATCGCTTG 
166 (768-933, 
528-693) 45 
765 do 
H O X B l CTCCTCTCCGAGGACAAGGAA 
CTGTCTTGGGTGGGTTTCTCTTAA 
103 
(481-583) 50 
51 5d 10 nM 
ATRA 
H 0 X B 2 TCCTTGGCCGTCTACTGGAA 
AGTGGATTAAACGCTAATTCAGTAATACC 
105 
(1228-1332) 50 
51 5d 10 nM 
ATRA 
H 0 X B 3 CCTGGCCTGAGAGGTTGCT 
TCCCGGGCGTGGAATT 
145 
(2304-2448) 50 
51 5d 10 nM 
ATRA 
G A P D H ATGGGGAAGGTGAAGGTCGGAG 
TCGCCCCACTTGATTTTGGAGG 
266 
(103-368) 40 
RTPrimer 
DB 
ID: 2072 
do 
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Data processing 
Data were analysed using Sequence Detection Software Version 1.4 (Applied Biosystems). Standard 
curves were constructed for each PCR analysis, consisting o f six serial dilutions of c D N A analysed in 
triplicate. The cDNA sample selected as the standard for each gene is shown in Table 6-4. An example 
calibration curve is shown in Appendix 3. The average correlation coefficients (R") was 0.99 (range = 
0.999-0.958). Greater than 99% o f samples with detectable levels o f gene expression were within the 
standard range {>90% o f all samples). 
To account for variations in RT efficiency, individual gene expression values were normalised using 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as the reference gene. This gene has been 
previously demonstrated to be stably expressed in this cell line under similar experimental 
conditions."" 
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Appendix 1: Structures of natural and synthetic retinoids and RAMBAs discussed 
in text 
(numbering distinct from synthetic scheme in Chapter 2) 
.COjH 
CO2H 
CO2H 
A ATRA B 9-c/5-retinoic acid C 13-cw-retinoic acid 
COjH 
COOH CO2H 
DTTNPB E Targretin® 
(LGD1069, bexarotene) FLG100268 
COjH C02H 
COjH 
G AGN 193109 H AGN 190730 I CD437 
(AHPN, AGN 192837) 
COOH 
MeO' 
J Fenretinide 
(4-HPR) 
K ST 1926 L Adapalene 
(CD271)) 
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Appendix 2: Crystallographic data 
Crystal structure and refinement data for compounds 4, 5,14 and 17. 
Molecule 4 - C E B 1 7 5 - C E B 1 8 14 17 
Identification 
code 05srvl67 06srv233 05srvl33 05srvl96 
Empirical 
formula C23H26O2 C25H26O2 C17H24O C i 4 H i 9 B r 
Formula weight 334.44 358.46 244.36 267.20 
Temperature / 
K 120(2) 120(2) 120(2) 120(2) 
Crystal system triclinic triclinic monoclinic orthorhombic 
Space group P-l P-l P2(l)/c P2|2,2, (No. 19) 
Unit Ceil 
dimensions: 
a / A 5.9101(18) 5.9191(10) 10.0785(12) 7.760(1) 
b / A 8.622(3) 8.5375(15) 13.9074(17) 10.508(1) 
c / A 17.961(6) 19.455(3) 10.5905(13) 15.461(1) 
a / ° 84.739(6) 96.334(16) 90 90 
p / ° 89.610(6) 92.672(14) 95.808(2) 90 
Y / ° 84.674(7) 103.035(13) 90 90 
Volume / A^ 907.4(5) 949.4(3) 1476.8(3) 1260.7(2) 
Z 2 2 4 4 
Density 
(calculated) / 
Mg/m^ 
1.224 1.254 1.099 1.408 
Absorption 
coefficient / 
mm'' 
0.076 0.078 0.066 3.228 
Crystal size / 
mm^ 0.28x0.12x0.05 0.2x0.1 x0.02 0.45 x0 .40x0.35 0.35 X 0.31 X 0.29 
Theta range for 
data collection 
1° 
2.55 to 30.51 2.56 to 24.25 2.03 to 30.24 2.3 to 30.0 
Reflections 
collected 10605 1049 10343 23007 
Independent 
reflections 
5376 [R(int) = 
0.0834] 3293 
4006 [R(int) = 
0.0241] 
3666 [R(int) = 
0.0210] 
Absorption 
correction none none none 
semi-empirical 
from equivalents 
Data / restraints 
/ parameters 5376 /0 /232 3293 / 0 / 2 3 5 4006 / 0 / 259 3666 /0 /176 
Final R indices 
[I>2sigma(I)l 
R l =0.0875 
wR2 = 0.2535 
Rl =0.0778 Rl =0.0451 
wR2 = 0.1154 
R l = 0.0170 
wR2 = 0.0402 
R indices (all 
data) 
R l =0.1445 
wR2 = 0.2722 
Rl =0.1316 R l =0.0616 
wR2 = 0.1249 
R l = 0.0201 
wR2 = 0.0413 
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Appendix 3: Typical standard curve generated during rt qPCR analysis. 
Six dilutions o f an appropriate standard were prepared and analysed in triplicate for each gene on each 
PCR plate. Overall, greater than 99% o f samples with detectable levels o f gene expression were within 
the corresponding standard range (>90% o f all samples). 
Slandaro Curvn 
24,516 B 
-3.000 -2.800 
15 Show al rtanttard oorti 
(of telected tjeiscaotlsj 
! ! « « * » : |CBAflP-ll 3 
: 
X u iw . 
-2.000 -1.000 
Loo CO 
-0.800 -0,002 
Standard curve generated for one plate o f the CRABP-II rt qPCR analysis. The fluorescence o f all 
samples in this analysis was within the standard range. 
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